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Abstract 
Publication 1 comprises a review article concerned with palladium-catalyzed Ullmann cross- 
coupling reactions. Specifically, it details modern variants of these type of reactions and their 
extensive use, most notably by the Banwell group, in the synthesis of various heterocyclic systems, 
including ones encountered in natural products. Publication 1 contextualizes the research described 
in Publications 2-4. 
Publication 2 is concerned with the palladium-catalyzed Ullmann cross-coupling reactions of β-
iodoenones or β-iodoacrylates with o-iodonitrobenzenes or o-iodobenzonitriles, as well as the 
reductive cyclization of the resulting products to give various heterocyclic systems. Thus, this 
publication is concerned with a two-step approach to the synthesis of structurally diverse and 
biologically active heterocycles, including quinolones and benzomorphans which are normally only 
accessible via multistep-syntheses.  
Publication 3 outlines research on palladium-catalyzed Ullmann cross-coupling reactions of α-
iodoenones with o-iodonitrobenzenes and the reductive cyclization of the ensuing coupling products.  
Specifically, it details the exploration of two distinct modes of reductive cyclization that allow for the 
synthesis of structurally “complementary” heterocyclic ring systems from a common precursor.  
Publication 4 describes a chemoenzymatic synthesis of a highly functionalized and homochiral -
iodocyclohexenone that it is expected will serve as a precursor, through the application of 
palladium-catalyzed Ullmann cross-coupling and reductive cyclization reactions, to the complex 
indole alkaloids aspidophytine and haplophytine. The synthesis starts with an enantiomerically pure 
cis-1,2-dihydrocatechol that is itself obtained through the whole-cell biotransformation of 
bromobenzene.  
Publication 5 is concerned with the developing syntheses of certain C7N aminocyclitols, a significant 
group of biologically active natural products. In particular, this paper details chemoenzymatic total 
syntheses of several novel compounds within the class, including analogues of the recently isolated 
natural product kirkamide. The syntheses exploit, as starting materials, enzymatically-derived and 
homochiral cis-1,2-dihydrocatechols obtained from either iodo- or bromo-benzene. Methods for 
obtaining the enantiomers of the reported C7N aminocyclitol derivatives have been identified. Once 
again, palladium-catalyzed cross-coupling chemistries were employed as key steps in these 
syntheses.  
Publication 6 is concerned with developing chemical syntheses of cochliomycins and related, 
biologically active natural products. Specifically, this is an extensive literature review on the chemical 
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synthesis of an important subset of the large class of structurally distinct and biologically significant 
natural products known as resorcylic acid lactones.  
Synopsis 
Cross-coupling reactions provide a particularly effective means for the formation of carbon-carbon 
bonds. Many, well-established methods for forming such bonds now exist, perhaps the most 
noteworthy being palladium-catalyzed cross-couplings that involve the linking of a halide or pseudo-
halide with an organometallic or metalloid species. While these reactions often give good yields of a 
single product, one drawback is the need to form the requisite organometallic species, usually from 
the corresponding organo-halide. While the classical Ullmann cross-coupling reaction has the 
advantage that it can affect the direct coupling of two distinct organo-halides, harsh reaction 
conditions are usually involved (temperatures in excess of 250 °C are frequently required) and often 
homo-coupling is the predominant, if not the only process observed.1 The palladium-catalyzed 
Ullmann cross-coupling affords many of the advantages of the standard palladium-catalyzed 
processes as well as those associated with the original Ullmann reaction. As such, it is now possible 
to carry out hetero-couplings of two distinct organo-halides under mild conditions. 
The focus of the research described in this thesis is the deployment of palladium-catalyzed Ullmann 
cross-coupling reactions in the synthesis of biologically active heterocyclic systems, as well as the 
total synthesis of natural products. A common theme is the cross-coupling of iodoenones with 
substituted o-iodo- or o-bromo-benzenes as shown, for example, in Scheme 1. The substituents (R’) 
associated with the haloarenes are usually strongly electron-withdrawing ones, such as nitrile or 
nitro groups.  The proposed reaction mechanism for this type of couplings is based on a previously 
reported reaction mechanism by Shimizu and co-workers.2 In the first step the Pd(0) catalyst 
undergoes an oxidative addition into the C-I bond of enone I, whereas the iodoarene III undergoes a 
halogen-metal exchange by reacting with Cu(0) and thus forming cuprate IV. Pd-species II can then 
undergo a ligand exchange reaction with cuprate IV to yield intermediate V. A reductive elimination 
will then generate product VI and regenerate the Pd(0) catalyst. 
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Scheme 1: An Example of the Palladium-Catalyzed Ullmann Cross-Coupling Reaction and the 
Proposed Reaction Mechanism  
Such palladium-catalyzed Ullmann cross-couplings can be conducted using a range of iodinated 
enones, as described in Publications 2 and 3, and so providing ready access to diverse heterocyclic 
systems in just one or two steps. As described in Publication 4, it is anticipated that the reaction can 
also be deployed for the assembly of more elaborate systems. The application of related cross-
coupling reactions to syntheses of natural products and natural product analogues are described in 
Publications 5 and 6. 
Thesis Overview 
Publication 1: The Palladium-catalysed Ullmann Cross-coupling Reaction: 
A Modern Variant on a Time-honored Process 
In Publication 1 the focus is on the applicability of palladium-catalyzed Ullmann cross-coupling 
reactions to the synthesis of heterocycles and natural products. Special attention is given to the 
manifold contributions of the Banwell group in this field. A representative palladium-catalyzed 
Ullmann cross-coupling regime is shown in Scheme 2 and has been used to synthesize, after 
reductive cyclization of the initial cross-coupling product, indoles such as compound 4. The particular 
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reaction sequence shown in Scheme 2 is also one direct example of the author’s immediate 
contributions to this publication.  
 
Scheme 2: Synthesis of Indole 4 
Another example is the synthesis of a class of compounds called carbolines. There are four isomeric 
carbolines, as shown in Figure 1, and each of these is encountered in natural products and/or within 
pharmacologically significant compounds.  
 
Figure 1: The Structures of the Four Isomeric Carbolines 
The synthesis of the carboline-type natural product harman (13)3 (possessing anti-HIV activity4) 
shown in Scheme 3 further exemplifies the utility of the protocols developed by the Banwell group.  
 
Scheme 3: Synthesis of the Natural Product Harman 
 
Publication 2. Palladium-Catalyzed Ullmann Cross-Coupling of β-Iodoenones and β-Iodoacrylates 
with o-Halonitroarenes or o-Iodobenzonitriles and Reductive Cyclization of the Resulting Products 
to Give Diverse Heterocyclic Systems 
This paper is concerned with the palladium-catalyzed Ullmann cross-coupling of diverse β-
iodoenones and β-iodoacrylates with o-halonitroarenes and the reductive cyclization of the ensuing 
products. By such means a powerful, two-step synthetic pathway leading to a range of novel 
heterocyclic systems has been established.  
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Previous work conducted by the Banwell group on the palladium-catalyzed Ullmann cross-coupling 
reaction was largely focussed on the coupling of α-iodoenones with o-halonitrobenzenes. 
Transformations of this type provide access to different types of natural products including the 
carbazoles shown in Figure 2.5 
 
Figure 2: Structures of Diverse Carbazoles 
The successful syntheses of the members of the the uleine alkaloid family shown in Figure 3 further 
highlight the power of such methodologies.6  
 
Figure 3: Members of the Uleine Alkaloid Family Accessible Using the Palladium-Catalyzed Ullmann 
Cross-Coupling/Reductive Cyclization Protocols 
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The research reported in Publication 2 is complementary to such earlier work. The focus in this 
publication is on the participation of β-iodoenones and β-iodoacrylates (rather than, say, α-
iodoenones) in palladium-catalyzed Ullmann cross-coupling reactions. Depending on the precise 
nature of such coupling partners, as well as the methods used for the reductive cyclization, then 
various heterocyclic systems including quinolones, dihydroquinolones, benzomorphanes and 
naphthydrines can be obtained. A number of these have now become much more readily accessible 
as a result. The benzomorphans reported in this publication are of particular interest, as many of 
them have a number of notable medicinal properties including by serving as analgesics.7 Scheme 4 
highlights some such transformations.   
 
Scheme 4: Palladium-Catalyzed Ullmann Cross-Coupling of β-iodoenones with o-Halonitrobenzenes 
Giving Access to Heterocyclic Systems such as Azacoumarins and Benzomorphans 
In this study it was also shown that depending upon the mode of reduction of the initial Ullmann 
cross-coupling product different cyclization products can be obtained. For instance, if compound 37 
(Scheme 5) is treated with Fe in AcOH/HCl then quinolone 38 is obtained while exposing the same 
substrate to standard hydrogenation conditions (H2/Pd on C) affords the fully reduced product, 
namely dihydroquinolone 36.  
 
  
Scheme 5: Possible Cyclization Pathways for 37 using either Fe in AcOH/HCl or H2/Pd on C 
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On the basis of the studies reported in Publication 2, it is clear that palladium-catalyzed Ullmann 
cross-couplings involving β-iodoenones and β-iodoacrylates provide a versatile means for obtaining 
hitherto unknown or less readily accessible heterocyclic frameworks.  
 
Publication 3: Reductive Cyclization of o-Nitroarylated-α,β-Unsaturated Aldehydes and Ketones 
with TiCl3/HCl or Fe/HCl Leading to 1,2,3,9-Tetrahydro-4H-carbazol-4-ones and Related 
Heterocycles 
Publication 3 further articulates the utility of the palladium-catalyzed Ullmann cross-coupling 
/reductive cyclization sequence. In particular, it focuses on different methods for effecting the 
reductive cyclizations of the coupling products. Significantly, depending upon the mode of the 
reductive cyclization a given coupling product may afford distinct heterocyclic products. This further 
extends the range of heterocycles that can be obtained. In particular, Publication 3 focuses on the 
complementary behaviours of the H2/Pd on C and the TiCl3/HCl reduction systems. So, as shown in 
Scheme 6, if coupling product 40 is treated with H2 in presence of Pd on C then it reacts to give 
product 39 while on treatment with TiCl3/HCl then congener 41 is obtained.   
 
Scheme 6: Divergent Reductive Cyclization Pathways for Compound 40 
Similarly, as shown in Scheme 7, while subjection of cross-coupling products 46 or 47 to reductive 
cyclization using H2 and Pd on C provides indole 45, on treating the same substrates with TiCl3 in HCl 
then the C3-acylated indole 48 is formed, albeit in variable yields. 
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  Scheme 7: Synthesis of Reductive Cyclization Products 45 and 48 
In contrast, the readily available cinnamaldehyde derivative 49 shown in Scheme 8 affords the 
known anti-proliferative agent 508 on treatment with TiCl3/HCl in acetone.  
 
Scheme 8: TiCl3-Mediated Cyclization of Compound 49 
In a further example of the utility of such cyclization reactions, levoglucosenone derivative 51 
provides, as depicted in Scheme 9, the tetracyclic product 52 upon treatment with TiCl3 in HCl. 
 
Scheme 9: TiCl3-Mediated Cyclization of Compound 51 to Give the Tetracyclic Levoglucosenone-
Based Compound 52  
With this method it is also possible to form novel dihydroquinolines. Thus, ketones such as acetone 
can be incorporated into the reductive cyclization product. As illustrated in Scheme 10, this 
presumably occurs via Schiff base condensation, electrocyclic ring-closure then a prototropic shift 
and accompanying re-aromatization. If, for instance, compound 31 is reacted with TiCl3/HCl in 
presence of a ketone, then in the first step the nitro group is reduced to the corresponding aniline 
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53. The amine residue so-formed then undergoes a Schiff base condensation with the added ketone 
to yield intermediate 55 that undergoes electrocyclic ring closure to give intermediate 56. A 
prototropic shift and accompanying re-aromatization then leads to the final product 54, the 
structure of which was confirmed by single-crystal X-ray analysis. 
 
Scheme 10: Formation of Dihydroquinoline 54 from Cross-coupling Product 31 and Acetone in the 
Presence of TiCl3/HCl 
As shown in Scheme 11 a range of other dihydroquinolines was prepared by simply reacting 
compound 53 with aldehydes or ketones, usually in presence of aqueous HCl. For instance, when 
this substrate was reacted with benzaldehyde, then product 57 was obtained. Similarly, the reaction 
between compound 53 and butanone afforded compound 58, while the reaction involving 
cyclohexanone gave the spirocyclic product 59.  
 
Scheme 11: Acid-Promoted Reactions of Compound 53 with Aldehydes or Ketones to Give 
Dihydroquinolines 57-59 
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Overall, then, Publication 3 builds, in a distinctly complementary way, on the work reported in 
Publication 2.  
 
Publication 4:  Synthesis of a Highly Functionalised and Homochiral 2-Iodocyclohexenone Related 
to the C-ring of the Polycyclic, Indole Alkaloids Aspidophytine and Haplophytine 
Aspidophytine is a constituent of the heterodimeric compound (+)-haplophytine (Figure 4) that 
occurs in the Mexican cockroach plant Haplophyton cimididum.9 Dried leaves of this plant have been 
used for their insecticidal properties since at least the Aztec era. A range of synthetic studies has 
been conducted on the total synthesis of aspidophytine, the first synthesis of the  
(–)-enantiomeric form having been reported by Corey and his co-workers in 1999.10 This was 
followed by the reports of Fukuyama (2003)11,12, Padwa (2006)13,14, Marino (2006)15, Nicolaou 
(2008)16, Tokuyama (2013)17 and Qiu (2013).18 
 
Figure 4: Structures of the Alkaloids Haplophytine and Aspidophytine 
A nine step synthesis of a highly functionalized and homochiral 2-iodocyclohexenone that is related 
to the C-Ring of aspidophytine and haplophytine is reported in Publication 4. Unlike all previously 
reported asymmetric total syntheses of these compounds, a chemo-enzymatic approach is used to 
establish the required functionality and stereochemistry.   
The starting material employed is the enantiomerically pure cis-dihydrocatechol 62 depicted in 
Scheme 12 and which can be obtained through the whole-cell biotransformation of bromobenzene. 
Using metabolite 62 would give access to the non-natural enantiomeric form of aspidophytine and 
haplophytine. However, since compound ent-62 is also available, the illustrated reaction sequence 
should also provide access to the natural products themselves.  
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Scheme 12: Synthesis of the Homochiral 2-Iodocyclohexenone 70 
 
The aminoalkyl chain associated with the target 2-iodocyclohexenone was introduced via Suzuki–
Miyaura cross-coupling of compounds 63 and 64. The quaternary stereocenter of the target was 
then established using the allylic alcohol moiety embedded within compound 66 by treating it with 
dimethylformamide dimethyl acetal (DMADMA) and thus effecting an Eschenmoser–Claisen 
rearrangement. Deprotection of the newly generated allylic alcohol, followed by oxidation and 
Johnson -iodination then gave α-iodoenone 70.  
As shown in Scheme 13, the highly substituted enone 70 has the potential to engage in a palladium-
catalyzed Ullmann cross-coupling reaction with the substituted o-nitrobenzene 71. The anticipated 
coupling product from this reaction, namely compound 72, would then be engaged in a reductive 
cyclization reaction to give the pentacyclic intermediate 73. 
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Scheme 13: Possible Elaboration of the Palladium-Catalyzed Ullmann Cross-Coupling Product 70 to 
Tetracyclic Compound 73 
Scheme 14 illustrates a series of possible further reactions, including a Corey–Winter olefination, 
that could be applied to compound 73 and so yielding ent-aspidophytine. Compound 73 may be 
reacted with 2-bromoethanol to yield amino-alcohol 74, which can then be mesylated. Treating the 
indole moiety with a strong base should then lead to deprotonation and subsequently to an 
intramolecular displacement of the mesylate and ring-formation. The unprotected diol in compound 
76 would then be converted to the corresponding olefin via Corey–Winter olefination. Hydrolysis of 
the dimethyl amide and esterification should then give ent-aspidophytine.   
 
 
Scheme 14: Potential Pathway for the Completion of a Synthesis of ent-Aspidophytine 
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Publication 5: Syntheses of Structurally and Stereochemically Varied Forms of C7N Aminocyclitol 
Derivatives from Enzymatically-derived and Homochiral cis-1,2-Dihydrocatechols 
 
In 2015 the isolation of the new C7N aminocyclitol kirkamide as well as an eleven step synthesis of it 
from methyl N-acetyl-D-glucosamine was reported by Gademann and co-workers (Scheme 15).19 
 
Scheme 15: Gademann’s Synthesis of Kirkamide 
 
Kirkamide is found in leaf nodules of the plant Psychotria kirkii and likely produced by Candidatus 
Burkholderia kirkii, a leaf symbiont of this plant.20,21 Since kirkamide has shown to be toxic to aquatic 
arthropods and insects it might be acting as an anti-feedant and thus protecting the leaves of the 
host plant. 
In Publication 5 total syntheses of several derivatives of kirkamide, including an epimer, are 
reported. In contrast to the previously reported synthesis, the approach taken in the author’s work is 
a chemo-enzymatic one. The starting material for this purpose is the cis-dihydrocatechol 62, which 
also served as the starting material for the synthesis described in Publication 4.  
In Scheme 16 the total synthesis of epi-kirkamide is shown. Thus, treatment of previously reported 
acetamide derivative, 87, with KHMDS gave, via the intermediate aziridine 88, the isomeric oxazoline 
89. The introduction of the hydroxymethyl group associated with the C7N aminocyclitols was 
achieved via a palladium-catalyzed cross-coupling reaction. In particular, carbopalladation of the 
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iodoalkene 91 in presence of N,O-dimethylhydroxylamine under a carbon monoxide atmosphere 
gave the α,β-unsaturated Weinreb amide 92. A two-step reduction of this amide (using lithium 
aluminium hydride for the formation of the corresponding aldehyde and subsequent Luche 
reduction) yielded compound 95 and global deprotection of this using aqueous acetic acid then gave 
epi-kirkamide (96).  
 
 
Scheme 16: A Total Synthesis of epi-Kirkamide (96) 
A distinct synthetic route to the kirkamide framework is shown in Scheme 17. Thus, the same cis-1,2-
dihydrocatechol, 62, used for the synthesis of epi-kirkamide, is now reacted with 
N-bromosuccinimide in THF and water to give bromohydrin 97, that undergoes an intramolecular 
nucleophilic substitution reaction on treatment with NaH to yield epoxide 98. Compound 98 was 
then subjected to a two-fold Mitsunobu reaction using p-nitrobenzoic acid as the nucleophile and 
the resulting diester then saponified with NaOMe in MeOH to yield diol 99. Treatment of this last 
compound with TsNCO afforded intermediate 100 that upon hydrolysis with NaOH in 
methanol/water gave triol 101 which bears the same trans-relationship between the amine moiety 
and the neighbouring homoallylic hydroxyl group as seen in kirkamide. A halogen exchange reaction 
was then applied to compound 101 and so affording alkenyl iodide 102 that served as the substrate 
for carbopalladation reactions.  
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Scheme 17: Synthesis of Alkenyl Iodide 102 from cis-Dihydrocatechol 62  
Compound 102 was also synthesized in a more direct manner from the cis-dihydrocatechol 103 
(Figure 5). However, while compound ent-62 is known, congener ent-103 is not. As such, only 
synthetic sequences starting from the bromo-compound 62 can be used to produce the 
enantiomeric forms of the targeted kirkamide analogues. 
 
Figure 5: cis-Dihydrocatechol 103 
Compound 102 was engaged in two carbopalladation reactions (Scheme 18) and thereby affording 
the C7N-aminocyclitols 104 and 105. Furthermore, upon treating compound 105 with freshly 
prepared sodium naphthalenide, tandem deoxygenation and double bond migration reactions 
occurred and so affording compound 106 in high yield.    
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Scheme 18: Synthesis of New C7N-Aminocyclitol Derivatives 104, 105 and 106 from Iodoalkenyl 102 
The three new aminocyclitols 104, 105 and 106 thus obtained have the potential to serve as 
precursors to a diverse range of aminocarbasugars. Compounds 104 and 105 can also be regarded as 
precursors to ent-kirkamide (ent-86) (Figure 6). 
 
Figure 6: ent-Kirkamide (ent-86) 
 
Publication 6. Chemical syntheses of the cochliomycins and certain related resorcylic acid lactones 
Small molecule natural products (SMNPs) are often utilized as therapeutic agents, as precursors to 
these or as an inspiration for them.22 Among SMNPs the resorcylic acid lactones (RALs) are notable 
for the diversity of their biological activities, their unique structural features and their frequent 
occurrence among fungal metabolites.23 This article reviews synthetic studies on and the biological 
properties of certain resorcylic acid lactones, particularly neocosmosin A (107) and the 
cochliomycins 108-113 depicted in Figure 7. A specific focus of this review article is on the total 
synthesis of several cochliomycins completed by the Banwell group, as well as the establishment of 
the correct absolute stereochemistry of neocosmosin A, to which the author of this thesis 
contributed.24  This last compound was isolated from the fungus Neocosmospora sp. (UM-031509)25 
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and is particularly interesting from a medicinal point of view because it shows good binding affinity 
for human opioid receptors.  
 
Figure 7: Structures of Various Cochliomycins 
Scheme 19 shows the total synthesis of cochliomycin C as reported by the Banwell group. This 
synthesis featuring a Stille cross-coupling as a crucial step is another example highlighting the broad 
applicability of cross-coupling reactions for the total synthesis of natural products.  
It begins with an olefin cross metathesis and this is followed by hydrogenation of the newly 
generated olefin 116. A trans-esterification of compound 118 with alcohol 117 followed by 
protection of the newly generated phenol moiety gave intermediate 120. These reactions were 
followed by a Stille cross-coupling process to introduce an allylic alcohol residue with a Loh-type α-
allylation reaction then being used to form the pivotal macrolactone substructure, as seen in 
compound 124, of the target. Finally, deprotection and chlorination of the aryl moiety afforded the 
target compound cochliomycin C 110.   
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Scheme 19: Total Synthesis of Cochliomycin C  
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The Palladium-Catalyzed Ullmann Cross-Coupling Reaction:
A Modern Variant on a Time-Honored Process
Faiyaz Khan, Michael Dlugosch, Xin Liu, and Martin G. Banwell*
Research School of Chemistry, Institute of Advanced Studies, The Australian National University, Canberra, ACT 2601, Australia
CONSPECTUS: Cross-coupling reactions, especially those that are catalyzed by palladium, have revolutionized the way in
which carbon−carbon bonds can be formed. The most commonly deployed variants of such processes are the Suzuki−Miyaura,
Mizoroki−Heck, Stille, and Negishi cross-coupling reactions, and these normally involve the linking of an organohalide or
pseudohalide (such as a triﬂate or nonaﬂate) with an organo-metallic or -metalloid such as an organo-boron, -magnesium, -tin,
or -zinc species. Since the latter type of coupling partner is often prepared from the corresponding halide, methods that allow for
the direct cross-coupling of two distinct halogen-containing compounds would provide valuable and more atom-economical
capacities for the formation of carbon−carbon bonds. While the venerable Ullmann reaction can in principle achieve this, it has
a number of drawbacks, the most signiﬁcant of which is that homocoupling of the reaction partners is a competitive, if not the
dominant, process. Furthermore, such reactions normally occur only under forcing conditions (viz., often at temperatures in
excess of 250 °C). As such, the Ullmann reaction has seen only limited application in this regard, especially as a mid- to late-
stage feature of complex natural product synthesis. This Account details the development of the palladium-catalyzed Ullmann
cross-coupling reaction as a useful method for the assembly of a range of heterocyclic systems relevant to medicinal and/or
natural products chemistry. These couplings normally proceed under relatively mild conditions (<100 °C) over short periods of
time and, usually, to the exclusion of (unwanted) homocoupling events. The keys to success are the appropriate choice of
coupling partners, the form of the copper metal employed, and the choice of reaction solvent.
At the present time, the cross-coupling partners capable of engaging in the title reaction are conﬁned to halogenated and
otherwise electron-deﬁcient arenes and, as complementary reactants, α- or β-halogenated, α,β-unsaturated aldehydes, ketones,
esters, lactones, lactams, and cycloimides. Nitro-substituted (and halogenated) arenes, in particular, serve as eﬀective
participants in these reactions, and the products of their coupling with the above-mentioned carbonyl-containing systems can be
manipulated in a number of diﬀerent ways. Depending on the positional relationship between the nitro and carbonyl groups in
the cross-coupling product, the reduction of the former group, which can be achieved under a range of diﬀerent conditions,
provides, through intramolecular nucleophilic addition reactions, including Schiﬀ base condensations, access to a diverse range
of heterocyclic systems. These include indoles, quinolines, quinolones, isoquinolines, carbazoles, and carbolines. Tandem
variants of such cyclization processes, in which Raney cobalt is used as a catalyst for the chemoselective reduction (by
dihydrogen) of nitro and nitrile groups (but not oleﬁns), allow for the assembly of a range of structurally challenging natural
products, including marinoquinoline A, (±)-1-acetylaspidoalbidine, and (±)-gilbertine.
1. INTRODUCTION
Arguably, carbon−carbon bond formation is the most
important process in organic chemistry, and the development
of means for doing so has been a source of conscious eﬀort for
almost two centuries.1 In modern times, cross-coupling
reactions, perhaps most especially those catalyzed by
palladium, nickel, copper, and iron species, have revolutionized
the way in which more complex organic compounds are
assembled from simpler ones.2 Named reactions such as the
Suzuki−Miyaura, Mizoroki−Heck, Stille, Sonogashira, and
Negishi cross-couplings immediately spring to mind in
considering such matters.2a The coupling partners involved
in these processes are normally an organohalide or
pseudohalide (e.g., a triﬂate or nonaﬂate) and an organo-
metallic species that is, more often than not, obtained from a
halide precursor. In view of this and the frequently unstable/
sensitive nature of the organometallic species, there have been
many eﬀorts directed at eﬀecting the reductive cross-coupling
of two structurally distinct organohalides, the most con-
spicuous examples of which involve adaptations of the
venerable Wurtz1 and Ullmann3 reactions. In their traditional
forms, however, these processes have not found extensive
application because of competition from homocoupling
reactions and/or the need to use rather aggressive reaction
conditions that are incompatible with other functionalities
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present in the substrates. In recent times, so-called cross-
electrophile couplings (XECs), especially ones carried out in
reductive mode and often involving multimetallic catalysts,
have come to the fore, with notable contributions having been
reported in the past few years by various groups.4 The
versatility of such processes is quickly becoming apparent.
Herein we detail the outcomes of our own ongoing work
concerned with the development of the palladium-catalyzed
Ullmann cross-coupling reaction of structurally distinct, sp2-
hybridized, halogen-associated electrophiles with one anoth-
er.5,6 These reactions enable the construction of products that
are useful in their own right and/or can participate in reductive
cyclization reactions and thus aﬀording various heterocyclic
motifs encountered in a range of interesting natural products.
2. THE CLASSICAL ULLMANN REACTION
The Ullmann reaction (Scheme 1) was ﬁrst reported in 19013a
and in the intervening period has found extensive application
in chemical synthesis, most notably in the reductive coupling
of aryl halides (e.g., 1) to form the corresponding symmetrical
biaryls (e.g., 2).3,6 Its limitations also became evident rather
quickly. These include the need to use high reaction
temperatures (>200 °C), the attendant functional group
incompatibilities, an inability to cleanly generate unsym-
metrical biaryls from two structurally distinct aryl halide
precursors (because of competing homocoupling processes),
and the frequently erratic yields obtained. Manifold eﬀorts to
redress such deﬁciencies have been undertaken over the years,
including through the application of on-surface processes,3g the
introduction of metal-chelating species,3e and the use of
varying forms of copper as well as other metal species.3,6 These
have had useful impacts, as summarized in a range of recent
review articles.3
3. DISCOVERY OF THE PALLADIUM-CATAYLZED
ULLMANN CROSS-COUPLING REACTION
Some years ago, in connection with work directed toward
establishing a total synthesis of the alkaloid rhazinal,7 a potent
spindle toxin, we required access to an arylated pyrrole. We
initially attempted to prepare this key intermediate through
conventional Ullmann cross-coupling of commercially available
o-bromonitrobenzene (1) with the known iodinated pyrrole 3
(see Scheme 2), but only traces of target 4 were obtained.
Upon undertaking an extensive literature survey, we came
across the work of Thompson8 and Shimizu,9 both of whom
reported that the synthesis of certain arylated pyridines
through the Ullmann cross-coupling of the relevant aryl halide
and halogenated pyridine is greatly facilitated by the addition
of a palladium catalyst. Upon applying such observations to
our system,7 using DMF as solvent and three equivalents of
compound 1, we were able to obtain, under ultrasonication
conditions, target 4 in 88% yield (based on recovered starting
material (brsm)), with the major byproduct being 2,2′-
dinitrobiphenyl (2) (55%) (Scheme 2).
These observations triggered extensive studies of the title
process that continue in our group to this day. These studies
have provided, through the reductive cyclization of the initially
formed cross-coupling products, useful new means for the
construction of a wide range of heterocyclic compounds,
including ones embodying previously unreported frameworks.
Details of these processes are presented in the following
sections and categorized according to the heterocyclic
frameworks that are generated.
4. APPLICATION TO THE SYNTHESIS OF
HETEROCYCLES
4.1. Indoles
Our ﬁrst eﬀorts to comprehensively develop the title reaction
involved the cross-coupling of readily available α-halo-enones
and -enals with o-halonitroarenes and the reductive cyclization
of the ensuing α-arylated-enones and -enals to give indoles,
including annulated variants.10 The simple reaction sequences
shown in Scheme 3 serve to highlight the possibilities for the
assembly of such heterocycles, and others have since exploited
these processes in the total synthesis of a range of natural
products.11 Some of our own eﬀorts in this regard are detailed
in the next section.
In the course of optimizing these sorts of cross-coupling
processes, we established that a range of diﬀerent sources of
Pd[0] can be used, that DMSO appears to be the optimal
solvent, that electron-deﬁcient, halogenated arenes are
required, and that a lower reaction temperature leads to a
better ratio of cross-coupling to homocoupling products.
Indeed, in favorable circumstances the cross-coupling reactions
can be conducted at near ambient temperatures and essentially
to the exclusion of the homocoupling process. Thus, a close to
1:1 ratio of coupling partners could often be employed, an
important consideration in exploiting these processes in
complex natural product synthesis, where such transformations
are exploited at a late stage. Mechanistically speaking, we
believe that these couplings proceed as suggested by Shimizu9
Scheme 1. Original (1901) Ullmann Reaction Resulting in
the Reductive Coupling of o-Bromonitrobenzene (1) To
Aﬀord o,o′-Dinitrobiphenyl (2)
Scheme 2. Palladium-Catalyzed Ullmann 1 and 3 Leading to Arylated Pyrrole 4
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(see the penultimate section for details), wherein palladium[0]
oxidatively adds to the α-iodo-enone or -enal and the resulting
palladium[II] complex reacts with the ortho-cuprated nitro-
arene arising from the other coupling partner, thereby
producing a palladated intermediate that undergoes reductive
elimination to deliver the observed product (and, of course,
regenerates the Pd[0] catalyst). The nature of the copper used
in these reactions has some impact on the eﬃciency of the
process, with freshly prepared activated copper12 being
particularly eﬀective though somewhat tedious to prepare.
The simple expedient of adding some sand to the reaction
mixture containing normal copper powder (copper bronze),
and thus continuously generating a fresh metal surface through
abrasion, is an operationally simple means of achieving often
equivalent outcomes. Furthermore, adding small amounts of
cuprous iodide to the starting reaction mixture can enhance
the desired process,11b although the precise origins of this
beneﬁt remain to be fully understood.
Highly functionalized indolic substructures are encountered
in therapeutically signiﬁcant alkaloids such as vincristine
(Scheme 4), and we sought to establish methods for
assembling these using our protocols.13 In a representative
process, α′-carbomethoxylated cycloheptenone 12 was sub-
jected to Pinhey arylation with plumbated indole 13, thereby
aﬀording compound 14, which was itself engaged in a Johnson-
type α-iodination14 reaction to aﬀord iodide 15. The
palladium-catalyzed Ullmann cross-coupling of this last
compound with o-iodonitrobenzene (5) gave product 16,
which upon reductive cyclization aﬀorded bis(indole) 17
embodying key structural elements associated with the
“Southern” hemisphere of vincristine.
Scheme 3. Palladium-Catalyzed Ullmann Cross-Coupling/Reductive Cyclization Sequences Leading to Indoles 8 and 11
Scheme 4. Synthetic Sequence Leading to Bis(indole) 17 Resembling the Southern Hemisphere of Vincristine
Scheme 5. Palladium-Catalyzed Ullmann Cross-Coupling/Reductive Cyclization Sequence Leading to Oxindole 20
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4.2. Oxindoles
Oxindoles, which represent privileged structures in medicinal
chemistry and motifs encountered in biologically active natural
products,15 are readily obtained using analogous processes
wherein an α-brominated α,β-unsaturated cycloimide, lactam,
or lactone is used as the coupling partner in a reaction with an
o-halonitroarene and the product of this process then subjected
to reductive cyclization.15 The eﬃcient 5 and 18 (Scheme 5)
to produce arylated N-methylmaleimide 19 followed by its
reductive cyclization under standard conditions to give
oxindole 20 is illustrative of these types of processes.
4.3. Quinolines and Related Heterocycles
A further extension of our original processes, as shown in
Scheme 3, has allowed the formation of quinolones and related
systems. In such cases (Scheme 6), the electrophiles employed
are β-halo-enals, -enones, or -esters. So, for example, the cross-
coupling of arene 2 with aldehyde 21 aﬀords arylated enal 22,
which, upon reductive cyclization, produces cyclopenta-
annulated quinolone 23. In a related but less eﬃcient manner,
cross-coupling of compounds 2 and 24 aﬀords ester 25 which
upon reductive cyclization delivers the 2-quinolone 26. By
similar means a range of alternately substituted/annulated
quinolones, phenanthridines, and 6(5H)-phenanthridinones
can be obtained. The capacity to generate electrophiles such as
21 directly from the corresponding ketone (in this case
cyclopentenone) through a Vilsmeier−Haack haloformylation
reaction is likely to enhance the utility of these processes.16
4.4. Carbazoles
When α-iodocyclohex-2-en-1-ones are cross-coupled with
halogenated nitroarenes such as 1 and 5 using the protocols
detailed above and the aryl enone products are subjected to
reductive cyclization, tetrahydrocarbazoles are obtained. Given
Scheme 6. Palladium-Catalyzed Ullmann Cross-Coupling/Reductive Cyclization Sequences Leading to Quinoline 23 and
Quinolone 26
Scheme 7. Synthetic Routes to the Carbazole Natural Products Clauszoline K (32) and Karapinchamine A (34)
Accounts of Chemical Research Article
DOI: 10.1021/acs.accounts.8b00169
Acc. Chem. Res. 2018, 51, 1784−1795
1787
27
that their fully aromatic counterparts (viz., carbazoles) are
encountered in a wide range of biologically active natural
products, we sought to produce such heterocycles using
variations of our earlier protocols. The routes to clauszoline K
and karapinchamine A shown in Scheme 7 are illustrative of
the possibilities the title reaction oﬀers in this regard.17 Thus,
reductive cross-coupling of electrophiles 27 and 28 under our
now standard conditions aﬀorded product 29 (80%), which
upon reductive cyclization using dihydrogen in the presence of
Raney nickel aﬀorded tetrahydrocarbazole 30 (65%). This
could then be oxidized to its fully aromatic counterpart,
namely carbazole 31 (88%), upon exposure to 10% Pd on C in
diphenyl ether at 210 °C (various attempts to eﬀect the
conversion 29 → 31 in a direct manner, or at least in a one-
pot-process, have been unsuccessful to date). Upon exposure
of compound 31 to 2,3-dichloro-5,6-dicyano-1,4-benzoqui-
none (DDQ) it was oxidized, in 66% yield, to the natural
product clauszoline K (32). On the other hand, treatment of
compound 31 with BBr3 eﬀected cleavage of the associated
ether residue and, thereby, the formation of the anticipated
phenolic product 33 (84%). Deprotonation of the latter
compound with n-butyllithium and reaction of the ensuing
anion with geranyl bromide resulted in alkylation at nitrogen
and the formation of the carbazole-containing natural product
karapinchamine A (34), which was obtained in 50% yield.
4.5. Carbolines
There are four isomeric carbolines, namely, the α, β, γ, and δ
forms (35−38, respectively; Figure 1), and each of these
frameworks is encountered in both natural products and
pharmacologically active agents.18 While various methods have
been developed for their synthesis, a uniﬁed approach to them
had remained elusive until our recent deployment of the title
cross-coupling reaction for this purpose.18
An illustrative example of our approach is presented in
Scheme 8. It starts with the palladium-catalyzed Ullmann
cross-coupling of bromonitropyridine 39 with readily available
α-iodinated cyclohexenone 40. Engaging the ensuing product
41 (80%) in a reductive cyclization reaction gives tetrahy-
drocarboline 42 (83%), which is then dehydrogenated to give
the fully aromatic compound 43 (83%) representing the
structure of the natural product harman.18
The challenge associated with deploying this type of
approach to the carbolines is the need to construct the
requisite polysubstituted pyridine-based coupling partner.
Thus, for example, the nitration reaction associated with the
synthetic sequence leading to compound 39 also produced a
regioisomer, and these could only be separated from one
another by HPLC techniques.18
4.6. β-Haloenones and Related Compounds as
Cross-Coupling Partners
Recently we have established that β-haloenones such as 44
couple particularly eﬀectively with electrophiles including 5
(Scheme 9) to form the anticipated cross-coupling product 45
(91%), a compound that upon exposure to standard reductive
cyclization conditions using methanol as the solvent aﬀords
3,4-benzomorphan 46 in 73% yield.19 In a further illustration
of the extensive utility of these types of processes, the coupling
of brominated pyridine 47 with the β-iodinated crontonate 48
proceeded with retention of conﬁguration and aﬀorded the
anticipated product 49 (84%). Reductive cyclization of this last
compound using iron ﬁlings in an acidic medium then gave the
1,8-naphthyridin-2(1H)-one 50 (76%). Interestingly, o-iodo-
benzonitriles can be engaged in related couplings,19 although
these are less eﬃcient than those involving iodinated
nitroarenes, presumably because of the weaker electron-
withdrawing properties of the cyano group.
4.7. Formation of Unsymmetrical Biaryls
An obvious application of the title reaction is in the production
of unsymmetrical biaryls. While we have yet to explore such
processes in any comprehensive fashion, early indications have
been very positive. Thus, as shown in Scheme 10 for example,
the cross-coupling of aryl iodide 51 with bromide 52 under our
by now standard conditions provided the desired biaryl 53
(60%).20 This last compound was readily elaborated to the
alkaloid zephycandidine III, a natural product reported to
possess acetylcholinesterase (AChE) inhibitory properties,20
which were not evident in the synthetically derived material
despite the spectroscopic equivalence of the natural and
synthetic materials. More pertinent to the present discussion is
that all our attempts to prepare compound 53 and related
systems using Suzuki−Miyaura cross-coupling reactions were
unsuccessful.20
5. APPLICATION TO THE TOTAL SYNTHESIS OF
NATURAL PRODUCTS
As our understanding of the palladium-catalyzed Ullmann
cross-coupling reaction has developed, we have been exploiting
it on an increasingly frequent basis in developing syntheses of
various natural products. Such is our conﬁdence in the
reliability of the process that we have often deployed it at
relatively advanced stages of synthetic pathways, normally in
Figure 1. The four isomeric carbolines.
Scheme 8. Synthetic Route to the Carboline Natural
Product Harman (43)
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conjunction with reductive cyclization reactions that enable the
conversion of the cross-coupling products into various
heterocyclic frameworks. Speciﬁc examples are given in the
following sections.
5.1. Synthesis of Marinoquinoline A
As part of an ongoing interest in the cross-coupling chemistries
of pyrroles,21 we were attracted to the development of a
synthesis of marinoquinoline A, an alkaloid isolated from a
marine gliding bacterium that displays AChE inhibitory22 and
antimalarial activities. The route that we ultimately established
in obtaining this compound is shown in Scheme 11. It starts
with the palladium-catalyzed Ullmann cross-coupling of o-
bromonitrobenzene (1) with iodinated pyrrole 54 to aﬀord the
target 55 in 74% yield. Signiﬁcantly, all of our attempts to
eﬀect the Suzuki−Miyaura cross-coupling of compound 54
with o-nitrophenylboronic acid failed.22 In a related vein, when
o-iodonitrobenzene (5) was used as a coupling partner in this
process, its homocoupling (to give 2,2′-dinitrobiphenyl)
became the dominant process. Such outcomes highlight the
capacity to facilitate cross-coupling processes by attenuating
the reactivity of one substrate through changing the associated
halogen.
The elaboration of coupling product 55 to the target alkaloid
was straightforward and involved the initial addition of
methyllithium to the associated aldehyde residue and oxidation
of the resulting alcohol, 56, to the corresponding methyl
ketone 57 using the Dess−Martin periodinane (DMP).
Reductive cyclization of this last compound to the target
framework was eﬀected using magnesium in methanol, and this
was accompanied by cleavage of the tosyl group, thus aﬀording
marinoquinoline A (58) in 85% yield.
5.2. Total Syntheses of the Aspidosperma Alkaloids
Aspidospermidine, Limaspermidine, and
1-Acetylaspidoalbidine and Approaches to Vindoline
In a more elaborate reaction sequence and as part of an
ongoing campaign to develop a synthesis of the binary indole−
indoline alkaloid vincristine (see Scheme 4), we ﬁrst developed
a route to the alkaloid aspidospermidine.23 This entailed, as
one of two key steps, the cross-coupling of α-iodinated
cyclohexenone 59 with arene 5 to aﬀord product 60 in 75%
yield (Scheme 12). Compound 60 was readily elaborated to
azide 61 that upon heating engaged in an intramolecular [3 +
2] cycloaddition reaction followed by nitrogen extrusion to
aﬀord aziridine 62, thereby establishing the piperidine ring
associated with the ﬁnal product. Various straightforward steps,
including a TiCl3-mediated reductive cyclization reaction, were
Scheme 9. Palladium-Catalyzed Ullmann Cross-Coupling/Reductive Cyclization Sequences Leading to Heterocycles 46 and 50
Scheme 10. Palladium-Catalyzed Ullmann Cross-Coupling of Halogenated Arenes 51 and 52 Leading to Biaryl 53, a Precursor
the Alkaloid Zephycandidine III
Scheme 11. Total Synthesis of Marinoquinoline A
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then deployed in elaborating compound 62 to aspidospermi-
dine.
A related but more convergent protocol was employed in
obtaining the alkaloid limaspermidine.24 As shown in Scheme
13, compounds 5 and 63 were cross-coupled to give the α-
arylated enone 64 (85%). When this was subjected to
reductive cyclization using dihydrogen in the presence of
Raney cobalt, the indole-annulated and cis ring-fused
octahydroquinoline 65 was obtained in 85% yield. This
conversion involves the selective reduction of the nitro and
cyano groups within substrate 64 while the enone moiety
remains intact. As a result, the associated ketone carbonyl
engages in an intramolecular Schiﬀ base condensation reaction
with the aniline or N-hydroxyaniline arising from reduction of
the nitro group while the 1° amine arising from the cyano
residue undergoes a hetero-Michael addition reaction, thus
forming both the indole and piperidine rings in a one-pot
operation. The use of properly prepared Raney cobalt25 is
critical to the success of this transformation because of the
chemoselectivities it allows for. If the more active Raney nickel
is used as the catalyst, then reduction of the carbon−carbon
double bond of the enone residue also occurs, with the result
that piperidine ring formation does not take place.24
Elaboration of compound 65 to (±)-limaspermidine was
achieved over four additional steps, including several closely
related to those employed in the conversion of compound 62
into (±)-apsidospermidine (Scheme 12). Two additional
steps, including an oxidative cyclization reaction employing
mercuric acetate, were required to convert (±)-limaspermidine
into (±)-1-acetylaspidoalbidine.24
The extension of the protocols deﬁned above in an
enantioselective approach to the alkaloid vindoline (represent-
ing a crucial substructure of vincristine) is shown in Scheme
14.26 Cross-coupling of iodinated nitroarene 66 with
homochiral α-iodinated cyclohexenone 67 (a compound
obtained from an enzymatically derived cis-1,2-dihydrocate-
chol27) gave the anticipated product 68 in 92% yield.
Reduction of this last compound using dihydrogen in the
presence of Raney cobalt resulted in the formation of the
tandem reductive cyclization product 69 (85%) embodying a
cis ring-fused octahydroquinoline. Over a further four steps
this could be elaborated to the hexacyclic compound 70
embodying many of the features of vindoline, which we are
seeking to convert into that alkaloid.
5.3. Formal Total Synthesis of the Cage-like Alkaloid
Kopsihainanine A
The tandem reductive cyclizations of the palladium-catalyzed
Ullmann cross-coupling products 64 and 68 are presumed to
proceed under kinetic control, thus aﬀording cis ring-fused
products. Given that trans ring-fused perhydroquinolines are
encountered in a range of natural products, we sought methods
to access such systems. Despite extensive investigations of the
cyclization reactions, including examination of a range of
modiﬁcations to the conditions employed, the cis ring-fused
products were invariably formed on an exclusive basis.
Scheme 12. Total Synthesis of (±)-Aspidospermidine
Scheme 13. Total Syntheses of (±)-Limaspermidine and (±)-1-Acetylaspidoalbidine
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Therefore, we sought ways to eﬀect epimerization at the ring-
junction carbon center bearing the piperidine nitrogen. This
turned out to be a straightforward process, as illustrated in our
formal total synthesis of the cage-like alkaloid kopsihainanine A
(Scheme 15).28 The reductive cyclization product 65 could be
converted, over ﬁve steps, into the angularly allylated congener
71, which upon exposure to iodosobenzene in dichloro-
methane at ambient temperatures was oxidized to the
corresponding imine 72. Upon reduction of compound 72
with sodium borohydride, the epimeric octahydroquinoline 73
was obtained. Since this last compound has previously been
converted into kopsihainanine A, the illustrated synthetic
sequence constitutes a formal total synthesis of the racemic
modiﬁcation of this alkaloid.
5.4. Syntheses of the Uleine Alkaloids and Approaches to
the Strychnos Alkaloids
Another cross-coupling/tandem reductive cyclization se-
quence, shown in Scheme 16, has allowed syntheses of various
members of the uleine family of alkaloids.29 Cross-coupling of
compounds 5 and 74 under the usual conditions aﬀorded the
anticipated product 75 (88%), and the reductive cyclization of
this with dihydrogen in the presence of Raney cobalt aﬀorded
the tetracyclic product 76 (60%) as a result of the same type of
tandem processes as shown in Schemes 13 and 14. Selective
Boc protection of the piperidine nitrogen within compound 76
aﬀorded carbamate 77, and this could be elaborated over two
steps, including a pyridinium chlorochromate-mediated
oxidation reaction to introduce a carbonyl moiety at the
methylene adjacent to the indole ring, to hydroxyketone 78.
Reaction of this last compound with methyllithium proceeded
smoothly, and the resulting tertiary alcohol engaged in a
cycloetheriﬁcation reaction upon treatment with protic acid.
Cleavage of the Boc group also occurred under these
conditions, and the resulting 2° amine was subjected to
reductive N-methylation to aﬀord (±)-gilbertine.29a
By means of closely related protocols, the somewhat simpler
uleine alkaloids shown in Figure 2 could also be prepared in a
Scheme 14. Synthesis of Compound 70, an Analogue of the Alkaloid Vindoline
Scheme 15. Conversion of cis Ring-Fused Octahydroquinoline 65 into Its trans-Conﬁgured Congener 73, an Advanced
Precursor to the Alkaloid Kopsihainanine A
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stereoselective manner,29b while the ABCDE ring system of the
Strychnos alkaloids proved accessible by similar means.30
6. MECHANISTIC AND SYNTHETIC OVERVIEW
Our current thinking about the title process is dominated by
the original mechanistic proposals of Shimizu.9 Thus, as shown
in Scheme 17, aryl iodide 79 is presumed to react with the
added copper through an oxidative addition/reductive
deiodination process to give arylcopper(I) 80, representing
the aryl anion synthon 81. This reacts with the aryl cation
synthon 82, which is produced through oxidative addition of
Pd[0] to the carbonyl-containing coupling partner 83, thus
aﬀording intermediate 84. The coupling event presumably
Scheme 16. Total Synthesis of the Alkaloid (±)-Gilbertine
Figure 2. Structures of the simpler uleine alkaloids.
Scheme 17. Mechanistic and Synthetic Analysis of a Key Example of the Palladium-Catalyzed Ullmann Cross-Coupling
Reaction and Certain Currently Problematic Substrates
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involves nucleophilic substitution at the palladium of
intermediate 84 by organometallic 80, and after reductive
elimination product 85 is formed. Concurrently, of course, a
Pd[0] species is formed and re-enters the catalytic cycle.
Presumably, analogous pathways are involved in the potentially
broadly applicable couplings shown in Schemes 9 and 10.
Currently problematic substrates are also shown in Scheme 17.
While the majority of the title cross-coupling reactions we
have studied to date are of the general form shown in Scheme
17, their utility is considerable because of the diﬀering modes
of reductive cyclization12,31,32 that can be applied to the
products 85. Thus, as demonstrated in the multitude of
settings presented above, when such products incorporate a
nitro group, cyclizations using dihydrogen in the presence of
various catalysts provide a range of indoles of the general form
86. Using TiCl3
13 or iron ﬁlings in acidic media33 for the same
purpose provides alternate cyclization products, while recent
but thus far unpublished work has shown that certain nitrile-
containing coupling products 85 (X = CN) can be converted
into isoquinolines of the general form 87.
It remains to be seen precisely how far palladium-catalyzed
Ullmann cross-coupling reactions can be extended beyond
those involving substrates incorporating the strongly electron-
withdrawing nitro and nitrile groups. Therefore, one of the
challenges in this regard will be deﬁning, if possible, how to
engage more electron-rich coupling partners in analogous
reactions.
7. FUTURE PROSPECTS
As is the case with other emergent XEC processes,4 the title
one is proving eﬀective in a range of settings, most particularly
when combined with reductive cyclization reactions that
thereby aﬀord heterocyclic compounds. Investigations of
intramolecular variants of the title XECs are also likely to be
proﬁtable areas of research. Furthermore, our recent
discovery19 that o-halobenzonitriles are also capable of
engaging in palladium-catalyzed Ulllmann cross-coupling
reactions suggests that access to other types of heterocyclic
systems (e.g., 87) will become available through the reductive
cyclization of such products. Of course, the development of a
more detailed mechanistic understanding of the palladium-
catalyzed Ullmann cross-coupling reaction, including the role
of additives such as cuprous iodide, will provide an important
basis for further developments in the area.
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Palladium-Catalyzed Ullmann Cross-Coupling of β‑Iodoenones and
β‑Iodoacrylates with o‑Halonitroarenes or o‑Iodobenzonitriles and
Reductive Cyclization of the Resulting Products To Give Diverse
Heterocyclic Systems
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ABSTRACT: The palladium-catalyzed Ullmann cross-coupling of β-iodoenones and β-iodoacrylates such as 5 (X = I) with o-
halonitroarenes and o-iodobenzonitriles including 2 aﬀords products such as compound 7. These can be engaged in a range of
reductive cyclization reactions leading to heterocyclic frameworks such as 3,4-benzomorphan derivative 43.
Some time ago, we described1 the palladium-catalyzedUllmann cross-coupling of α-iodinated α,β-unsaturated
ketones and related compounds with o-halonitroarenes, thus
providing the corresponding α-arylated enones. The conversion
1 + 2 → 3 shown in Scheme 1 is representative of such cross-
electrophile couplings,2 which are generally high-yielding and
proceed under mild conditions. Furthermore, coupling
products such as 3 can be reductively cyclized to give, for
example, tetrahydrocarbazole 4 in high yield.
In the intervening period, we have extended these protocols
to the preparation of quinolones, 2-quinolones, phenanthri-
dines, 6(5H)-phenanthridinones, oxindoles, carbazoles, and
carbolines.3 In addition, we have been able to apply them in the
total synthesis of a range of natural products and various
analogues.4 A number of other groups have also employed
these protocols in the synthesis of various biologically active
systems.5
We now report on the eﬀective participation of β-iodinated
α,β-unsaturated ketones and acrylates in related processes that
have provided a means for the rapid construction of a diverse
range of novel heterocyclic systems. As shown in Scheme 2, our
initial studies involved an examination of the cross-coupling of
readily available β-halo-2-cyclohexen-1-ones 5 (X = Br, I)6 with
o-halonitrobenzene 2 or 6 in anticipation of forming β-arylated
2-cyclohexen-1-one 7.
Products of this type, which have been prepared previously
by less direct methods,7 were targeted because they have been
Received: March 30, 2018
Published: April 20, 2018
Scheme 1. Previously Reported1 Palladium-Catalyzed
Ullmann Cross-Coupling of Compounds 1 and 2 and
Reductive Cyclization of Product 3 Leading to Indole 4
Scheme 2. Palladium-Catalyzed Ullmann Cross-Coupling of
β-Halo-2-cyclohexen-1-ones 5 with o-Halonitrobenzene 2 or
6 To Form β-Arylated 2-Cyclohexen-1-one 7
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shown to engage in eﬃcient reductive cyclization reactions to
form carbazolones, including one that has served as a precursor
to the carbazole alkaloid clausenalene.7b A series of cross-
coupling experiments involving both the brominated and
iodinated forms of the coupling partners, viz. compounds 2,
5 and 6, were examined, as were various coupling conditions.
The outcomes of these trials established that the best coupling
partners were the iodides. Thus, when these were used in
conjunction with 5 equiv of copper powder, 5 mol %
Pd(dppf)Cl2·CH2Cl2, and DMSO as the solvent, the reaction
proceeded at 50 °C in 16 h to give compound 7 in 91% yield.
The structure of compound 7 was conﬁrmed by single-crystal
X-ray analysis, details of which are provided in the Supporting
Information (SI). Cross-couplings involving 5 (X = Br) and 2
or 5 (X = I) and 6 required heating to 80 °C and produced
compound 7 in 75% and 83% yield, respectively, while the
reaction of bromides 5 (X = Br) and 6 under the same
conditions gave product 7 in 79% yield. Attempts were made to
eﬀect a carbonylative cross-coupling of the iodinated reaction
partners by carrying out the reaction under a carbon monoxide
atmosphere, but only product 7 (75%) was obtained. None of
the hoped-for diketone was observed.
Encouraged by these results, we sought to extend them to
the preparation of various related systems. For example, the
readily prepared6 β-iodinated 2-cyclopenten-1-ones 8 and 9
(Figure 1) also engaged in cross-coupling reactions with
compound 2 to give the anticipated products 10 (93%) and 11
(49%), respectively. Each of these was fully characterized by the
usual range of spectroscopic methods. In a similar manner,
bromonitropyridines 12,3e 13,3e and 143e were cross-coupled
with enone 5 (X = I) to aﬀord β-arylated enones 15 (69%), 16
(91%), and 17 (89%), respectively. β-Iodoalkenones incorpo-
rating an exocyclic oleﬁnic residue also participate in these same
types of reactions, as evidenced by the successful cross-coupling
of the readily available substrate 186 with arene 13 to give
compound 19 (87%), the structure of which was conﬁrmed by
X-ray analysis (see the SI).
o-Iodobenzonitriles also cross-couple with β-iodoenones, as
demonstrated by the successful reaction of the easily accessible8
compounds 20, 21, 22, and 23 (Figure 2) with 5 (X = I) to give
products 24 (40%), 25 (61%), 26 (34%), and 27 (79%),
respectively. The poorer yields associated with these o-
iodobenzonitrile-based couplings are attributed to the weaker
electron-withdrawing capacities of the nitrile group compared
with the nitro group and, therefore, the intervention of
competing homocouplings of the reaction partners.
β-Iodinated acrylates proved to be generally competent
partners in palladium-catalyzed Ullmann cross-couplings with
o-iodonitrobenzenes and o-iodobenzonitriles. For example,
when methyl (Z)-3-iodobut-2-enoate (28)9 (Figure 3) was
reacted with compounds 13, 14, 20, 23, and 2910 under the
usual conditions, the cross-coupling products 30 (84%), 31
(69%), 32 (55%), 33 (43%), and 34 (59%), respectively, were
obtained.
Ethyl β-iodocinnamate (35)9 (Figure 4) behaved in a similar
fashion. Thus, cross-coupling of this compound with o-
iodonitrobenzene (2) aﬀorded product 3611 (61%), while
coupling of compounds 15 and 35 gave ester 37 (50%). The
Figure 1. Substrates 8, 9, 12−14, and 18 and the cross-coupling
products 10, 11, 15−17, and 19.
Figure 2. o-Iodobenzonitriles 20−23 and the products 24−27 arising
from their cross-coupling with 5 (X = I).
Figure 3. β-Iodoacrylate 28 and the products 30−34 arising from its
cross-coupling with o-iodonitroarenes and o-iodobenzonitriles.
Figure 4. β-Iodocinnamate 35 and the products 36−38 arising from
its cross-coupling with certain o-halonitroarenes.
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analogous reaction of substrates 16 and 35 gave ester 38
(81%).
Many of the cross-coupling products described above engage
in useful reductive cyclization processes, thus giving rise, in a
direct manner, to heterocyclic frameworks of synthetic and/or
biological relevance. For example, upon exposure of an
ethanolic solution of coupling product 30 (Scheme 3) to iron
ﬁlings in the presence of acetic and hydrochloric acid then
reduction of the nitro group occurred and the product aniline
underwent spontaneous cyclization onto the pendant ester
residue, thus forming 8-azaquinolone 3912 in 76% yield.
Under analogous conditions, cinnamate 36 was converted
into quinolone 4013 (67%) while when the same substrate was
exposed to hydrogen in the presence of 10% palladium on
carbon more extensive reduction occurred to aﬀord dihy-
droquinolone 4114 (85%). Given the ease of formation of the
substrates through the title cross-coupling reactions, these
conversions provide especially concise routes to quinolones and
their 8-aza analogues, classes of compounds that have attracted
considerable attention because of, inter alia, their enzyme-
inhibiting and DNA-intercalating properties.13−15 1,8-Napthyr-
idines, another medicinally signiﬁcant class of compound,16 are
also available via related protocols, as highlighted by the
conversion 19→ 42 shown in Scheme 3. This proceeds in 74%
yield when a mixture of iron powder and calcium chloride in
ethanol is used as the reducing medium and a basic workup is
employed.
Quite distinct reductive cyclization processes are observed
when the β-aryl-2-cycloalken-1-one coupling products are
employed as substrates. Thus, as shown in Scheme 4, exposure
of a methanolic solution of compound 7 to hydrogen in the
presence of Pd on C aﬀorded 3,4-benzomorphan 43 (73%),
while analogous treatment of a toluene solution of the same
substrate aﬀorded compound 4417 (64%) bearing a bridgehead
hydroxyl group. In a similar manner, a methanolic solution of
cross-coupling product 10 was converted into B-norbenzomor-
phan 45 (43%). The structures of compounds 43 and 45 were
conﬁrmed through X-ray analyses, details of which are provided
in the SI.
Deoxygenated variants of compounds 43−45 were readily
prepared by the pathways shown in Scheme 5. Thus, Luche-
type reductions of compounds 7 and 10 aﬀorded the
corresponding allylic alcohols 46 (96%) and 47 (67%),
respectively. These 1,2-reduction products underwent catalytic
hydrogenation (and accompanying hydrogenolysis of the nitro
group) in ethyl acetate to give saturated amino alcohols 48
(75% yield of a 5:3 mixture of cis and trans isomers) and 49
(51% yield of the cis isomer only), respectively. The twofold
reduction products 48 and 49 were then converted, under
standard conditions, into the corresponding sulfonamides 50
(82% yield of a 5:3 mixture of cis and trans isomers) and 51
(85% yield of the cis isomer only). Compound trans-50, for
which a single-crystal X-ray analysis was obtained (see the SI
for details), readily engaged in a Mitsunobu cyclization reaction
upon exposure to Ph3P/diethyl azodicarboxylate (DEAD),
aﬀording 3,4-benzomorphan 52 (89%). Unsurprisingly, the
congener cis-50 failed to cyclize under these same conditions.
On the other hand, successive treatment of compound cis-51
under Appel conditions using CCl4 and Ph3P gave what is
presumed to be the corresponding trans-chloride, which upon
Scheme 3. Reductive Cyclization of Cross-Coupling
Products 30, 36, and 19 Leading to Heterocycles 39−42
Scheme 4. Reductive Cyclization of Cross-Coupling
Products 7 and 10 Leading to Heterocycles 43−45
Scheme 5. Conversion of Cross-Coupling Products 7 and 10
into Bridged Heterocyclic Compounds 52 and 53
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treatment with potassium carbonate in methanol cyclized to
give norbenzomorphan 53 in 86% yield.
Presumably, these protocols could be readily adapted to the
preparation of the nonracemic forms of these heterocycles
through, for example, enantioselective 1,2-reduction of the
starting enones 7 and 10. In view of the extensive and ongoing
interest in benzomorphans and related systems,18 the processes
outlined in Schemes 4 and 5 should be of considerable utility in
a range of settings.
The possibilities for reductive cyclization of the above-
mentioned cross-coupling products extend beyond those
delineated above, as evidenced by, for example, the report11
that compound 36 (prepared by diﬀerent means than those
described here) can be engaged in a Cadogan cyclization to give
2-carboethoxy-3-phenylindole in 90% yield. As such, the work
detailed above serves to highlight the capacities of the title
cross-electrophile coupling reactions to deliver a wide range of
products capable of engaging in various useful reductive
cyclization processes, thus forming new or otherwise diﬃcult-
to-access heterocyclic systems.
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(9) Akpinar, G. E.; Kus, M.; Ucüncü, M.; Karakus, E.; Artok, L. Org.
Lett. 2011, 13, 748.
(10) Krizan, T. D.; Martin, J. C. J. Org. Chem. 1982, 47, 2681.
(11) Yamamoto, Y.; Yamada, S.; Nishiyama, H. Adv. Synth. Catal.
2011, 353, 701.
(12) Chunavala, K. C.; Adimurthy, S. Synth. Commun. 2011, 41,
1843.
(13) Han, J.; Wu, X.; Zhang, Z.; Wang, L. Tetrahedron Lett. 2017, 58,
3433.
(14) Linsenmeier, A. M.; Braje, W. M. Tetrahedron 2015, 71, 6913.
(15) For example, see: Poppe, L.; Tegley, C. M.; Li, V.; Lewis, J.;
Zondlo, J.; Yang, E.; Kurzeja, R. J. M.; Syed, R. J. Am. Chem. Soc. 2009,
131, 16654.
(16) Madaan, A.; Verma, R.; Kumar, V.; Singh, A. T.; Jain, S. K.;
Jaggi, M. Arch. Pharm. 2015, 348, 837.
(17) Reisman, S. E.; Ready, J. M.; Weiss, M. M.; Hasuoka, A.; Hirata,
M.; Tamaki, K.; Ovaska, T. V.; Smith, C. J.; Wood, J. L. J. Am. Chem.
Soc. 2008, 130, 2087.
(18) Li, Y.; Feng, C.; Shi, H.; Xu, X. Org. Lett. 2016, 18, 324.
Organic Letters Letter
DOI: 10.1021/acs.orglett.8b01015
Org. Lett. 2018, 20, 2770−2773
2773
39
! S1 
Supporting Information for: 
 
Palladium-Catalyzed Ullmann Cross-Coupling of β-Iodoenones and  
β-Iodoacrylates with o-Halonitroarenes or o-Iodobenzonitriles and the Reductive 
Cyclization of the Resulting Products to Give Diverse Heterocyclic Systems  
 
Faiyaz Khan, Michael Dlugosch, Xin Liu, Marium Khan, 
 Martin G. Banwell* Jas S. Ward and Paul Carr 
 
Research School of Chemistry, Institute of Advanced Studies 
The Australian National University, Canberra, ACT 2601, Australia 
 
CONTENTS PAGE 
 
General Experimental Protocols         S2 
Specific Chemical Transformations         S3 
X-ray Crystallographic Data for Compounds 7, 19, 39, 43, 45 and trans-50   S28 
Figure S1: Anisotropic Displacement Ellipsoid Plot from the Single-crystal X-ray 
Analysis of Compound 7          S29 
Figure S2: Anisotropic Displacement Ellipsoid Plot from the Single-crystal X-ray 
Analysis of Compound 19          S30 
Figure S3: Anisotropic Displacement Ellipsoid Plot from the Single-crystal X-ray 
Analysis of Compound 39          S31 
Figure S4: Anisotropic Displacement Ellipsoid Plot from the Single-crystal X-ray 
Analysis of Compound 43          S32 
Figure S5: Anisotropic Displacement Ellipsoid Plot from the Single-crystal X-ray 
Analysis of Compound 45          S33 
Figure S6: Anisotropic Displacement Ellipsoid Plot from the Single-crystal X-ray 
Analysis of Compound trans-50         S34 
References            S35 
1H and 13C NMR Spectra of Compounds 5 (X = I and Br), 7,  
[1,1´-bi(cyclohexane)]-1,1´-diene-3,3´-dione, 8-11, 15-19, 24-27, 30-34, 36-47,  
49, trans-50, cis-50, cis-51, 52, 53 and trans-N-(2-(3-chlorocyclopentyl)phenyl) 
-4-methylbenzenesulfonamide S36 
  
40
! S2 
General Experimental Protocols 
 
Unless otherwise specified, proton (1H) and carbon (13C) NMR spectra were recorded at room 
temperature in base-filtered CDCl3 on a spectrometer operating at 400 MHz for proton and 
100 MHz for carbon nuclei. For 1H NMR spectra, signals arising from the residual protio-
forms of the solvent were used as internal standards. 1H NMR data are recorded as follows: 
chemical shift (δ) [multiplicity, coupling constant(s) J (Hz), relative integral] where 
multiplicity is defined as: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet or 
combinations of the above. The signal due to residual CHCl3 appearing at δH 7.26 and the 
central resonance of the CDCl3 “triplet” appearing at δC 77.0 were used to reference 1H and 
13C NMR spectra, respectively. IR spectra were recorded, using neat samples, on an 
attenuated total reflectance (ATR) infra-red spectrometer. Low-resolution ESI mass spectra 
were recorded on a single quadrupole liquid chromatograph-mass spectrometer, while high-
resolution measurements were conducted on a time-of-flight instrument. Low- and high-
resolution EI mass spectra were recorded on a magnetic-sector machine. Melting points were 
measured on an automated melting point system and are uncorrected. Analytical thin layer 
chromatography (TLC) was performed on aluminum-backed 0.2 mm thick silica gel 60 F254 
plates. Eluted plates were visualized using a 254 nm UV lamp and/or by treatment with a 
suitable dip followed by heating. These dips included phosphomolybdic acid : ceric sulfate : 
sulfuric acid (conc.) : water (37.5 g : 7.5 g : 37.5 g : 720 mL) or potassium permanganate : 
potassium carbonate : 5% sodium hydroxide aqueous solution : water (3 g : 20 g: 5 mL : 300 
mL). Flash chromatographic separations were carried out following protocols defined by Still 
et al.1 with silica gel 60 (40– 63 µm) as the stationary phase and using the AR- or HPLC-
grade solvents indicated. Starting materials, reagents and drying agents as well as other 
inorganic salts were generally available from commercial sources and used as supplied. 
Tetrahydrofuran (THF), diethyl ether, methanol, acetonitrile and dichloromethane were dried 
using a solvent purification system that is based upon a technology originally described by 
Grubbs et al.2 Where necessary, reactions were performed under a nitrogen atmosphere. 
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Specific Chemical Transformations 
Compound 5 (X = I) 
 
 
A magnetically stirred solution of triphenylphosphine (2.89 g, 11.0 mmol) in dry acetonitrile 
(50 mL) maintained at 22 °C was treated, in portions, with powdered molecular iodine (2.79 
g, 11.0 mmol). After 0.5 h the reaction mixture was treated with triethylamine (1.53 mL, 11.0 
mmol) then cyclohexane-1,3-dione (1.12 g, 10.0 mmol) and the resulting mixture heated 
under reflux for 16 h. The cooled reaction mixture was then concentrated under reduced 
pressure and the residue thus obtained stirred vigorously with diethyl ether (30 mL) and the 
supernatant liquid decanted. This process was repeated twice more and the combined organic 
phases then diluted with 40-60 petroleum ether (50 mL) to precipitate triphenylphosphine 
oxide. The ensuing mixture was filtered through a plug of TLC-grade silica gel topped with 
diatomaceous earth and the filtrate concentrated under reduced pressure to afford compound 
5 (X = I) (1.84 g, 83%) as a light-yellow oil. The spectral data obtained on this material 
matched those published in the literature.3 
 
Compound 5 (X = Br) 
 
 
A magnetically stirred solution of triphenylphosphine (4.33 g, 16.5 mmol) in dry acetonitrile 
(75 mL) maintained at 0 °C was treated, dropwise via addition funnel, with a solution of 
molecular bromine (851 µL, 16.5 mmol) in dry acetonitrile (8.25 mL). The resulting mixture 
was then warmed to 22 °C and after 0.5 h it was treated with triethylamine (2.30 mL. 16.5 
mmol) then cyclohexane-1,3-dione (1.68 g, 15.0 mmol) before being stirred at 22 °C for 16 h 
then concentrated under reduced pressure. The residue thus obtained was stirred vigorously 
with diethyl ether (30 mL) and the supernatant liquid decanted. This process was repeated 
twice more and the combined organic phases then diluted with 40-60 petroleum ether (50 
mL) to precipitate triphenylphosphine oxide. The ensuing mixture was filtered through a plug 
of TLC-grade silica gel topped with diatomaceous earth and the filtrate concentrated under 
reduced pressure to afford compound 5 (X = Br) (2.05 g, 78%) as a light-yellow oil. The 
spectral data obtained on this material matched those published in the literature.3 
 
 
 
O
I
5 (X = I)
O
Br
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Compound 7 
 
 
A magnetically stirred suspension of compound 5 (X = I) (222 mg, 1.00 mmol), o-
iodonitrobenzene (2) (498 mg, 2.00 mmol) and copper powder (318 mg, 5.00 mmol) in dry 
DMSO (5 mL) maintained at 50 °C was treated with Pd(dppf)Cl2•CH2Cl2 (41 mg, 0.05 
mmol). After 18 h the reaction mixture was cooled to 22 °C, diluted with ethyl acetate (5 mL) 
and the ensuing mixture filtered through a plug of TLC-grade silica gel topped with 
diatomaceous earth and the solids so retained were washed with ethyl acetate (20 mL). The 
combined filtrates were washed with ammonia (2 x 25 mL of a 5% v/v aqueous solution), 
water (2 x 25 mL) and brine (1 x 25 mL) before being dried (Na2SO4), filtered, then 
concentrated under reduced pressure. The residue so obtained was subjected to flash column 
chromatography (, 1:9 v/v diethyl ether/toluene elution) and thus affording, after 
concentration of the appropriate fractions (Rf = 0.2), compound 74 (198 mg, 91%) as a pale-
yellow, crystalline solid, m.p. = 74 °C. 
1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 7.8 Hz, 1H), 7.67 (t, J = 7.8 Hz, 1H), 7.55 (t, J = 
7.8 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 5.98 (s, 1H), 2.58–2.48 (complex m, 4H), 2.25–2.17 
(complex m, 2H). 
13C NMR (100 MHz, CDCl3) δ 199.0, 160.8, 146.8, 136.7, 134.0, 129.8, 129.7, 127.7, 125.1, 
37.4, 31.0, 23.4. 
IR (ATR) νmax 2938, 2870, 1659, 1521, 1345, 1257, 1190, 959, 895, 856, 788, 742, 703 cm–1. 
MS (ESI, +ve) m/z 240 [(M+Na)+, 100%]. 
HRMS m/z 218.0813 [M+H]+ (calcd for C12H11NO3, 218.08112). 
 
Cross-coupling reactions of compound 5 (X = I) such as the one detailed immediately above 
sometimes delivered small quantities of the corresponding homo-coupling product, viz. [1,1'-
bi(cyclohexane)]-1,1'-diene-3,3'-dione and so an authentic sample of this material was 
produced by the method detailed immediately below. 
    
[1,1'-Bi(cyclohexane)]-1,1'-diene-3,3'-dione 
 
 
 
A magnetically stirred mixture of compound 5 (X = I) (222 mg, 1.00 mmol) and copper 
powder (318 mg, 5.00 mmol) in dry DMSO (5 mL) was heated at 80 °C (41 mg, 0.05 mmol) 
for 22 h then cooled to 22 °C, diluted with ethyl acetate (5 mL) then filtered through a plug of 
O
NO2
7
O
O
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TLC-grade silica gel topped with diatomaceous earth and the solids so retained were washed 
with ethyl acetate (20 mL). The combined filtrates were washed with ammonia (1 x 25 mL of 
a 5% v/v aqueous solution), water (1 x 25 mL) and brine (1 x 25 mL) before being dried 
(Na2SO4), filtered, then concentrated under reduced pressure. The residue thus obtained was 
subjected to flash column chromatography (silica, 2:3 v/v ethyl acetate/40-60 petroleum ether 
elution) and thus affording, after concentration of the appropriate fractions (Rf = 0.2), the title 
compound5 (46 mg, 48%) as a brown powder, m.p. = 104 °C. 
1H NMR (400 MHz, CDCl3) δ 6.29 (s, 2H), 2.52 (td, J = 6.2 and 1.2 Hz, 4H), 2.44 (t, J = 6.2 
Hz, 4H), 2.12–2.02 (complex m, 4H). 
13C NMR (100 MHz, CDCl3) δ 199.8, 156.7, 128.1, 37.6, 26.0, 22.4. 
IR (ATR) νmax 2951, 2881, 1661, 1637, 1575, 1415, 1328, 1263, 1186, 1144, 899, 770 cm–1. 
MS (ESI, +ve) m/z 213 [(M+Na)+, 100%]. 
HRMS m/z 191.1062 [M+H]+ (calcd for C12H14O2, 191.1067). 
 
Compound 8 
 
A magnetically stirred solution of triphenylphosphine (2.89 g, 11.0 mmol) in dry acetonitrile 
(50 mL) maintained at 22 °C was treated, in portions, with powdered molecular iodine (2.92 
g, 11.5 mmol). After 0.5 h the reaction mixture was treated with triethylamine (1.67 mL. 12.0 
mmol) and cyclopentene-1,3-dione (981 mg, 10.0 mmol) then it was heated under reflux 16 h 
before being cooled and concentrated under reduced pressure. The residue thus obtained was 
stirred vigorously with diethyl ether (30 mL) and the supernatant liquid decanted. This 
process was repeated twice more and the combined organic phases then diluted with 40-60 
petroleum ether (50 mL) to precipitate triphenylphosphine oxide. The ensuing mixture was 
filtered through a plug of TLC-grade silica gel topped with diatomaceous earth and the 
filtrate concentrated under reduced pressure to afford compound 8 (1.37 g, 66%) as a white, 
crystalline solid. The spectral data obtained on this material matched those published in the 
literature.3 
 
Compound 9 
 
A magnetically stirred solution of triphenylphosphine (2.89 g, 11.0 mmol) in dry acetonitrile 
(50 mL) maintained at 22 °C was treated, in portions, with powdered molecular iodine (2.92 
g, 11.5 mmol). After 0.5 h the reaction mixture was treated with triethylamine (1.67 mL. 12.0 
mmol) and 2-methylcyclopentane-1,3-dione (1.12 g, 10.0 mmol) before being heated under 
reflux for 18 h. The cooled reaction mixture was concentrated under reduced pressure and the 
residue thus obtained stirred vigorously with diethyl ether (30 mL) and the supernatant liquid 
decanted. This process was repeated twice more and the combined organic phases then 
diluted with 40-60 petroleum ether (50 mL) to precipitate triphenylphosphine oxide. The 
ensuing mixture was filtered through a plug of TLC-grade silica gel topped with 
diatomaceous earth and the filtrate concentrated under reduced pressure to afford 9 (1.80 g, 
O
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81%) as a pale-yellow, crystalline solid. The spectral data obtained on this material matched 
those published in the literature.3 
 
Compound 10 
 
 
A magnetically stirred suspension of compound 8 (728 mg, 3.50 mmol), o-iodonitrobenzene 
(2) (1.74 g, 7.00 mmol) and copper powder (1.11 g, 17.5 mmol) in dry DMSO (15 mL) 
maintained at 50 °C was treated with Pd(dppf)Cl2•CH2Cl2 (143 mg, 0.18 mmol). The ensuing 
mixture was stirred at 50 °C for 17 h then cooled to 22 °C and diluted with ethyl acetate (15 
mL) before being filtered through a plug of TLC-grade silica gel topped with diatomaceous 
earth. The solids so retained were washed with ethyl acetate (60 mL) and the combined 
filtrates washed with ammonia (2 x 75 mL of a 5% v/v aqueous solution), water (2 x 75 mL) 
and brine (1 x 75 mL) before being dried (Na2SO4), filtered, then concentrated under reduced 
pressure. The ensuing residue was subjected to flash column chromatography (silica, 1:9 v/v 
diethyl ether/toluene elution) and thus affording, after concentration of the appropriate 
fractions (Rf = 0.2), compound 10 (663 mg, 93%) as a pale-yellow powder, m.p. = 89 °C. 
1H NMR (400 MHz, CDCl3) δ 8.06 (dd, J = 7.8 and 1.0 Hz, 1H), 7.69 (td, J = 7.8 and 1.0 Hz, 
1H), 7.57 (td, J = 7.8 and 1.0 Hz, 1H), 7.38 (dd, J = 7.8 and 1.0 Hz, 1H), 6.17 (t, J = 1.9 Hz, 
1H), 2.95–2.86 (complex m, 2H), 2.64–2.57 (complex m, 2H).!
13C NMR (100 MHz, CDCl3) δ 208.5, 173.9, 147.1 133.7, 132.6, 132.0, 130.2, 129.4, 124.9, 
35.7, 31.9. 
IR (ATR) νmax 3065, 2929, 2850, 1702, 1686, 1592, 1509, 1437, 1345, 1321, 1287, 1254, 
1184, 1083, 876, 849, 788, 746 cm–1. 
MS (ESI, +ve) m/z 226 [(M+Na)+, 100%]. 
HRMS m/z 226.0482 [M+Na]+ (calcd for C11H9NO3, 226.0480). 
 
Compound 11 
 
 
A magnetically stirred suspension of compound 9 (516 mg, 2.32 mmol), o-iodonitrobenzene 
(2) (1.16 g, 4.65 mmol), copper(I) iodide (221 mg, 1.16 mmol) and copper powder (738 mg, 
11.6 mmol) in dry DMSO (10 mL) maintained at 50 °C was treated with Pd(dppf)Cl2•CH2Cl2 
(190 mg, 0.23 mmol). After 23 h the reaction mixture was cooled to 22 °C then diluted with 
ethyl acetate (10 mL) before being filtered through a plug of TLC-grade silica gel topped 
with diatomaceous earth and the solids so retained were washed with ethyl acetate (30 mL). 
The combined filtrates were washed with ammonia (2 x 40 mL of a 5% v/v aqueous 
solution), water (2 x 40 mL) and brine (1 x 40 mL) before being dried (Na2SO4), filtered, then 
concentrated under reduced pressure. The residue so obtained was subjected to flash column 
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chromatography (silica, 1:9 v/v diethyl ether/toluene elution) and thus affording, after 
concentration of the appropriate fractions (Rf = 0.2), compound 11 (247 mg, 49%) as a pale-
yellow oil. 
1H NMR (400 MHz, CDCl3) δ 8.02 (dd, J = 8.2 and 1.2 Hz, 1H), 7.6 (td, J = 7.5 and 1.2 Hz, 
1H), 7.50 (m, 1H), 7.22 (dd, J = 7.5 and 1.2 Hz, 1H), 2.69 (m, 2H), 2.45 (m, 2H), 1.44 (t, J = 
2.2 Hz, 3H).!
13C NMR (100 MHz, CDCl3) δ 208.3, 166.2, 146.8, 138.0, 133.8, 132.8, 129.4, 129.1, 124.7, 
34.2, 30.6, 8.4. 
IR (ATR) νmax 2919, 1698, 1644, 1515, 1438, 1382, 1353, 1337, 1219, 1102, 1056, 857, 787, 
753, 707, 698 cm–1. 
MS (ESI, +ve) m/z 240 [(M+Na)+, 100%]. 
HRMS m/z 218.0822 [M+H]+ (calcd for C12H11NO3, 218.0817). 
 
Compound 15   
 
 
A magnetically stirred suspension of compound 5 (X = I) (1.32 g, 5.91 mmol), copper(I) 
iodide (845 mg, 4.44 mmol) and copper powder (600 mg, 2.96 mmol) in dry DMSO (40 mL) 
maintained at 50 °C  was treated with Pd(dppf)Cl2•CH2Cl2 (241 mg, 0.30 mmol). After 0.75 h 
the reaction mixture was treated, dropwise over 1 h, with a solution of 2-bromo-3-
nitropyridine (12) (600 mg, 2.96 mmol) in dry DMSO (10 mL). After a further 4 h the 
reaction mixture was cooled to 22 °C before being diluted with ethyl acetate (20 mL). The 
ensuing mixture was filtered through a plug of TLC-grade silica gel topped with 
diatomaceous earth and the solids thus retained were washed with ethyl acetate (40 mL). The 
combined filtrates were washed with ammonia (2 x 60 mL of a 5% v/v aqueous solution), 
water (2 x 60 mL) and brine (1 x 60 mL) before being dried (Na2SO4), filtered and then 
concentrated under reduced pressure. The residue thus obtained was subjected to flash 
column chromatography (silica, 4:6 v/v ethyl acetate/40-60 petroleum ether elution) and so 
affording, after concentration of the appropriate fractions (Rf = 0.2 in 1:1 v/v ethyl acetate/40-
60 petroleum ether), compound 15 (650 mg, 69%) as an oily, brown solid. 
1H NMR (400 MHz, CDCl3) δ 8.80 (d, J = 4.6 Hz, 1H), 8.27 (d, J = 8.2 Hz, 1H), 7.50 (m, 
1H), 5.96 (s, 1H), 2.68 (t, J = 6.3 Hz, 2H), 2.48 (t, J = 6.3 Hz, 2H), 2.19 (p, J = 6.3 Hz, 2H). 
13C NMR (100 MHz, CDCl3) δ 198.5, 158.0, 152.8(4), 152.8(2), 144.3, 132.6, 128.1, 123.9, 
37.2, 28.7, 22.8. 
IR (ATR) νmax 2980, 1669, 1593, 1524, 1346, 1325, 1251, 959, 818, 762, 725 cm–1. 
MS (ESI, +ve) m/z 241 [(M+Na)+, 100%]. 
HRMS m/z 219.0769 [M+H]+ (calcd for C11H10N2O3, 219.0770). 
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Compound 16   
 
 
A magnetically stirred suspension of compound 5 (X = I) (1.96 g, 8.83 mmol), 3-bromo-2-
nitropyridine (13) (900 mg, 4.41 mmol), copper(I) iodide (1.26 g, 6.62 mmol) and copper 
powder (1.15 g, 18.1 mmol) in dry DMSO (44 mL) maintained at 50 °C  was treated with 
Pd(dppf)Cl2•CH2Cl2 (241 mg, 0.30 mmol). After 5 h the reaction mixture was cooled to 22 
°C then diluted with ethyl acetate (20 mL). The ensuing mixture was filtered through a plug 
of TLC-grade silica gel topped with diatomaceous earth and the solids so retained were 
washed with ethyl acetate (40 mL). The combined filtrates were washed with ammonia (2 x 
60 mL of a 5% v/v aqueous solution), water (2 x 60 mL) and brine (1 x 60 mL) before being 
dried (Na2SO4), filtered, then concentrated under reduced pressure. The residue thus obtained 
was subjected to flash column chromatography (silica, 1:4 v/v ethyl acetate/40-60 petroleum 
ether elution) and so affording, after concentration of the appropriate fractions (Rf = 0.2), 
compound 16 (894 mg, 91%) as a yellow, crystalline solid, m.p. = 90-93 °C.!
1H NMR (400 MHz, CDCl3) δ 8.59 (dd, J = 4.7 and 1.7 Hz, 1H), 7.81 (dd, J = 7.7 and 1.7 
Hz, 1H), 7.67 (dd, J = 7.7 and 4.7 Hz, 1H), 6.00 (s, 1H), 2.56-2.51 (complex m, 4H), 2.20 (m, 
2H). 
13C NMR (100 MHz, CDCl3) δ 198.3, 156.7, 155.1, 148.8, 139.7, 130.8, 128.8, 128.3, 37.3, 
30.3, 23.2.  
IR (ATR) νmax 3061, 2950, 2886, 1668, 1537, 1346, 1238, 1188, 982, 958, 807, 703 cm–1.  
MS (ESI, +ve) m/z 241 [(M+Na)+, 100%], 219 [(M+H)+, 10%]. 
HRMS m/z 219.0755 [M+H]+ (calcd for C11H10N2O3 219.0764). 
 
Compound 17 
 
 
A magnetically stirred suspension of compound 5 (X = I) (80.0 mg, 0.36 mmol), 3-bromo-4-
nitropyridine (14) (102 mg, 0.50 mmol) and copper powder (160 mg, 2.52 mmol) in dry 
DMSO (4 mL) maintained at 80 °C was treated with Pd2(dba)3•CHCl3 (37.3 mg, 0.036 
mmol). After 16 h the reaction mixture was cooled to 22 °C, diluted with ethyl acetate (4 
mL), filtered through a plug of TLC-grade silica gel topped with diatomaceous earth and the 
solids so retained washed with ethyl acetate (10 mL). The combined filtrates were washed 
with ammonia (2 x 20 mL of a 5% v/v aqueous solution), water (2 x 20 mL) and brine (1 x 20 
mL) before being dried (Na2SO4), filtered, then concentrated under reduced pressure. The 
residue thus obtained was subjected to flash column chromatography (silica, 1:9 to 4:6 v/v 
diethyl ether/40-60 petroleum ether elution) and so affording, after concentration of the 
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appropriate fractions (Rf = 0.2 in 1:1 v/v ethyl acetate/40-60 petroleum ether), compound 17 
(70 mg, 89%) as a clear, colorless oil.!
1H NMR (400 MHz, CDCl3) δ 8.87 (d, J = 5.3 Hz, 1H), 8.66 (s, 1H), 7.85 (d, J = 5.3 Hz, 
1H), 6.01 (s, 1H), 2.51 (m, 4H), 2.19 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 198.1, 155.9, 152.2, 151.0, 129.6, 129.1, 117.0, 37.2, 30.6, 
23.2 (signal due to one carbon obscured or overlapping). 
IR (ATR) νmax 2925, 1669, 1554, 1530, 1348, 1246, 728, 689, 672 cm–1. 
MS (ESI, +ve) m/z 241 [(M+Na)+, 100%], 219 [(M+H)+, 18%]. 
HRMS m/z 219.0766 [M+H]+ (calcd for C11H10N2O3, 219.0764). 
 
Compound 18 
 
 
Compound 18 was prepared using a procedure reported earlier.3 Thus, a magnetically stirred 
solution of triphenylphosphine (2.16 g, 8.25 mmol) in dry acetonitrile/HMPA (55 mL of a 
10:1 v/v mixture) maintained at 22 °C was treated, in portions, with powdered molecular 
iodine (2.10 g, 8.25 mmol). After 0.5 h the reaction mixture was treated with triethylamine 
(1.20 mL, 8.25 mmol) and a solution of (E)-2-(hydroxymethylene)cyclohexan-1-one3 (800 
mg, 6.35 mmol) in dry acetonitrile (10 mL). The resulting mixture was stirred at 22 °C for 15 
h then concentrated under reduced pressure. The residue thus obtained was dissolved in ethyl 
acetate (50 mL) and the resulting solution washed with water (3 x 30 mL) before being dried 
(Na2SO4), filtered then concentrated under reduced pressure. The residue so obtained was 
subjected to flash column chromatography (silica, 1:20 v/v ethyl acetate/40-60 petroleum 
ether elution) and thus affording, after concentration of the appropriate fractions (Rf = 0.5), 
compound 18 (1.18 g, 79%) as a light-yellow oil. The spectral data acquired on this material 
were identical, in all respects, with those reported in the literature.3 
 
Compound 19 
 
 
A magnetically stirred suspension of compound 18 (472 g, 2.00 mmol), 3-bromo-2-
nitropyridine (13) (808 mg, 4.00 mmol), copper(I) iodide (570 g, 3.00 mmol) and copper 
powder (512 mg, 8.00 mmol) in dry DMSO (20 mL) maintained at 50 °C  was treated with 
Pd(dppf)Cl2•CH2Cl2 (16 mg, 0.02 mmol). After 5 h the reaction mixture was cooled to 22 °C 
then diluted with ethyl acetate (20 mL) and the ensuing mixture filtered through a plug of 
TLC-grade silica gel topped with diatomaceous earth. The solids so retained were washed 
with ethyl acetate (40 mL) and the combined filtrates were washed with ammonia (2 x 60 mL 
of a 5% v/v aqueous solution), water (2 x 60 mL) and brine (1 x 60 mL) before being dried 
(Na2SO4), filtered and then concentrated under reduced pressure. The residue thus obtained 
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was subjected to flash column chromatography (silica, 1:4 v/v ethyl acetate/40-60 petroleum 
ether elution) and thus affording, after concentration of the appropriate fractions (Rf = 0.2), 
compound 19 (402 mg, 87%) as a yellow, crystalline solid, m.p. = 95-98 °C. 
1H NMR (400 MHz, [(CD3)2CO]) δ 8.56 (dd, J = 4.6 and 1.5 Hz, 1H), 8.12 (dd, J = 7.7 and 
1.5 Hz, 1H), 7.85 (dd, J = 7.7 and 4.6 Hz, 1H), 7.32 (t, J = 4.6 Hz, 1H), 2.64 (m, 2H), 2.51 
(m, 2H), 1.93 (m, 2H), 1.76 (m, 2H).  
13C NMR (100 MHz, [(CD3)2CO]) δ 200.0, 148.8, 142.3, 142.2, 128.7, 126.8, 125.9, 41.0, 
29.2, 24.4, 24.1. (resonance due to one carbon obscured or overlapping).  
IR (ATR) νmax 2941, 2868, 1690, 1595, 1540, 1405, 1360, 1142, 862, 813 cm–1.  
MS (ESI, +ve) m/z 255 [(M+Na)+, 100%].  
HRMS m/z 233.0912 [M+H]+ (calcd for C12H12N2O3, 233.0921). 
 
Compound 24 
 
 
A magnetically stirred suspension of compound 5 (X = I) (84.4 mg, 0.38 mmol), compound 
206 (126 mg, 0.38 mmol) and copper powder (170 mg, 2.68 mmol) in dry DMSO (5 mL) 
maintained at 80 °C was treated with Pd2(dba)3•CHCl3 (39.3 mg, 0.038 mmol). After 16 h the 
reaction mixture was cooled to 22 °C, diluted with ethyl acetate (5 mL), filtered through a 
plug of TLC-grade silica gel topped with diatomaceous earth and the solids so retained were 
washed with ethyl acetate (20 mL). The filtrate was washed with ammonia (2 x 25 mL of a 
5% v/v aqueous solution), water (2 x 25 mL) and brine (1 x 25 mL) before being dried 
(Na2SO4), filtered, then concentrated under reduced pressure. The residue thus obtained was 
subjected to flash column chromatography (silica, 1:9 to 4:6 v/v diethyl ether/40-60 
petroleum ether elution) and so affording, after concentration of the appropriate fractions (Rf 
= 0.2 in 2:3 v/v diethyl ether/40-60 petroleum ether elution), compound 24 (45 mg, 40%) as a 
white, crystalline solid, m.p. = 163 °C. 
1H NMR (400 MHz, CDCl3) δ 8.75 (m, 2H), 8.36 (d, J = 9.3 Hz, 1H), 7.94–7.74 (complex 
m, 4H), 7.70 (m, 1H), 6.26 (s, 1H), 2.89 (m, 1H), 2.71 (m, 3H), 2.41 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 198.6, 158.6, 145.9, 132.0, 131.6, 130.2, 129.8, 128.7(0), 
127.6(9), 128.4, 128.1, 127.6, 127.1, 126.6, 123.5, 123.1, 116.6, 107.1, 37.6, 31.3, 23.4. 
IR (ATR) νmax  3340, 3067, 2949, 2220, 1678, 1450, 907, 757, 725 cm–1. 
MS (ESI, +ve) m/z 320 [(M+Na)+, 100 %]. 
HRMS m/z 320.1049 [M+Na]+ (calcd for C21H15NO, 320.1051). 
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Compound 25 
 
 
A magnetically stirred suspension of compound 5 (X = I) (222 mg, 1.00 mmol), compound 
216 (458 mg, 2.00 mmol), triphenylarsine (61.0 mg, 0.20 mmol) and copper powder (318 mg, 
5.00 mmol) in dry DMSO (5 mL) maintained at 80 °C was treated with Pd2(dba)3•CHCl3 (52 
mg, 0.05 mmol). After 20 h the reaction mixture was cooled to 22 °C, diluted with ethyl 
acetate (5 mL) and the resulting mixture filtered through a plug of TLC-grade silica gel 
topped with diatomaceous earth and the solids so retained were washed with ethyl acetate (20 
mL). The combined filtrates were washed with ammonia (2 x 25 mL of a 5% v/v aqueous 
solution), water (2 x 25 mL) and brine (1 x 25 mL) before being dried (Na2SO4), filtered then 
concentrated under reduced pressure. The residue thus obtained was subjected to flash 
column chromatography (silica, 1:9 v/v ethyl acetate/40-60 petroleum ether elution) and so 
affording, after concentration of the appropriate fractions (Rf = 0.3), compound 257 (120 mg, 
61%) as a white, crystalline solid, m.p. = 86 °C. 
1H NMR (400 MHz, CDCl3) δ 7.73 (dd, J = 7.7 and 1.4 Hz, 1H), 7.63 (td, J = 7.7 and 1.4 Hz, 
1H), 7.48 (m, 1H), 7.39 (dd, J = 7.8 and 1.4 Hz, 1H), 6.20 (s, 1H), 2.80 (m, 2H), 2.54 (m, 
2H), 2.21 (m, 2H).!
13C NMR (100 MHz, CDCl3) δ 198.9, 158.6, 144.5, 133.9, 133.2, 130.1, 129.2, 128.1, 117.9, 
110.2, 37.4, 30.2, 23.3. 
IR (ATR) νmax 2949, 2870, 2226, 1669, 1615, 1346, 1326, 1248, 1189, 957, 894, 764 cm–1. 
MS (ESI, +ve) m/z 220 [(M+Na)+, 100%]. 
HRMS m/z 220.0733 [M+Na]+ (calcd for C13H11NO, 220.0738). 
 
Compound 26 
 
 
A magnetically stirred suspension of compound 5 (X = I) (84.4 mg, 0.38 mmol), compound 
226 (176 mg, 0.57 mmol) and copper powder (160 mg, 2.52 mmol) in dry DMSO (5 mL) 
maintained at 80 °C was treated with Pd2(dba)3•CHCl3 (39.3 mg, 0.038 mmol). After 16 h the 
reaction mixture was cooled to 22 °C, diluted with ethyl acetate (5 mL) and the resulting 
mixture filtered through a plug of TLC-grade silica gel topped with diatomaceous earth. The 
solids so retained were washed with ethyl acetate (20 mL) and the filtrate was washed with 
ammonia (2 x 25 mL of a 5% v/v aqueous solution), water (2 x 25 mL) and brine (1 x 25 mL) 
before being dried (Na2SO4), filtered then concentrated under reduced pressure. The residue 
thus obtained was subjected to flash column chromatography (silica, 2:8 to 1:1 v/v ethyl 
acetate/40-60 petroleum ether elution) and so affording, after concentration of the appropriate 
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fractions (Rf = 0.6 in 2:3 v/v ethyl acetate/40-60 petroleum ether elution), compound 26 (36 
mg, 34%) as a white, crystalline solid, m.p. = 123 °C. 
1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 2.0 Hz, 1H), 7.75 (dd, J = 8.4 and 2.0 Hz, 1H), 
7.26 (d, J = 8.4 Hz, 1H), 6.18 (m, 1H), 2.80–2.73 (complex m, 2H), 2.56–2.49 (complex m, 
2H), 2.24–2.15 (complex m, 2H). 
13C NMR (100 MHz, CDCl3) δ 198.5, 157.3, 143.3, 136.4, 136.3, 130.3, 129.6, 123.0, 116.5, 
112.0, 37.3, 30.1, 23.2. 
IR (ATR) νmax 3062, 2951, 2869, 2227, 1669, 1547, 1346, 1252, 822 cm–1. 
MS (ESI, +ve) m/z 300 and 298 [(M+Na)+, 98 and 100 %]. 
HRMS m/z 297.9843 [M+Na]+ (calcd for C13H1079BrNO, 297.9843). 
 
Compound 27 
 
 
A magnetically stirred suspension of compound 5 (X = I) (84.4 mg, 0.38 mmol), compound 
236 (176 mg, 0.57 mmol) and copper powder (160 mg, 2.52 mmol) in dry DMSO (5 mL) 
maintained at 80 °C was treated with Pd2(dba)3•CHCl3 (39.3 mg, 0.038 mmol). After 16 h the 
reaction mixture was cooled to 22 °C, diluted with ethyl acetate (5 mL) and the resulting 
mixture filtered through a plug of TLC-grade silica gel topped with diatomaceous earth and 
the solids so retained were washed with ethyl acetate (20 mL). The combined filtrates were 
washed with ammonia (2 x 25 mL of a 5% v/v aqueous solution), water (2 x 25 mL) and 
brine (1 x 25 mL) before being dried (Na2SO4), filtered then concentrated under reduced 
pressure. The residue thus obtained was subjected to flash column chromatography (silica, 
2:8 to 1:1 v/v ethyl acetate/40-60 petroleum ether elution) and so affording, after 
concentration of the appropriate fractions (Rf = 0.6 in 2:3 v/v ethyl acetate/40-60 petroleum 
ether elution), compound 27 (73 mg, 79%) as a red, crystalline solid, m.p. = 152 °C. 
1H NMR (400 MHz, CDCl3) δ 8.60 (d, J = 2.2 Hz, 1H), 8.47 (dd, J = 8.6 and 2.2 Hz, 1H), 
7.61 (d, J = 8.6 Hz, 1H), 6.24 (t, J = 1.7 Hz, 1H), 2.80 (td, J = 5.9 and 1.7 Hz, 2H), 2.58 (dd, 
J = 7.6 and 5.9 Hz, 2H), 2.26 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 198.9, 155.9, 150.1, 147.6, 131.1, 129.6, 128.9, 127.8, 115.8, 
111.8, 37.2, 29.8, 23.1. 
IR (ATR) νmax 3081, 2953, 2233, 1673, 1526, 1353, 1324, 1247, 744 cm–1. 
MS (ESI, +ve) m/z 265 [(M+Na)+, 100 %]. 
HRMS m/z 265.0591 [M+Na]+ (calcd for C13H10N2O3 265.0589). 
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Compound 30 
 
 
A magnetically stirred suspension of compound 288 (79.1 mg, 0.35 mmol), 3-bromo-2-
nitropyridine (12) (102 mg, 0.50 mmol) and copper powder (160 mg, 2.52 mmol) in dry 
DMSO (5 mL) maintained at 80 °C was treated with Pd2(dba)3•CHCl3 (29.0 mg, 0.028 
mmol). After 16 h the reaction mixture was cooled to 22 °C then diluted with ethyl acetate (5 
mL) before being filtered through a plug of TLC-grade silica gel topped with diatomaceous 
earth and the solids so retained were washed with ethyl acetate (20 mL). The combined 
filtrates were washed with ammonia (2 x 25 mL of a 5% v/v aqueous solution), water (2 x 25 
mL) and brine (1 x 25 mL) before being dried (Na2SO4), filtered then concentrated under 
reduced pressure. The residue thus obtained was subjected to flash column chromatography 
(silica, 4:6 to 1:1 v/v ethyl acetate/40-60 petroleum ether elution) and so affording, after 
concentration of the appropriate fractions (Rf = 0.3 in 3:7 v/v ethyl acetate/40-60 petroleum 
ether elution), compound 30 (66 mg, 84%) as a yellow, crystalline solid, m.p. = 68 °C. 
1H NMR (400 MHz, CDCl3) δ 8.56 (dd, J = 4.5 and 1.8 Hz, 1H), 7.68 (dd, J = 7.6 and 1.8 
Hz, 1H), 7.62 (dd, J = 7.6 and 4.5 Hz, 1H), 6.00 (q, J = 1.5 Hz, 1H), 3.52 (s, 3H), 2.29 (d, J = 
1.5 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.4, 154.8, 150.5, 147.5, 139.0, 132.0, 128.0, 118.9, 51.5, 
26.1. 
IR (ATR) νmax 2953, 1714, 1650, 1539, 1359, 1249, 1172, 1042, 859, 814, 659 cm–1. 
MS (ESI, +ve) m/z 245 [(M+Na)+, 100 %]. 
HRMS m/z 245.0536 [M+Na]+ (calcd for C10H10N2O4 245.0538). 
 
Compound 31 
!
 
A magnetically stirred suspension of compound 28 (22.6 mg, 0.10 mmol), 3-bromo-4-
nitropyridine (14) (40.6 mg, 0.20 mmol) and copper powder (31.8 mg, 0.50 mmol) in dry 
DMSO (1 mL) maintained at 55 °C was treated with Pd(dppf)Cl2•CH2Cl2 (8.2 mg, 0.010 
mmol). After 18 h the reaction mixture was cooled to 22 °C, diluted with ethyl acetate (5 
mL), filtered through a plug of TLC-grade silica gel topped with diatomaceous earth and the 
solids so retained were washed with ethyl acetate (10 mL). The filtrate was washed with 
ammonia (2 x 15 mL of a 5% v/v aqueous solution), water (2 x 15 mL) and brine (1 x 15 mL) 
before being dried (Na2SO4), filtered, then concentrated under reduced pressure. The residue 
obtained was subjected to flash chromatography (silica, 1:9 v/v diethyl ether/toluene elution) 
and thus affording, after concentration of the appropriate fractions (Rf = 0.12 in 1:9 v/v 
diethyl ether/toluene), compound 31 (15.3 mg, 69%) as a clear, colorless oil. 
1H NMR (400 MHz, CDCl3) δ 8.82 (d, J = 5.4 Hz, 1H), 8.55 (s, 1H), 7.91 (d, J = 5.4 Hz, 
1H), 6.08 (d, J = 1.5 Hz, 1H), 3.53 (s, 3H), 2.29 (d, J = 1.5 Hz, 3H). Irradiation of the 
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resonance at δ 2.29 led to a significant enhancement of the one at δ 6.08 and so establishing 
the illustrated Z-configuration about the acrylate double-bond. 
13C NMR (100 MHz, CDCl3) δ 165.4, 152.3, 150.8, 150.6, 149.7, 130.8, 119.9, 116.5, 51.5, 
26.3. 
IR (ATR) νmax 2953, 1716, 1650, 1532, 1442, 1354, 1243, 1163, 1047, 858, 676 cm–1. 
MS (ESI, +ve) m/z 245 [(M+Na)+, 100 %]. 
HRMS m/z 245.0539 [M+Na]+ (calcd for C10H10N2O4 245.0538). 
 
Compound 32 
 
 
A magnetically stirred suspension of compound 28 (84.4 mg, 0.38 mmol), compound 20 (160 
mg, 0.49 mmol) and copper powder (160 mg, 2.52 mmol) in dry DMSO (5 mL) maintained at 
80 °C was treated with Pd2(dba)3•CHCl3 (39.3 mg, 0.030 mmol). After 16 h the reaction 
mixture was cooled to 22 °C, diluted with ethyl acetate (5 mL), filtered through a plug of 
TLC-grade silica gel topped with diatomaceous earth and the solids so retained were washed 
with ethyl acetate (20 mL). The combined filtrates were washed with ammonia (2 x 25 mL of 
a 5% v/v aqueous solution), water (2 x 25 mL) and brine (1 x 25 mL) before being dried 
(Na2SO4), filtered, then concentrated under reduced pressure. The residue thus obtained was 
subjected to flash column chromatography (silica, 1:4 to 1:1 v/v ethyl acetate/40-60 
petroleum ether elution) and so affording, after concentration of the appropriate fractions (Rf 
= 0.2), compound 32 (62 mg, 55%) as a pink, crystalline solid, m.p. = 153-155 °C. 
1H NMR (400 MHz, CDCl3) δ 8.75 (d, J = 8.4 Hz, 1H), 8.72 (m, 1H), 8.31 (m, 1H), 7.86 (dd, 
J = 8.4 and 1.6 Hz, 1H), 7.80 (m, 1H), 7.77–7.73 (complex m, 2H), 7.65 (m, 1H), 6.46 (q, J = 
1.6 Hz, 1H), 3.48 (s, 3H), 2.40 (d, J = 1.6 Hz, 3H). Irradiation of the resonance at δ 2.40 led 
to a significant enhancement of the one at δ 6.46 and so establishing the illustrated Z-
configuration about the acrylate double-bond. 
13C NMR (100 MHz, CDCl3) δ 164.9, 152.2, 147.8, 131.8, 129.7, 129.6, 128.8, 128.2, 128.0, 
127.9, 127.6, 126.5, 126.3, 123.5, 123.1, 122.4, 116.9, 106.0, 51.4, 26.0. 
IR (ATR) νmax 2950, 2220, 1723, 1651, 1438, 1450, 1208, 1158, 1133, 1044, 759, 725 cm–1. 
MS (ESI, +ve) m/z 340 [(M+K)+, 100%], 324 [(M+Na)+, 90%]. 
HRMS m/z 324.1003 [M+Na]+ (calcd for C20H15NO2, 324.1000). 
 
Compound 33 
 
A magnetically stirred suspension of compound 28 (84.4 mg, 0.38 mmol), compound 23 (155 
mg, 0.56 mmol) and copper powder (160 mg, 2.52 mmol) in dry DMSO (5 mL) maintained at 
80 °C was treated with Pd2(dba)3•CHCl3 (31.1 mg, 0.030 mmol). After 16 h the reaction 
mixture was cooled to 22 °C, diluted with ethyl acetate (5 mL) and the resulting mixture 
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filtered through a plug of TLC-grade silica gel topped with diatomaceous earth and the solids 
so retained were washed with ethyl acetate (20 mL). The combined filtrates were washed 
with ammonia (2 x 25 mL of a 5% v/v aqueous solution), water (2 x 25 mL) and brine (1 x 25 
mL) before being dried (Na2SO4), filtered then concentrated under reduced pressure. The 
residue so obtained was subjected to flash column chromatography (silica, 1:4 to 1:1 v/v 
diethyl ether/40-60 petroleum ether elution) and thus affording, after concentration of the 
appropriate fractions (Rf = 0.3), compound 33 (36 mg, 43%) as a white, crystalline solid, m.p. 
= 106-107 °C. 
1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 2.3 Hz, 1H), 8.43 (dd, J = 8.6 and 2.3 Hz, 1H), 
7.43 (d, J = 8.6 Hz, 1H), 6.19 (q, J = 1.6 Hz, 1H), 3.60 (s, 3H), 2.26 (d, J = 1.6 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.1, 152.2, 150.6, 146.9, 128.7, 127.8, 127.5, 121.5, 115.6, 
112.3, 51.7, 26.0. 
IR (ATR) νmax 2954, 2236, 1721, 1606, 1529, 1439, 1353, 1241, 1166, 1042, 797 cm–1. 
MS (ESI, +ve) m/z 269 [(M+Na)+, 100 %].   
HRMS m/z 269.0539 [M+Na]+ (calcd for C12H10N2O4, 269.0538). 
 
Compound 34 
 
 
A magnetically stirred suspension of compound 28 (84.4 mg, 0.38 mmol), compound 299 
(134 mg, 0.53 mmol) and copper powder (160 mg, 2.52 mmol) in dry DMSO (5 mL) 
maintained at 80 °C was treated with Pd2(dba)3•CHCl3 (31.1 mg, 0.030 mmol). After 16 h the 
reaction mixture was cooled to 22 °C, diluted with ethyl acetate (5 mL) then filtered through 
a plug of TLC-grade silica gel topped with diatomaceous earth and the solids so retained 
were washed with ethyl acetate (20 mL). The combined filtrates were washed with ammonia 
(2 x 25 mL of a 5% v/v aqueous solution), water (2 x 25 mL) and brine (1 x 25 mL) before 
being dried (Na2SO4), filtered then concentrated under reduced pressure. The residue thus 
obtained was subjected to flash column chromatography (silica, 1:4 to 1:1 v/v diethyl 
ether/40-60 petroleum ether elution) and so affording, after concentration of the appropriate 
fractions (Rf = 0.2), compound 34 (50 mg, 59%) as a clear, colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.90 (d, J = 7.8 Hz, 2H), 7.54 (t, J = 7.8 Hz, 1H), 6.28 (d, J = 
1.6 Hz, 1H), 3.61 (s, 3H), 2.30 (d, J = 1.6 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 164.9, 149.9, 149.1, 136.5, 128.5, 123.0, 115.9, 112.2, 51.8, 
25.1. 
IR (ATR) νmax 2954, 2236, 1719, 1654, 1455, 1434, 1352, 1244, 1166, 1041, 808, 760 cm–1. 
MS (ESI, +ve) m/z 249 [(M+Na)+, 100 %].   
HRMS m/z 249.0647 [M+Na]+ (calcd for C13H10N2O2, 249.0640). 
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Compound 36 
 
 
A magnetically stirred suspension of compound 358 (100 mg, 0.33 mmol), compound 5 (X = 
I) (124 mg, 0.50 mmol) and copper powder (160 mg, 2.52 mmol) in dry DMSO (5 mL) 
maintained at 80 °C was treated with Pd2(dba)3•CHCl3 (31.1 mg, 0.030 mmol). After 16 h the 
reaction mixture was cooled to 22 °C, diluted with ethyl acetate (5 mL) and the ensuing 
mixture filtered through a plug of TLC-grade silica gel topped with diatomaceous earth and 
the solids so retained were washed with ethyl acetate (20 mL). The combined filtrates were 
washed with ammonia (2 x 25 mL of a 5% v/v aqueous solution), water (2 x 25 mL) and 
brine (1 x 25 mL) before being dried (Na2SO4), filtered and then concentrated under reduced 
pressure. The residue so obtained was subjected to flash column chromatography (silica, 1:9 
to 1:1 v/v diethyl ether/40-60 petroleum ether elution) and thus affording, after concentration 
of the appropriate fractions (Rf = 0.3 in 1:4 v/v diethyl ether/40-60 petroleum ether elution), 
compound 3610 (60 mg, 61%) as a clear, yellow oil. 
1H NMR (400 MHz, CDCl3) δ 8.12 (dd, J = 8.3 and 1.4 Hz, 1H), 7.60 (td, J = 7.5 and 1.3 Hz, 
1H), 7.49 (m, 1H), 7.29–7.18 (complex m, 6H), 6.41 (s, 1H), 3.92 (m, 2H), 1.03 (t, J = 7.2 
Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.5, 153.5, 138.3, 135.2, 133.3, 131.2, 129.9, 128.9, 128.7, 
127.6, 127.2, 124.7, 117.2, 60.4, 14.1. 
IR (ATR) νmax 3036, 1712, 1625, 1523, 1346, 1168, 1032, 771, 69 cm–1. 
MS (ESI, +ve) m/z 320 [(M+Na)+, 100 %].   
HRMS m/z 320.0899 [M+Na]+ (calcd for C17H15NO4, 320.0899). 
 
Compound 37 
 
 
A magnetically stirred suspension of compound 358 (130 mg, 0.43 mmol), 3-bromo-2-
nitropyridine (13) (122 mg, 0.60 mmol) and copper powder (160 mg, 2.52 mmol) in dry 
DMSO (5 mL) maintained at 80 °C was treated with Pd2(dba)3•CHCl3 (31.1 mg, 0.030 
mmol). After 16 h the reaction mixture was cooled to 22 °C, diluted with ethyl acetate (5 
mL), filtered through a plug of TLC-grade silica gel topped with diatomaceous earth and the 
solids so retained were washed with ethyl acetate (20 mL). The combined filtrates were 
washed with ammonia (2 x 25 mL of a 5% v/v aqueous solution), water (2 x 25 mL) and 
brine (1 x 25 mL) before being dried (Na2SO4), filtered and then concentrated under reduced 
pressure. The residue thus obtained was subjected to flash column chromatography (silica, 
3:7 v/v ethyl acetate/40-60 petroleum ether elution) and so affording, after concentration of 
the appropriate fractions (Rf = 0.5), compound 37 (65 mg, 50%) as a white, crystalline solid, 
m.p. = 102-103 °C. 
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1H NMR (400 MHz, CDCl3) δ 8.64 (dd, J = 4.6 and 1.8 Hz, 1H), 7.76 (dd, J = 7.7 and 1.7 
Hz, 1H), 7.67 (dd, J = 7.7 and 4.6 Hz, 1H), 7.47–7.29 (complex m, 5H), 6.52 (s, 1H), 4.00 
(m, 2H), 1.14 (t, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.2, 155.9, 150.5, 148.0, 141.2, 137.6, 130.4, 129.9, 129.0, 
127.7(3), 127.7(0), 118.3, 60.7, 14.1. 
IR (ATR) νmax 3061, 2983, 1709, 1624, 1540, 1367, 1349, 1270, 1175, 1093, 1027, 771, 692 
cm–1. 
MS (ESI, +ve) m/z 321 [(M+Na)+, 100 %].   
HRMS m/z 321.0851 [M+Na]+ (calcd for C16H14N2O4, 321.0851). 
 
Compound 38 
 
 
A magnetically stirred suspension of compound 358 (380 mg, 1.26 mmol), 3-bromo-4-
nitropyridine (14) (510 mg, 2.52 mmol) and copper powder (400 mg, 6.29 mmol) in dry 
DMSO (5 mL) maintained at 55 °C was treated with PdCl2(dppf)•CH2Cl2 (103 mg, 0.13 
mmol). After 16 h the reaction mixture was cooled to 22 °C, diluted with ethyl acetate (5 mL) 
and the resulting mixture filtered through a plug of TLC-grade silica gel topped with 
diatomaceous earth and the solids so retained washed with ethyl acetate (20 mL). The 
combined filtrates were washed with ammonia (2 x 25 mL of a 5% v/v aqueous solution), 
water (2 x 25 mL) and brine (1 x 25 mL) before being dried (Na2SO4), filtered and then 
concentrated under reduced pressure. The residue thus obtained was subjected to flash 
column chromatography (silica, 1:9 to 1:1 v/v diethyl ether/40-60 petroleum ether elution) 
and so affording, after concentration of the appropriate fractions (Rf = 0.3 in 3:7 v/v ethyl 
acetate/40-60 petroleum ether elution), compound 38 (303 mg, 81%) as a clear, yellow oil. 
1H NMR (400 MHz, CDCl3) δ 8.91 (broad s, 1H), 8.64 (broad s, 1H), 7.99 (d, J = 5.4 Hz, 
1H), 7.42–7.29 (complex m, 5H), 6.59 (s, 1H), 4.03 (m, 2H), 1.15 (t, J = 7.2 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ 165.3, 153.3, 152.5, 151.3, 149.7, 137.7, 130.4, 129.0, 127.5, 
119.2, 60.8, 14.1(two resonances obscured or overlapping). 
IR (ATR) νmax 2982, 1711, 1624, 1533, 1352, 1268, 1177, 1028, 847, 770, 676 cm–1. 
MS (ESI, +ve) m/z 321 [(M+Na)+, 100 %].   
HRMS m/z 321.0844 [M+Na]+ (calcd for C16H14N2O4, 321.0851). 
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Compound 39 
 
 
A magnetically stirred mixture of compound 30 (55.4 mg, 0.25 mmol), glacial acetic acid (1 
mL) and iron powder (30.0 mg, 0.54 mmol) in ethanol (5 mL) maintained at 22 °C was 
treated with hydrochloric acid (2 drops of a 37% aqueous solution). After 1 h the reaction 
mixture was quenched with sodium bicarbonate (10 mL of a saturated aqueous solution) and 
extracted with ethyl acetate (2 x 5 mL). The combined organic phases were dried (Na2SO4), 
filtered and then concentrated under reduced pressure to give compound 3911 (30.4 mg, 76%) 
as a brown solid, no m.p., decomposition above 200 °C. 
 1H NMR (400 MHz, CDCl3) δ 9.78 (broad s, 1H), 8.57 (d, J = 4.1 Hz, 1H), 7.99 (d, J = 7.8 
Hz, 1H), 7.22 (m, 1H), 6.57 (s, 1H), 2.48 (s, 3H). 
13C NMR (100 MHz, CDCl3) δ 163.7, 150.4, 149.8, 147.2, 133.4, 122.4, 118.4, 115.9, 18.5. 
IR (ATR) νmax 2874, 1664, 1612, 1564, 1423, 1388, 1086, 966, 862, 779, 672, 510 cm–1. 
MS (ESI, +ve) m/z 183 [(M+Na)+, 100%]. 
HRMS m/z 183.0536 [M+Na]+ (calcd for C9H8N2O, 183.0534). 
 
Compound 40 
 
 
A magnetically stirred mixture of compound 36 (20.3 mg, 0.068 mmol), glacial acetic acid (1 
mL) and iron powder (50.0 mg, 0.94 mmol) in ethanol (5 mL) maintained at 60 °C was 
treated with hydrochloric acid (2 drops of a 37% aqueous solution). After 16 h the reaction 
mixture was cooled to 22 °C then quenched with sodium bicarbonate (10 mL of a saturated 
aqueous solution) and extracted with ethyl acetate (2 x 5 mL). The combined organic phases 
were dried (Na2SO4), filtered then concentrated under reduced pressure. The residue thus 
obtained was subjected to flash column chromatography (silica, 1:1 v/v ethyl acetate/40-60 
petroleum ether elution) and so affording, after concentration of the appropriate fractions (Rf 
= 0.2), compound 4012 (10.1 mg, 67%) as a white, crystalline solid, m.p. = 189-191 °C 
 1H NMR (400 MHz, CDCl3) δ 12.64 (broad s, 1H), 7.57–7.46 (complex m, 8H), 7.17 (m, 
1H), 6.71 (s, 1H). 
13C NMR (100 MHz, CDCl3) δ 164.6, 153.9, 139.4, 137.6, 131.2, 129.3(3), 129.3(0), 129.1, 
127.2, 123.0, 121.3, 120.1, 117.1. 
IR (ATR) νmax 2957, 2920, 2851, 1661, 1610, 1563, 1432, 1386, 876, 751, 700 cm–1. 
MS (ESI, +ve) m/z 465 [(2M+Na)+, 100%], 244 [(M+Na)+, 78%]. 
HRMS m/z 244.0744 [M+Na]+ (calcd for C15H11NO, 244.0738). 
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Compound 41 
 
 
A magnetically stirred mixture of compound 36 (27.4 mg, 0.092 mmol) and 10% palladium 
on carbon (27 mg) in dry ethanol (5 mL) maintained at 22 °C was placed under a hydrogen 
atmosphere. After 16 h the reaction mixture was filtered through a pad of diatomaceous earth 
and the filtrate concentrated under reduced pressure. The residue thus obtained was subjected 
to flash column chromatography (silica, 4.6 to 1:1 v/v diethyl ether/40-60 petroleum ether 
elution) and thus affording, after concentration of the appropriate fractions (Rf = 0.4), 
compound 4113 (17.5 mg, 85%) as a white, crystalline solid, m.p. = 177-179 °C. 
 1H NMR (400 MHz, CDCl3) δ 7.96 (broad s, 1H), 7.39–7.30 (complex m, 2H), 7.30–7.27 
(complex m, 1H), 7.23–7.17 (complex m, 3H), 7.02–6.89 (complex m, 2H), 6.82 (d, J = 7.9 
Hz, 1H), 4.30 (t, J = 7.5 Hz, 1H), 2.93 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 170.3, 141.5, 137.1, 129.1, 128.6, 128.2, 128.0, 127.4, 126.9, 
123.5, 115.6, 42.2, 38.6. 
IR (ATR) νmax 3212, 2911, 1679, 1593, 1486, 1376, 1245, 1159, 754, 700 cm–1. 
MS (ESI, +ve) m/z 246 [(M+Na)+, 100%]. 
HRMS m/z 246.0894 [M+Na]+ (calcd for C15H13NO, 246.0895). 
 
Compound 42 
 
 
A magnetically stirred mixture of compound 19 (232 mg, 1.00 mmol) and iron powder (168 
mg, 3.00 mmol) in a mixture of ethanol and water (10 mL of a 7:3 v/v mixture) maintained at 
22 °C was treated with calcium chloride (333 mg, 3.00 mmol). The resulting mixture was 
heated under reflux and after 2 h the reaction mixture was cooled to 22 °C then treated with 
sodium hydroxide (200 mg, 5.00 mmol) then heated under reflux again. After 1 h the reaction 
mixture was cooled to 22 °C before diluted with ethyl acetate (20 mL) then filtered through a 
plug of TLC-grade silica gel topped with diatomaceous earth. The solids so retained were 
washed with ethyl acetate (2 x 20 mL) and the separated organic phase associated with the 
combined filtrates dried (MgSO4) before being concentrated under reduced pressure. The 
residue thus obtained was subjected to flash column chromatography (silica, 1:99 v/v 
methanol/ethyl acetate elution) and so affording, after concentration of the appropriate 
fractions (Rf = 0.2), compound 4214 (136 mg, 74%) as a yellow solid, no m.p., decomposition 
above 118 °C.!
1H NMR (400 MHz, CDCl3) δ 9.01 (dd, J = 4.3 and 2.0 Hz, 1H), 8.07 (dd, J = 8.1 and 2.0 
Hz, 1H), 7.83 (s, 1H), 7.39 (dd, J = 8.1 and 4.3 Hz, 1H), 3.23 (t, J = 6.6 Hz, 2H), 3.00 (t, J = 
6.0 Hz, 2H), 2.01 (m, 2H), 1.91 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 163.3, 154.8, 152.6, 136.1, 135.6, 132.4, 121.5, 121.3, 33.9, 
29.2, 23.0, 22.8. 
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IR (ATR) νmax 3048, 2936, 2921, 1607, 1597, 1548, 1474, 1446, 1411, 1301, 1245, 1227, 
1148, 824, 797, 718, 608 cm–1. 
MS (ESI, +ve) m/z 391 [(M+Na)+, 37%], 207 [(M+Na)+, 100], 185 [(M+H)+, 30]. 
HRMS m/z 185.1068 [M+H]+ (calcd for C12H12N2, 185.1073). 
 
Compound 43 
 
 
 
A magnetically stirred suspension of compound 7 (1.00 g, 4.56 mmol) and 10% palladium on 
carbon (460 mg) in dry methanol (50 mL) maintained at 50 °C was placed under a hydrogen 
atmosphere. After 2 h the reaction mixture was cooled to 22 °C then filtered through a pad of 
diatomaceous earth and the filtrate concentrated under reduced pressure. The residue thus 
obtained was subjected to flash column chromatography (silica, 5:95 v/v ethyl acetate/40-60 
petroleum ether elution) and so affording, after concentration of the appropriate fractions (Rf 
= 0.11 in 1:9 v/v ethyl acetate/40-60 petroleum ether elution), compound 43 (684 mg, 73%) 
as white crystals, m.p. = 108 °C. 
1H NMR (400 MHz, CDCl3) δ 7.02 (m, 1H), 6.94 (dd, J = 7.3 and 1.3 Hz, 1H), 6.63 (m, 1H), 
6.55 (dd, J = 8.0 and 1.3 Hz, 1H), 3.82 (s, 1H), 3.32 (s, 3H), 3.14 (m, 1H), 2.26 (m, 1H), 1.79 
(m, 2H), 1.72–1.64 (complex m, 3H), 1.65–1.46 (complex m, 2H). 
13C NMR (100 MHz, CDCl3) δ 145.8, 128.0, 127.2, 125.7, 117.3, 113.3, 83.9, 48.4, 41.5, 
36.3, 34.0, 32.0, 19.5. 
IR (KBr) νmax 3315, 2943, 1606, 1487, 1274, 1114, 1067, 1059, 753 cm–1. 
MS (ESI, +ve) m/z 226 [(M+Na)+, 45%], 204 [(M+H)+, 100]. 
HRMS m/z 204.1389 [M+H]+ (calcd for C13H17NO, 204.1388). 
 
Compound 44 
 
 
A magnetically stirred suspension of compound 7 (100 mg, 0.46 mmol) and 10% palladium 
on carbon (46 mg) in dry toluene (5 mL) maintained at 50 °C was placed under a hydrogen 
atmosphere. After 1 h the reaction mixture was cooled to 22 °C then filtered through a pad of 
diatomaceous earth and the filtrate concentrated under reduced pressure. The residue thus 
obtained was subjected to flash column chromatography (silica, 1:4 v/v ethyl acetate/40-60 
petroleum ether elution) and so affording, after concentration of the appropriate fractions (Rf 
= 0.4), compound 4415 (55.2 mg, 64%) as a clear, yellow oil.  
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1H NMR (400 MHz, CDCl3) δ 7.01 (m, 1H), 6.94 (dd, J = 7.5 and 1.6 Hz, 1H), 6.65 (m, 1H), 
6.50 (dd, J = 7.5 and 1.6 Hz, 1H), 4.17 (broad s, 1H), 3.12 (t, J = 3.3 Hz, 1H), 2.24 (broad s, 
1H), 2.03–1.90 (complex m, 2H), 1.90–1.82 (complex m, 2H), 1.70–1.59 (complex m, 2H), 
1.61–1.44 (complex m, 2H). 
13C NMR (100 MHz, CDCl3) δ 144.9, 128.1, 127.3, 125.7, 117.8, 113.2, 80.5, 40.9, 38.8, 
36.7, 33.5, 19.5. 
IR (KBr) νmax 3361, 2930, 2847, 1608, 1493, 1478, 1300, 1267, 1127, 1080, 1063, 979, 910, 
744 cm–1. 
MS (ESI, +ve) m/z 212 [(M+Na)+, 100%], 190 [(M+H)+, 70]. 
HRMS m/z 190.1236 [M+H]+ (calcd for C12H15NO, 190.1232). 
 
Compound 45 
 
 
A magnetically stirred suspension of compound 10 (52.4 mg, 0.26 mmol) and 10% palladium 
on carbon (26 mg) in dry, degassed methanol (20 mL) maintained at 65 °C was treated with 
glacial acetic acid (0.2 mL) then placed under a hydrogen atmosphere. After 20 h the reaction 
mixture was cooled to 22 °C, filtered through a pad of diatomaceous earth and the filtrate 
concentrated under reduced pressure. The ensuing reside was portioned between diethyl ether 
(10 mL) and sodium bicarbonate (10 mL of a saturated aqueous solution) then the separated 
aqueous phase was extracted with diethyl ether (2 x 10 mL) and the combined organic phases 
washed with brine (1 x 20 mL) before being dried (Na2SO4), filtered and concentrated under 
reduced pressure to give compound 45 (22 mg, 43%) as a white, crystalline solid, m.p. = 77 
°C (Rf = 0.1 in 1:9 v/v diethyl ether/n-hexane). 
1H NMR (400 MHz, CDCl3) δ 7.00 (m, 1H), 6.90 (m, 1H), 6.64 (m, 1H), 6.58 (m, 1H), 3.83 
(broad s, 1H), 3.46 (s, 3H), 3.03 (m, 1H), 2.21–2.05 (complex m, 4H), 1.99–1.89 (complex 
m, 2H). 
13C NMR (100 MHz, CDCl3) δ 143.9, 131.6, 127.2, 126.6, 118.5, 115.5, 94.3, 52.3, 40.7, 
40.0, 35.6, 34.4. 
IR (ATR) νmax 3339, 2941, 2855, 1606, 1493, 1470, 1318, 1298, 1245, 1217, 1199, 1150, 
1112, 1070, 1034, 1001, 942, 747 cm–1. 
MS (ESI, +ve) m/z 190 [(M+H)+, 69%], 158 (62), 153 (100), 102 (93). 
HRMS m/z 190.1233 [M+H]+ (calcd for C12H15NO, 190.1232). 
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Compound 46 
 
 
A magnetically stirred solution of compound 7 (652 mg, 3.0 mmol) and cerium(III) chloride 
heptahydrate (1.23 g, 3.3 mmol) in dry methanol/dichloromethane (6 mL of a 1:1 v/v 
mixture) maintained at 0 °C was treated, in portions, with sodium borohydride (125 mg, 3.30 
mmol). After 2 h the reaction mixture was concentrated under reduced pressure and the 
residue dissolved in diethyl ether (10 mL) and the resulting mixture treated hydrochloric acid 
(10 mL of a 1 M aqueous solution). The separated aqueous phase was extracted with diethyl 
ether (2 x 10 mL) and the combined organic phases washed with brine (1 x 30 mL) before 
being dried (Na2SO4), filtered, then concentrated under reduced pressure. The residue so 
obtained was subjected to flash column chromatography (silica, 1:9 v/v diethyl 
ether/dichloromethane elution) and thus affording, after concentration of the appropriate 
fractions (Rf = 0.3), compound 46 (631 mg, 96%) as a clear, yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.88 (dd, J = 8.1 and 1.3 Hz, 1H), 7.55 (td, J = 7.6 and 1.3 Hz, 
1H), 7.40 (td, J = 8.1 and 1.4 Hz, 1H), 7.29 (dd, J = 7.6 and 1.3 Hz, 1H), 5.67 (m, 1H), 4.30 
(m, 1H), 2.31–2.14 (complex m, 2H), 1.99–1.86 (complex m, 2H), 1.80–1.66 (complex m, 
3H). 
13C NMR (100 MHz, CDCl3) δ 148.3, 139.9, 138.5, 133.0, 130.8, 128.5, 128.1, 124.3, 65.7, 
31.4, 29.7, 19.5. 
IR (ATR) νmax 3342, 2937, 2863, 1521, 1346, 1049, 972, 912, 859, 785, 746 cm–1. 
MS (ESI, +ve) m/z 242 [(M+Na)+, 100%]. 
HRMS m/z 242.0794 [M+Na]+ (calcd for C12H13NO3, 242.0793). 
 
Compound 47 
 
 
A magnetically stirred solution of compound 10 (609 mg, 3.0 mmol) and cerium(III) chloride 
heptahydrate (1.23 g, 3.3 mmol) in methanol/dichloromethane (12 mL of a 1:1 v/v mixture) 
maintained at 0 °C was treated, in portions, with sodium borohydride (125 mg, 3.30 mmol). 
After 0.5 h the reaction mixture was concentrated under reduced pressure and the ensuing 
residue dissolved in diethyl ether (10 mL). The resulting solution was treated with 
hydrochloric acid (10 mL of a 1 M aqueous solution) and the separated aqueous phase 
extracted with diethyl ether (2 x 10 mL). The combined organic phases were washed with 
brine (1 x 30 mL) before being dried (Na2SO4), filtered and then concentrated under reduced 
pressure. The residue thus obtained was subjected to flash column chromatography (silica, 
1:9 v/v diethyl ether/dichloromethane elution) and so affording, after concentration of the 
appropriate fractions (Rf = 0.3), compound 47 (414 mg, 67%) as a clear, yellow oil. 
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1H NMR (400 MHz, CDCl3) δ 7.80 (dd, J = 8.1 and 1.3 Hz, 1H), 7.51 (td, J = 7.5 and 1.3 Hz, 
1H), 7.41–7.30 (complex m, 2H), 5.82 (q, J = 2.0 Hz, 1H), 4.94 (broad s, 1H), 2.71 (m, 1H), 
2.57 (s, 1H), 2.54–2.46 (complex m, 1H), 2.45–2.36 (complex m, 1H), 1.86 (m, 1H). 
13C NMR (100 MHz, CDCl3) δ 148.4, 144.1, 133.0, 132.7, 132.1, 130.6, 128.4, 124.0, 77.6, 
34.3, 34.0. 
IR (ATR) νmax 3338, 2937, 2854, 1520, 1345, 1274, 1239, 1048, 966, 854, 784, 744 cm–1. 
MS (ESI, +ve) m/z 228 [(M+Na)+, 100%].  
HRMS m/z 228.0638 [M+Na]+ (calcd for C11H11NO3, 228.0637). 
 
Compound 48 
 
 
A magnetically stirred mixture of compound 46 (798 mg, 3.64 mmol) and 10% palladium on 
carbon (80 mg) in dry methanol (8 mL) maintained at 22 °C was placed under a hydrogen 
atmosphere. After 2.5 h the reaction mixture was filtered through a pad of diatomaceous earth 
and the filtrate concentrated under reduced pressure. The residue so obtained was subjected to 
flash column chromatography (silica, 2.5:47.5:50 v/v/ methanol/ethyl acetate/40-60 
petroleum ether elution) and thus affording, after concentration of the appropriate fractions 
(Rf = 0.6 in 5:95 v/v methanol/ethyl acetate elution), compound 48 (524 mg, 75%) as a clear, 
light-brown oil. The product decomposes rapidly at ambient temperatures and so it was used 
immediately in the next step of the reaction sequence. 
IR (ATR) νmax 3349, 2927, 2855, 1621, 1496, 1453, 1293, 1251, 1051, 976, 959, 748 cm–1. 
MS (ESI, +ve) m/z 405 [(2M+Na)+, 48%],  214 [(M+Na)+, 100], 192 [(M+H)+, 34]. 
HRMS m/z 192.1381 [M+H]+ (calcd for C12H17NO, 192.1383). 
 
Compound 49 
 
 
A magnetically stirred mixture of compound 47 (235 mg, 1.14 mmol) and 10% palladium on 
carbon (24 mg) in dry methanol (5 mL) maintained at 22 °C was placed under a hydrogen 
atmosphere. After 2 h the reaction mixture was filtered through a pad of diatomaceous earth 
and the filtrate concentrated under reduced pressure. The residue so obtained was subjected to 
flash column chromatography (silica, 1:4 to 1:1 v/v diethyl ether/dichloromethane elution) 
and thus affording, after concentration of the appropriate fractions (Rf = 0.2), compound 49 
(102 mg, 51%) as a clear, light-brown oil.  
1H NMR (400 MHz, CDCl3) δ 7.19 (dd, J = 7.6 and 1.5 Hz, 1H), 7.05 (m, 1H), 6.76 (m, 1H), 
6.67 (dd, J = 7.8 and 1.2 Hz, 1H), 4.46 (m, 1H), 3.33 (broad s, 2H), 3.07 (m, 1H), 2.45–2.31 
NH2
48
OH
NH2
49
HO
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(complex m, 1H), 2.12–1.94 (complex m, 2H), 1.93–1.80 (complex m, 2H), 1.80–1.73 
(complex m, 1H) (resonance due to one proton not observed). 
13C NMR (100 MHz, CDCl3) δ 144.2, 129.0, 127.8, 127.1, 118.7, 116.2, 73.8, 40.9, 40.0, 
36.0, 29.5. 
IR (ATR) νmax 3350, 3244, 2951, 2865, 1620, 1495, 1454, 1295, 1078, 983, 748 cm–1. 
MS (ESI, +ve) m/z 200 [(M+Na)+, 50%], 178 [(M+H)+, 100], 160 (100).  
HRMS m/z 178.1232 [M+H]+ (calcd for C11H15NO, 178.1232). 
 
cis- and trans- Forms of Compound 50 
 
 
A magnetically stirred solution of compound 48 (524 mg, 2.74 mmol) and pyridine (665 µL, 
8.22 mmol) in dry dichloromethane (5.5 mL) maintained at 0 °C was treated, in portions, 
with p-toluenesulfonyl chloride (575 mg, 3.01 mmol) then warmed to 22 °C. After 16 h the 
reaction mixture was treated with heptane (20 mL) then concentrated under reduced pressure. 
This dilution/concentration process was repeated twice more in order to remove pyridine. The 
residue thus obtained was subjected to flash column chromatography (silica, 2:3 v/v ethyl 
acetate/40-60 petroleum ether elution) and so affording, two fractions, A and B. 
Concentration of fraction A (Rf = 0.2) gave compound trans-50 (304 mg, 32%) as a white 
crystalline solid, m.p. =145 °C. 
1H NMR (400 MHz, CDCl3) δ 7.71 (s, 1H), 7.65 (d, J = 8.3 Hz, 2H), 7.36 (m, 1H), 7.24 (d, J 
= 8.3 Hz, 2H), 7.20–7.11 (complex m, 3H), 4.20 (t, J = 2.9 Hz, 1H), 3.01 (s, 1H), 2.91 (m, 
1H), 2.37 (s, 3H), 1.84 (m, 1H), 1.74 (m, 1H), 1.68–1.55 (complex m, 1H), 1.43 (m, 3H), 
1.32–1.20 (complex m, 1H), 1.01 (d, J = 12.5 Hz, 1H).!
13C NMR (100 MHz, CDCl3) δ 143.7, 141.9, 136.9, 133.1, 129.7, 127.4, 127.3, 127.2, 126.9, 
126.6, 66.7, 40.4, 32.8, 32.0, 31.1, 21.6, 20.4. 
IR (ATR) νmax 3521, 3345, 3284, 2928, 1491, 1406, 1327, 1163, 1091, 976, 808, 756, 664 
cm–1. 
MS (ESI, +ve) m/z 368 [(M+Na)+, 100%]. 
HRMS m/z 368.1292 [M+Na]+ (calcd for C19H23NO3S, 368.1291). 
 
Concentration of fraction B (Rf = 0.1) gave compound cis-50 (469 mg, 50%) as a white 
powder, m.p. =152 °C. 
1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 8.3 Hz, 2H), 7.25–7.22 (complex m, 3H), 7.21–
7.11 (complex m, 3H), 6.38 (s, 1H), 3.51 (m, 1H), 2.48 (m, 1H), 2.40 (s, 3H), 1.99 (d, J = 
11.2 Hz, 1H), 1.75 (m, 1H), 1.54 (m, 2H), 1.33–1.09 (complex m, 4H) (resonance due to OH 
group proton not observed). 
13C NMR (100 MHz, CDCl3) δ 143.9, 141.7, 136.7, 132.7, 129.7, 127.5, 127.4, 127.3, 127.0 
126.7, 70.7, 42.8, 36.1, 35.1, 32.5, 24.4, 21.6. 
IR (ATR) νmax 3249, 2925, 1492, 1401, 1330, 1161, 1092, 915, 809, 756, 706, 671 cm–1. 
MS (ESI, +ve) m/z 368 [(M+Na)+, 100%]. 
HRMS m/z 368.1288 [M+Na]+ (calcd for C19H23NO3S, 368.1291). 
 
 
NHTs
trans-50
OH
NHTs
cis-50
OH
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Compound cis-51 
 
 
A magnetically stirred solution of compound 49 (165 mg, 0.93 mmol) and pyridine (226 µL, 
2.79 mmol) in dry dichloromethane (5 mL) maintained at 0 °C was treated, in portions, with 
p-toluenesulfonyl chloride (186 mg, 0.98 mmol) then warmed to 22 °C. After 19 h the 
reaction mixture was treated with heptane (20 mL) then concentrated under reduced pressure. 
This dilution/concentration process was repeated twice more in order to remove pyridine.  
The residue so obtained was subjected to flash column chromatography (silica, 1:9 v/v 
diethyl ether/dichloromethane elution) and thus affording, after concentration of the 
appropriate fractions (Rf = 0.2), compound cis-51 (262 mg, 85%) as a clear, colorless oil 
1H NMR (400 MHz, CDCl3) δ 8.49 (broad s, 1H), 7.78–7.66 (m, 2H), 7.37 (dd, J = 8.1 and 
1.3 Hz, 1H), 7.24–7.17 (complex m, 3H), 7.09 (m, 1H), 7.02 (m, 1H), 4.46 (m, 1H), 3.15 (m, 
1H), 2.65 (broad s, 1H), 2.37 (s, 3H), 2.17 (m, 1H), 1.91–1.76 (complex m, 3H), 1.76–1.65 
(complex m, 1H), 1.57 (dd, J = 14.6 and 7.0 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ 143.7, 137.2, 136.8, 134.5, 130.0, 129.6, 127.4, 127.1, 125.2, 
122.6, 74.0, 41.6, 40.7, 36.4, 30.9, 21.6. 
IR (ATR) νmax 3503, 3270, 2955, 2870, 1492, 1326, 1154, 1090, 814, 756, 661 cm–1. 
MS (ESI, +ve) m/z 354 [(M+Na)+, 100%]. 
HRMS m/z 354.1141 [M+Na]+ (calcd for C18H21NO3S, 354.1140). 
 
Compound 52 
 
 
A magnetically stirred solution of compound trans-50 (81.4 mg, 0.24 mmol) and 
triphenylphosphine (148 mg, 0.57 mmol) in dry tetrahydrofuran (5 mL) maintained at 0 °C 
was treated, dropwise, with DEAD (92!µL, 0.59 mmol). After 16 h the reaction mixture was 
concentrated under reduced pressure and the residue so obtained subjected to flash column 
chromatography (silica, 1:9 v/v ethyl acetate/40-60 petroleum ether elution) and thus 
affording, after concentration of the appropriate fractions (Rf = 0.3), compound 52 (69 mg, 
89%) as a clear, colorless oil.  
1H NMR (400 MHz, CDCl3) δ 7.87 (m, 1H), 7.62 (m, 2H), 7.21 (d, J = 8.1 Hz, 2H), 7.09 (m, 
1H), 6.99 (m, 1H), 6.94 (m, 1H), 4.80 (m, 1H), 2.93 (t, J = 3.4 Hz, 1H), 2.36 (s, 3H), 2.18 (m, 
1H), 1.78 (dt, J = 12.9 and 2.6 Hz, 1H), 1.74–1.62 (complex m, 3H), 1.54–1.47 (complex m, 
1H), 1.47–1.40 (complex m, 1H), 1.31–1.20 (complex m, 1H). 
13C NMR (100 MHz, CDCl3) δ 143.6, 138.5, 137.2, 130.7, 129.8, 129.0, 127.1, 126.7, 122.9, 
119.5, 52.3, 33.9, 33.7(2), 33.6(9), 28.4, 21.6, 17.3. 
IR (ATR) νmax 2931, 2853, 1489, 1453, 1341, 1158, 1089, 871, 814, 674 cm–1. 
MS (ESI, +ve) m/z 677 [(2M+Na)+, 78%], 350 [(M+Na)+, 100], 328 [(M+H)+, 5]. 
NHTs
cis-51
HO
NTs
52
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HRMS m/z 328.1361 [M+H]+ (calcd for C19H21NO2S, 328.1366). 
 
trans-N-(2-(3-Chlorocyclopentyl)phenyl)-4-methylbenzenesulfonamide 
 
 
 
A magnetically stirred solution of compound cis-51 (61 mg, 0.18 mmol) and 
triphenylphosphine (97 mg, 0.37 mmol) in dry dichloromethane (2 mL) maintained at 0 °C 
was treated, dropwise, with carbon tetrachloride (107 µL, 1.10 mmol) then warmed to 22 °C. 
After 15 h the reaction mixture was concentrated under reduced pressure and the residue so 
obtained subjected to flash column chromatography (silica, dichloromethane elution). After 
concentration of the appropriate fractions (Rf = 0.4), the title halide (55.7 mg, 87%) was 
obtained as a clear, colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.2 Hz, 2H), 7.34 (dd, J = 7.6 and 1.6 Hz, 1H), 
7.23 (d, J = 8.2 Hz, 2H), 7.20–7.10 (complex m, 3H), 6.73 (s, 1H), 4.49 (m, 1H), 3.38 (m, 
1H), 2.39 (s, 3H), 2.28 (m, 1H), 2.07–1.95 (complex m, 2H), 1.87 (dd, J = 9.0 and 4.2 Hz, 
2H), 1.51–1.37 (complex m, 1H). 
13C NMR (100 MHz, CDCl3) δ 143.9, 139.9, 136.6, 133.7, 129.8, 127.5, 127.4, 127.0, 126.9, 
126.7, 61.4, 45.0, 37.2, 36.4, 32.3, 21.6. 
IR (ATR) νmax 3267, 2972, 1492, 1399, 1328, 1156, 1091, 904, 813, 757, 732, 662 cm–1. 
MS (ESI, +ve) m/z 374 and 372 [(M+Na)+, 38 and 100%]. 
HRMS m/z 350.0962 [M+H]+ (calcd for C18H2035ClNO2S, 350.0976). 
 
Compound 53 
 
 
A magnetically stirred solution of the above-mentioned trans-N-(2-(3-chlorocyclopentyl)-
phenyl)-4-methylbenzenesulfonamide (55.7 mg, 0.16 mmol) in dry methanol (16 mL) 
maintained at 55 °C was treated with potassium carbonate (110 mg, 0.80 mmol). After 18 h 
the reaction mixture was cooled to 22 °C then concentrated under reduced pressure. The 
residue so obtained was subjected to flash column chromatography (silica, dichloromethane 
elution) and thus affording, after concentration of the appropriate fractions (Rf = 0.6), 
compound 53 (49.6 mg, 99%) as a white, crystalline solid, m.p. =111 °C. 
1H NMR (400 MHz, CDCl3) δ 7.85 (m, 1H), 7.65 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 
2H), 7.11 (m, 1H), 6.94 (m, 2H), 5.08 (m, 1H), 2.99 (s, 1H), 2.37 (s, 3H), 2.17–2.04 
(complex m, 1H), 1.99–1.89 (complex m, 1H), 1.87–1.74 (complex m, 2H), 1.48 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 143.7, 137.1, 135.2, 134.8, 129.7, 127.9, 127.2, 127.1, 123.7, 
121.1, 58.5, 41.4 35.9, 31.9, 31.4, 21.6. 
NHTsCl
53
NTs
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IR (ATR) νmax 2947, 2866, 1600, 1483, 1455, 1342, 1226, 1165, 1155, 1090, 812, 757, 680 
cm–1. 
MS (ESI, +ve) m/z 336 [(M+Na)+, 100%]. 
HRMS m/z 314.1196 [M+H]+ (calcd for C18H19NO2S, 314.1209). 
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X-ray Crystallographic Studies 
 
Crystallographic Data 
 
Crystallographic Data for Compound 7  
C12H11NO3, M = 217.22, T = 150 K, monoclinic, space group P21/c, Z = 4, a = 9.3274(2), b = 
14.6679(2), c = 7.9674(1) Å; β = 107.026(2)°; V = 1042.27(3) Å3, Dx = 1.384 g cm–3, 2088 
unique data (2θmax = 147.2°), R = 0.042 [for 1953 reflections with I > 2.0σ(I)]; Rw = 0.111 
(all data), S = 1.02. 
Crystallographic Data for Compound 19  
C12H12N2O3, M = 232.24, T = 150 K, monoclinic, space group C2/c, Z = 8, a = 7.87923(6), b 
= 19.95864(19), c = 13.93593(11) Å; β = 92.3804(7)°; V = 2189.66(3) Å3, Dx = 1.409 g cm–3, 
2224 unique data (2θmax = 147.2°), R = 0.035 [for 2127 reflections with I > 2.0σ(I)]; Rw = 
0.035 (all data), S = 1.01. 
Crystallographic Data for Compound 39  
C18H22N4O5, M = 374.40, T = 150 K, triclinic, space group P1, Z = 2, a = 7.0058(2), b = 
9.5456(3), c = 13.6950(46) Å; α = 79.998(3)°, β = 83.227(3)°, γ = 85.094(2)°; V = 893.65(5) 
Å3, Dx = 1.391 g cm–3, 3597 unique data (2θmax = 147.8°), R = 0.035 [for 3346 reflections 
with I > 2.0σ(I)]; Rw = 0.102 (all data), S = 0.97. 
Crystallographic Data for Compound 43  
C13H17NO, M = 203.28, T = 150 K, monoclinic, space group P21/c, Z = 4, a = 8.5291(3), b = 
18.2560(5), c = 7.6050(3) Å; β = 112.547(4)°; V = 1093.63(6) Å3, Dx = 1.235 g cm–3, 2919 
unique data (2θmax = 60°), R = 0.044 [for 2299 reflections with I > 2.0σ(I)]; Rw = 0.117 (all 
data), S = 1.06. 
Crystallographic Data for Compound 45  
C12H25NO, M = 189.25, T = 150 K, orthorhombic, space group Pccn, Z = 8, a = 19.6584(2), b 
= 13.0353(1), c = 7.9633(1) Å; V = 2040.62(4) Å3, Dx = 1.232 g cm–3, 2048 unique data 
(2θmax = 147.4°), R = 0.038 [for 1926 reflections with I > 2.0σ(I)]; Rw = 0.105 (all data), S = 
1.06. 
Crystallographic Data for Compound trans-50  
C19H23NO3S, M = 345.44, T = 150 K, triclinic, space group P1, Z = 4, a = 9.4185(4), b = 
12.9752(7), c = 16.0422(8) Å; α = 70.958(5)°, β = 77.623(4)°, γ = 78.202(4)°; V = 
1790.80(16) Å3, Dx = 1.281 g cm–3, 7108 unique data (2θmax = 147.6°), R = 0.048 [for 6495 
reflections with I > 2.0σ(I)]; Rw = 0.048 (all data), S = 1.05. 
 
Structure Determinations 
The image for compound 43 was measured on a diffractometer (Mo Kα, graphite 
monochromator, λ = 0.71073 Å) fitted with an area detector and the data extracted using the 
DENZO/Scalepack package.16 Images for compounds 7, 19, 39, 45, and trans-50 were 
measured on a diffractometer (Cu Kα, mirror monochromator, λ = 1.54184 Å) fitted with an 
area detector and the data extracted using the CrysAlis package.17 The structure solutions for 
all six compounds were either solved by direct methods (SIR92) and refined using the 
CRYSTALS program package, or solved with ShelXT18 and refined using ShelXL19 in 
OLEX2.20 Atomic coordinates, bond lengths and angles, and displacement parameters have 
been deposited at the Cambridge Crystallographic Data Centre (CCDC nos. 1832167, 
1832168, 1832169, 1832170, 1832171 and 1832172). These data can be obtained free-of-
charge via www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@ccdc.cam.ac.uk, 
or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge 
CB2 1EZ, UK; fax: +44 1223 336033. 
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Figure S1: Structure of compound 7 (CCDC 1832167). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S2: Structure of compound 19 (CCDC 1832168). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S3: Structure of compound 39 (CCDC 1832169) and associated water molecules. 
Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen atoms are drawn 
as circles with small radii. 
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Figure S4: Structure of compound 43 (CCDC 1832170). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S5: Structure of compound 45 (CCDC 1832171). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S6: Structure of compound trans-50 (CCDC 1832171). Anisotropic displacement 
ellipsoids show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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and Ketones with TiCl3/HCl or Fe/HCl Leading to 1,2,3,9-
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ABSTRACT: Compounds such as 3, the product of a
palladium[0]-catalyzed Ullmann cross-coupling of o-iodoni-
trobenzene and 2-iodocyclohex-2-en-1-one, undergo comple-
mentary modes of reductive cyclization depending upon the
conditions employed. Thus, on treatment with hydrogen in
the presence of palladium on carbon, the tetrahydrocarbazole
4 is formed, while reaction of the same substrate (3) with
TiCl3 in acetone aﬀords the 1,2,3,9-tetrahydro-4H-carbazol-4-
one 6.
■ INTRODUCTION
Sometime ago,1 we reported that 2-iodocyclohex-2-en-1-one
(1) (Scheme 1) could be eﬃciently cross-coupled with o-
iodonitrobenzene (2) in the presence of copper bronze and
catalytic quantities of palladium[0] at 50 °C. Catalytic
hydrogenation of the resulting o-nitroarylated cyclohexenone
3 then aﬀorded the tetrahydrocarbazole 4. We have since
extended this two-step and related reaction sequences in a
variety of settings, including ones that have led to a range of
alkaloids as well as medicinally relevant heterocycles.2
We now report that by treating cross-coupling products such
as 3 with titanium trichloride3/HCl or iron/HCl4 then quite
distinct reductive cyclization processes take place to give
heterocyclic systems of biological interest.
■ RESULTS AND DISCUSSION
As shown in Scheme 2, when compound 3 is treated with
either titanium trichloride/HCl or iron/HCl at ambient
Received: July 29, 2018
Published: September 5, 2018
Scheme 1. Palladium-Catalyzed Ullmann Cross-Coupling/
Reductive Cyclization Sequence Leading to
Tetrahydrocarbazole 4
Scheme 2. Reductive Cyclization of Compound 3 via N-
Hydroxyindole 5 to 1,2,3,9-Tetrahydro-4H-carbazol-4-one 6
and the Direct Reduction of Nitroarene 7 to Aniline 8
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temperatures for brief periods, then the primary product of the
reaction is the N-hydroxytetrahydro-4H-carbazol-4-one 5, the
structure of which was conﬁrmed by single-crystal X-ray
analysis (see the SI for details). Furthermore, when compound
3 or 5 was exposed to the same reagents for extended periods
of time, then the previously reported5 tetrahydro-4H-carbazol-
4-one 6 was obtained. Under optimal conditions (TiCl3/HCl
is generally the preferred reducing agent), the latter product
could be obtained, as the exclusive one, from precursor 3 in
82% yield. Fe/HCl was much less eﬀective in these
conversions (see the Experimental section and SI for details).
While the precise mode of the formation of product 5 from
substrate 3 remains to be established, it is clear that the former
compound is a precursor to tetrahydrocarbazol-4-one 6. The
formation of compound 6 by the means just described is
closely related to a protocol recently reported by Zhu and co-
workers as a key step in their elegant total synthesis of
aspidospermidine.3f
The cyclization process appears to be sensitive to stereo-
electronic eﬀects, as evidenced by the conversion of the
cyclopentenone-appended nitroarene 7 into the corresponding
aniline 8 (80%) rather than the lower homologue of
heterocycle 6. Interestingly, analogous treatment of the
cycloheptenone-appended nitroarene (viz. the higher homo-
logue of compound 3) only led to complex mixtures of
products.
The complementary nature of the original mode of reductive
cyclization of the palladium-catalyzed Ullmann cross-coupling
products and the one that can normally be best eﬀected using
TiCl3/HCl is emphasized through the example shown in
Scheme 3. Thus, cross-coupling of electrophiles 96 and 2 using
copper in the presence of catalytic Pd[0] aﬀorded product 10
(80%), and on treatment of this with hydrogen in the presence
of 10% palladium on carbon then the previously reported7 gem-
dimethylated tetrahydrocarbazole 11 is obtained in 92% yield.
In contrast, on treating the same substrate with TiCl3/HCl in
acetone at ambient temperatures, then compound 12, an
established precursor to demethoxycarazomycin B,8 is obtained
in 82% yield.
The utility of the “new” mode of reductive cyclization in
establishing multiheteroatom-containing ring systems is
revealed through the examples shown in Scheme 4. Thus,
exposure of the previously reported9 coupling product 13 to
TiCl3/HCl gives the 7-azaindole 14 (54%), while the products
derived from the cross-coupling of the homochiral iodide 1510
with aryl iodides 2 and 16,9 namely, compounds 17 (69%) and
18 (91%), respectively, react with TiCl3/HCl (in the former
case) or Fe/HCl (in the latter case) to aﬀord the tetracyclic
products 19 (97% from 17) and 20 (58% from 18). The
spectral data derived from these products were in complete
accord with the assigned structures, and a single-crystal X-ray
analysis of compound 19 was obtained.
Acyclic ketones behave similarly as shown in Scheme 5. So,
the Johnson α-iodination11 of chalcone (21) aﬀorded a
chromatographically separable mixture of compounds 2212
(58%) and 2312 (10%) that, upon palladium-catalyzed
Ullmann cross-coupling with compound 16, aﬀorded the
anticipated products 24 and 25 (59−85% combined yield).
The structure of the former product (24) was conﬁrmed by
single-crystal X-ray analysis. Since the cross-couplings of the
geometrically pure E- and Z-isomeric forms of 22 and 23 are
each accompanied by some double-bond isomerization, it was
most convenient to carry the mixture of iodinated products
through the illustrated reaction sequence rather than
separating these. Subjection of these cross-coupling products,
either separately or as a mixture, to reductive cyclization with
hydrogen in the presence of 10% palladium on carbon aﬀorded
the 3-benzyl-7-azaindole 2613 (63−80%), while treatment of
the same substrates with TiCl3 gave the 3-benzoyl-7-azaindole
27 in 15−49% yield. The structure of product 26 was
conﬁrmed by single-crystal X-ray analysis.
In contrast to the outcomes detailed immediately above,
when the readily obtained α-iodinated cinnamaldehyde 311
(Scheme 6) was subjected to palladium-catalyzed Ullmann
cross-coupling with compound 2 and the ensuing product, 321
(77%), treated with TiCl3, then a slowly interconverting
mixture of the partially chromatographically separable and
isomeric cyclization products 3314 and 3414 was obtained
(55% combined yield). The structure of oxindole 33, a known
Scheme 3. Complementary Behaviors of the Cross-Coupling
Product 10 under Two Distinct Reductive Cyclization
Conditions
Scheme 4. Reductive Cyclization Reactions of Substrates 13,
17, and 18
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antiproliferative agent,15 was conﬁrmed by single-crystal X-ray
analysis.
Very recently, we detailed16 the cross-coupling of various β-
iodoeneones and related compounds with o-iodonitrobenzene
(2) to aﬀord products, such as compound 35 (Scheme 7).
Accordingly, we sought to establish how this nitroarene and its
homologue 36 would behave on exposure to TiCl3/HCl. In the
event, when treated under our now standard conditions, each
produced the corresponding aniline, viz. compounds 37
(quant.) and 38 (98%), respectively, with the structure of
the latter being conﬁrmed by single-crystal X-ray analysis.
A more intriguing outcome was observed when an acetone
solution of the nonmethylated cross-coupling product 3916
(Scheme 8) was treated with TiCl3 at ambient temperatures.
Under these conditions, the chromatographically separable
products 4017 (40%) and 41 (60%) were obtained, and their
structures established by single-crystal X-ray analysis. Com-
pound 40 is undoubtedly the primary product of the reaction
and the precursor to the other through its Schiﬀ base
condensation with acetone to give imine 42 and electrocyclic
ring closure of this to give compound 43 that engages in a
prototropic shift with accompanying re-aromatization to
deliver the secondary product 41. Consistent with this
proposal, when THF solutions of compound 40 were treated,
at 22 °C, with methyl ethyl ketone, cyclohexanone, or
benzaldehyde then the cycloadducts 44 (73%) 45 (64%),
and 46 (quant.), respectively, are obtained. The structures of
products 44 and 45 were conﬁrmed by single-crystal X-ray
analysis (see the SI for details).
Scheme 5. Formation of the Mixture of Cross-Coupling
Products 24 and 25 and Their Divergent Reductive
Cyclizations To Give 7-Azaindoles 26 and 27
Scheme 6. Formation of Cinnamaldehyde 32 and Its
Reductive Cyclization
Scheme 7. Reduction of Nitroarenes 35 and 36 to the
Corresponding Anilines
Scheme 8. Formation of the Dihydroquinolines 41 and 44−
46
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■ CONCLUSIONS
The reductive cyclization processes detailed above consid-
erably enhance the utility of the various products available
through the palladium-catalyzed Ullmann cross-coupling of o-
halonitroarenes with either α- or β-iodinated-α,β-unsaturated
enones and related systems.2 The resulting, and in some
instances previously unreported, heterocyclic ring systems
should serve as useful scaﬀolds in a range of settings.
■ EXPERIMENTAL SECTION
General Experimental Procedures. Unless otherwise speciﬁed,
proton (1H) and carbon (13C) NMR spectra were recorded at room
temperature in base-ﬁltered CDCl3 on a spectrometer operating at
400 MHz for proton and 100 MHz for carbon nuclei. For 1H NMR
spectra, signals arising from the residual protio-forms of the solvent
were used as internal standards. 1H NMR data are recorded as
follows: chemical shift (δ) (multiplicity, coupling constant(s) J (Hz),
relative integral) where multiplicity is deﬁned as s = singlet; d =
doublet; t = triplet; q = quartet; m = multiplet; or combinations of the
above. The signal due to residual CHCl3 appearing at δH 7.26 and the
central resonance of the CDCl3 “triplet” appearing at δC 77.0 were
used to reference 1H and 13C NMR spectra, respectively. IR spectra
were recorded, using neat samples, on an attenuated total reﬂectance
(ATR) infrared spectrometer. Low-resolution ESI mass spectra were
recorded on a single quadrupole liquid chromatograph−mass
spectrometer, while high-resolution measurements were conducted
on a time-of-ﬂight instrument. Low- and high-resolution EI mass
spectra were recorded on a magnetic-sector machine. Melting points
were measured on an automated melting point system and are
uncorrected. Analytical thin layer chromatography (TLC) was
performed on aluminum-backed 0.2 mm thick silica gel 60 F254
plates. Eluted plates were visualized using a 254 nm UV lamp and/or
by treatment with a suitable dip followed by heating. These dips
included phosphomolybdic acid:ceric sulfate:sulfuric acid (conc.):-
water (37.5 g:7.5 g:37.5 g:720 mL) or potassium permanganate:po-
tassium carbonate:5% sodium hydroxide aqueous solution:water (3
g:20 g:5 mL:300 mL). Column chromatographic separations were
carried out following protocols deﬁned by Still et al.18 with silica gel
60 (40−63 μm) as the stationary phase and using the AR- or HPLC-
grade solvents indicated. Starting materials, reagents, and drying
agents as well as other inorganic salts were generally available from
commercial sources and used as supplied. Tetrahydrofuran (THF),
diethyl ether, methanol, and dichloromethane were dried using a
solvent puriﬁcation system that is based upon a technology originally
described by Grubbs et al.19 Where necessary, reactions were
performed under a nitrogen atmosphere.
Speciﬁc Chemical Transformations. Compound 5. Method i:
A magnetically stirred mixture of compound 31 (217 mg, 1.00 mmol)
in acetone (5 mL) maintained at 22 °C was treated with titanium(III)
chloride (5.0 mL of a 12% w/v solution in hydrochloric acid, 4.79
mmol). After 1 h, the reaction mixture was diluted with ethyl acetate
(20 mL), washed with water (3 × 10 mL), dried (Na2SO4), ﬁltered,
and then concentrated under reduced pressure. The residue so
obtained was subjected to ﬂash column chromatography (silica, 1:1 v/
v ethyl acetate/40−60 petroleum ether elution) and thus aﬀorded,
after concentration of the appropriate fractions (Rf = 0.2), compound
5 (100 mg, 50%) as a white, crystalline solid, no mp, decomposition at
147 °C. 1H NMR (400 MHz, DMSO-d6, δ): 11.70 (s, 1H), 7.99 (dd,
J = 7.4 and 1.2 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.25−7.19
(complex m, 2H), 2.98 (t, J = 6.2 Hz, 2H), 2.44 (m, 2H), 2.20−2.08
(complex m, 2H). 13C NMR (100 MHz, DMSO-d6, δ): 192.0, 148.4,
134.0, 122.7, 122.2, 120.5, 120.2, 108.8, 106.5, 37.6, 22.9, 20.3. IR
(ATR) νmax: 3062, 2946, 1710, 1575, 1462, 1311, 1256, 1182, 1096,
966, 741 cm−1. MS (ESI, +) (m/z): 224 [(M+Na)+, 100%], 202 [(M
+H)+, 10]. HRMS (ESI, +): [M + H]+ Calcd for C12H12NO2,
202.0863; found, 202.0860.
Method ii: A magnetically stirred solution of compound 31 (100
mg, 1.00 mmol) and hydrochloric acid (3 mL of a 2 M aqueous
solution) in THF (5 mL) maintained at 22 °C was treated with iron
powder (168 mg, 3.00 g·atom). After 18 h, the reaction mixture was
diluted with ethyl acetate (20 mL) and then ﬁltered through a plug of
TLC-grade silica topped with diatomaceous earth. The solids so
retained were washed with ethyl acetate (1 × 10 mL), and the
combined ﬁltrates were washed with water (2 × 20 mL) then brine (1
× 20 mL) before being dried (Na2SO4), ﬁltered, and then
concentrated under reduced pressure. The residue so obtained was
subjected to ﬂash column chromatography (silica, 1:1 v/v ethyl
acetate/40−60 petroleum ether elution) and thus aﬀorded, after
concentration of the appropriate fractions (Rf = 0.2), compound 5 (14
mg, 14%) as a white, crystalline solid. This material was identical, in
all aspects, with that obtained by Method i.
Compound 6. Method i: A magnetically stirred solution of
compound 5 (50 mg, 0.25 mmol) in acetone (1.3 mL) maintained at
22 °C was treated with titanium(III) chloride (1.3 mL of a 12% w/v
solution in hydrochloric acid, 1.24 mmol). After 16 h, the reaction
mixture was quenched with sodium carbonate (5 mL of a saturated
aqueous solution), and the resulting heterogeneous mixture was
ﬁltered through diatomaceous earth. The solids so retained were
washed with ethyl acetate (10 mL), the combined ﬁltrates were
separated, and the aqueous phase was extracted with ethyl acetate (2
× 5 mL). The combined organic phases were washed with brine (20
mL), dried (Na2SO4), ﬁltered, and then concentrated under reduced
pressure. The residue so obtained was subjected to ﬂash column
chromatography (silica, 1:1 v/v ethyl acetate/40−60 petroleum ether
elution) and thus aﬀorded, after concentration of the appropriate
fractions (Rf = 0.1), compound 6
5 (42 mg, 91%) as a white, crystalline
solid, mp 174 °C (lit.5b mp 225−228 °C). 1H NMR (400 MHz,
DMSO-d6, δ): 11.84 (s, 1H), 7.95 (m, 1H), 7.39 (dd, J = 8.0 and 1.4
Hz, 1H), 7.15 (m, 2H), 2.96 (t, J = 6.2 Hz, 2H), 2.42 (t, J = 6.2 Hz,
2H), 2.10 (m, 2H). 13C NMR (100 MHz, DMSO-d6, δ): 192.9, 152.3,
135.8, 124.5, 122.4, 121.5, 120.2, 111.7, 111.5, 37.8, 23.4, 22.7. IR
(ATR) νmax: 3056, 2954, 1604, 1576, 1462, 1445, 1411, 1251, 1177,
1145, 1016, 753 cm−1. MS (ESI, +) (m/z): 208 [(M+Na)+, 73%],
186 [(M+H)+, 100]. HRMS (ESI, +): [M + H]+ Calcd for
C12H12NO, 186.0913; found, 186.0912.
Method ii: A magnetically stirred solution of compound 5 (100 mg,
0.46 mmol) in hydrochloric acid (5 mL of a 3 M aqueous solution)
maintained at ca. 100 °C was treated with iron powder (154 mg, 2.76
g.atom). After 3 h, the reaction mixture was cooled to 22 °C, diluted
with ethyl acetate (20 mL), and ﬁltered through a plug of TLC-grade
silica topped with diatomaceous earth, and the solids so retained were
washed with ethyl acetate (1 × 10 mL). The combined ﬁltrates were
washed with water (2 × 20 mL) and brine (1 × 20 mL) before being
dried (Na2SO4), ﬁltered, and then concentrated under reduced
pressure. The residue so obtained was subjected to ﬂash column
chromatography (silica, ethyl acetate/40−60 petroleum ether elution)
and thus aﬀorded, after concentration of the appropriate fractions (Rf
= 0.2), compound 6 (10 mg, 12%) as a white, crystalline solid. This
material was identical, in all aspects, with that obtained by Method i.
Compound 8. A magnetically stirred solution of compound 71
(108 mg, 0.53 mmol) in acetone (5 mL) maintained at 22 °C was
treated with titanium(III) chloride (3.3 mL of a 12% w/v solution in
hydrochloric acid, 3.18 mmol). After 19 h, the reaction mixture was
quenched with sodium carbonate (10 mL of a saturated aqueous
solution), and the resulting mixture ﬁltered through a pad of
diatomaceous earth contained in a sintered glass funnel. The solids
thus retained were washed with ethyl acetate (20 mL). The separated
aqueous phase associated with the combined ﬁltrates was extracted
with ethyl acetate (2 × 10 mL), and the combined organic phases
were washed with brine (1 × 50 mL) before being dried (Na2SO4),
ﬁltered, and then concentrated under reduced pressure. The residue
so obtained was subjected to ﬂash column chromatography (silica, 4:6
v/v ethyl acetate/40−60 petroleum ether elution) and thus aﬀorded,
after concentration of the appropriate fractions (Rf = 0.2), compound
8 (74 mg, 80%) as a clear, red oil. 1H NMR (400 MHz, CDCl3, δ):
7.76 (t, J = 2.9 Hz, 1H), 7.15−7.10 (complex m, 2H), 6.77 (m, 1H),
6.72 (m, 1H), 4.04 (broad s, 2H), 2.80 (m, 2H), 2.60 (m, 2H). s13C
NMR (100 MHz, CDCl3, δ): 208.7, 162.7, 145.4, 144.8, 130.1, 129.6,
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118.8, 118.7, 117.0, 35.2, 27.2. IR (ATR) νmax: 3422, 3357, 2921,
1688, 1622, 1492, 1453, 1299, 1137, 935, 751 cm−1. MS (ESI, +) (m/
z): 196 [(M+Na)+, 100%], 174 [(M+H)+, 5]. HRMS (ESI, +): [M +
H] + Calcd for C11H12NO, 174.0913; found, 174.0910.
Compound 9. A magnetically stirred mixture of 4,4-dimethyl-2-
cyclohexan-1-one (640 mg, 5.2 mmol) in THF/water (24 mL of a 1:1
v/v mixture) maintained at 0 °C was treated with K2CO3 (860 mg,
6.2 mmol), DMAP (127 mg, 1.0 mmol), and in portions, powdered
molecular iodine (1.97 g, 7.8 mmol). The ensuing mixture was
warmed to 22 °C and after 3 h the reaction mixture was diluted with
ethyl acetate (20 mL) before being quenched with sodium sulﬁte (50
mL of a saturated aqueous solution) and then stirred vigorously until
two clear layers were formed. The separated aqueous phase was
extracted with ethyl acetate (2 × 20 mL), and the combined organic
phases were washed with sodium sulﬁte (1 × 50 mL of a saturated
aqueous solution), hydrochloric acid (1 × 50 mL of a 0.5 M aqueous
solution), and brine (1 × 50 mL) before being dried (Na2SO4) and
then ﬁltered through a plug of TLC-grade silica. The ﬁltrate was
concentrated under reduced pressure, and the residue so obtained was
subjected to ﬂash column chromatography (silica, 1:7 v/v ethyl
acetate/40−60 petroleum ether elution). Concentration of the
appropriate fractions (Rf = 0.2) then gave compound 9
6 (1.29 g,
91%) as a clear, yellow oil. 1H NMR (400 MHz, CDCl3, δ): 7.45
(broad s, 1H), 2.67 (t, J = 6.9 Hz, 2H), 1.92 (t, J = 6.9 Hz, 2H), 1.18
(broadened s, 6H). 13C NMR (100 MHz, CDCl3, δ): 191.9, 168.0,
101.8, 38.0, 36.0, 33.3, 27.4. IR (ATR) νmax: 2959, 2926, 2864, 1687,
1583, 1317, 1142, 991, 957, 801, 724, 693 cm−1. MS (ESI, +) (m/z):
273 [(M+Na)+, 100%], 251 [(M+H)+, 50]. HRMS (ESI, +): [M +
H]+ Calcd for C8H12IO, 250.9927; found, 250.9925.
Compound 10. A magnetically stirred suspension of compound 9
(1.17 g, 4.7 mmol), o-iodonitrobenzene (2) (2.33 g, 9.4 mmol), and
copper powder (1.50 g, 23.5 g.atom) in dry DMSO (10 mL)
maintained at 50 °C was treated with Pd(dppf)Cl2·CH2Cl2 (220 mg,
0.24 mmol). After 3 h, the reaction mixture was cooled to 22 °C and
diluted with ethyl acetate (10 mL) before being ﬁltered through a
plug of TLC-grade silica topped with diatomaceous earth. The solids
thus retained were washed with ethyl acetate (1 × 30 mL), and the
combined ﬁltrates were washed with ammonia (2 × 50 mL of a 5% v/
v aqueous solution), water (2 × 50 mL), and brine (1 × 50 mL)
before being dried (Na2SO4), ﬁltered, and then concentrated under
reduced pressure. The residue so obtained was subjected to ﬂash
column chromatography (silica, 1:5 v/v ethyl acetate/40−60
petroleum ether elution) and thus aﬀorded, after concentration of
the appropriate fractions (Rf = 0.2), compound 10 (920 mg, 80%) as a
pale-yellow, crystalline solid, mp 112 °C. 1H NMR (400 MHz,
CDCl3, δ): 8.02 (dd, J = 8.2 and 1.2 Hz, 1H), 7.59 (m, 1H), 7.46 (m,
1H), 7.24 (dd, J = 7.6 and 1.4 Hz, 1H), 6.65 (s, 1H), 2.61 (t, J = 6.8
Hz, 2H), 2.00 (m, 2H), 1.28 (s, 6H). 13C NMR (100 MHz, CDCl3,
δ): 196.4, 155.5, 148.6, 136.6, 133.2, 132.1, 131.7, 128.7, 124.2, 35.8,
34.7, 33.4, 27.7. IR (ATR) νmax: 2960, 1682, 1524, 1351, 1145, 859,
787, 725 cm−1. MS (ESI, +) (m/z): 268 [(M+Na)+, 100%], 246 [(M
+H)+, 56]. HRMS (ESI, +): [M + H]+ Calcd for C14H15NO3,
246.1125; found, 246.1126.
Compound 11. A magnetically stirred mixture of compound 10
(50 mg, 0.20 mmol) and 10% palladium on carbon (10 mg) in dry
methanol (5 mL) maintained at 22 °C was placed under a hydrogen
atmosphere. After 2 h, the reaction mixture was ﬁltered through a pad
of diatomaceous earth, and the ﬁltrate was concentrated under
reduced pressure. The residue thus obtained was subjected to ﬂash
column chromatography (silica, 5:95 v/v ethyl acetate/40−60
petroleum ether elution) and thus aﬀorded, after concentration of
the appropriate fractions (Rf = 0.4 in 1:10 v/v ethyl acetate/40−60
petroleum ether elution), compound 117 (37 mg, 92%) as a white,
crystalline solid, mp 99 °C. 1H NMR (400 MHz, CDCl3, δ): 7.66
(broad s, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.29 (m, 1H), 7.10−7.02
(complex m, 2H), 2.73 (t, J = 6.5 Hz, 2H), 2.52 (s, 2H), 1.68 (t, J =
6.5 Hz, 2H), 1.10 (s, 6H). 13C NMR (100 MHz, CDCl3, δ): 136.1,
132.8, 128.1, 120.9, 119.0, 117.6, 110.3, 109.7, 36.1, 34.9, 30.2, 28.2,
20.7. IR (ATR) νmax: 3406, 2950, 1468, 1357, 1327, 1236, 1187, 1008,
740, 635 cm−1. MS (ESI, −) (m/z): 198 [(M−H)−, 100%]. HRMS
(ESI, +): [M + H]+ Calcd for C14H18N, 200.1434; found, 200.1433.
Compound 12. A magnetically stirred solution of compound 10
(50 mg, 0.20 mmol) in acetone (3 mL) maintained at 22 °C was
treated with titanium(III) chloride (1.25 mL of a 12% w/v solution in
hydrochloric acid, 1.20 mmol). After 16 h, the reaction mixture was
cooled to 22 °C and then quenched with Na2CO3 (10 mL of a
saturated aqueous solution), and the resulting heterogeneous mixture
ﬁltered through a pad of diatomaceous earth. The solids so retained
were washed with ethyl acetate (1 × 20 mL), and the aqueous phase
associated with the combined ﬁltrates was extracted with ethyl acetate
(2 × 10 mL). The combined organic phases were washed with brine
(1 × 50 mL), dried (Na2SO4), and ﬁltered before being concentrated
under reduced pressure. The residue so obtained was subjected to
ﬂash column chromatography (silica, 1:8 v/v ethyl acetate/dichloro-
methane elution) and thus aﬀorded, after concentration of the
appropriate fractions (Rf = 0.2), compound 12
8 (35 mg, 82%) as a
white, crystalline solid, mp 258 °C (lit.8 mp 270−274 °C). 1H NMR
(400 MHz, CDCl3, δ): 8.80 (broad s, 1H), 8.26 (m, 1H), 7.38 (m,
1H), 7.24 (m, 2H), 2.68 (dd, J = 7.0 and 6.0 Hz, 2H), 2.10 (dd, J =
7.0 and 6.0 Hz, 2H), 1.48 (s, 6H). 13C NMR (100 MHz, CDCl3, δ):
194.0, 158.3, 135.6, 124.9, 123.4, 122.7, 121.7, 111.4, 111.0, 38.6,
35.4, 32.1, 27.4. IR (ATR) νmax: 3186, 2962, 1625, 1615, 1582, 1474,
1453, 1415, 1201, 881, 756 cm−1. MS (ESI, +) (m/z): 449 [(2M
+Na)+, 58%], 236 [(M+Na)+, 85] 214 [(M+H)+, 100]. HRMS (ESI,
+): [M + H]+ Calcd for C14H16NO, 214.1227; found, 214.1226.
Compound 14. A magnetically stirred solution of compound 139
(109 mg, 0.50 mmol) in acetone (2.5 mL) maintained at 22 °C was
treated with titanium(III) chloride (2.5 mL of a 12% w/v solution in
hydrochloric acid, 2.39 mmol). After 16 h, the reaction mixture was
quenched with sodium carbonate (10 mL of a saturated aqueous
solution), and the resulting heterogeneous mixture ﬁltered through a
pad of diatomaceous earth. The solids so retained were washed with
ethyl acetate (1 × 20 mL), and the aqueous phase associated with the
combined ﬁltrates was extracted with ethyl acetate (2 × 10 mL). The
combined organic phases were washed with brine (1 × 10 mL), dried
(Na2SO4), and ﬁltered before being concentrated under reduced
pressure. The residue so obtained was subjected to ﬂash column
chromatography (silica, ethyl acetate elution) and thus aﬀorded, after
concentration of the appropriate fractions (Rf = 0.2), compound 14
(50 mg, 54%) as a white, crystalline solid, mp 179 °C. 1H NMR (400
MHz, CDCl3, δ): 13.01 (broad s, 1H), 8.55 (dd, J = 7.7 and 1.4 Hz,
1H), 8.31 (d, J = 4.9 Hz, 1H), 7.29 (m, 1H), 3.13 (t, J = 6.2 Hz, 2H),
2.65 (t, J = 6.4 Hz, 2H), 2.40−2.26 (complex m, 2H). 13C NMR (100
MHz, CDCl3, δ): 194.0, 152.5, 148.8, 141.8, 130.5, 118.5, 118.2,
111.7, 37.9, 23.5, 23.4. IR (ATR) νmax: 3047, 2950, 2842, 1640, 1589,
1472, 1414, 1281, 1178, 1010, 776 cm−1. MS (ESI, +) (m/z): 209
[(M+H)+, 100%], 187 [(M + Na)+, 60]. HRMS (ESI, +): [M + H]+
Calcd for C11H11N2O, 187.0866; found, 187.0865.
Compound 15. A magnetically stirred solution of levoglucosenone
(1.50 g, 11.9 mmol) in dry dichloromethane (15 mL) maintained at
22 °C was treated, in portions, with powdered molecular iodine (4.53
g, 17.8 mmol) and then pyridine (1.05 mL, 13.1 mmol). After 48 h,
the reaction mixture was quenched with sodium sulﬁte (30 mL of a
saturated aqueous solution) and then stirred vigorously until two clear
layers were formed. The separated aqueous phase was extracted with
dichloromethane (2 × 20 mL), and the combined organic phases
were washed with sodium sulﬁte (1 × 60 mL of a saturated aqueous
solution), hydrochloric acid (1 × 100 mL of a 0.5 M aqueous
solution), and brine (1 × 100 mL) before being dried (Na2SO4) and
then ﬁltered through a plug of TLC-grade silica. The ﬁltrate was
concentrated under reduced pressure, and the residue so obtained was
subjected to ﬂash column chromatography (silica, 1:1 v/v diethyl
ether/40−60 petroleum ether elution). Concentration of the
appropriate fractions (Rf = 0.3) then gave compound 15
10 (2.24 g,
75%) as a pale-yellow, crystalline solid, mp 64 °C (lit.10 mp 85−90
°C). 1H NMR (400 MHz, CDCl3, δ): 7.96 (d, J = 5.0 Hz, 1H), 5.57
(s, 1H), 4.93 (m, 1H), 3.89−3.78 (complex m, 2H). 13C NMR (100
MHz, CDCl3, δ): 183.1, 155.5, 100.9, 99.8, 74.3, 66.5. IR (ATR) νmax:
3063, 2973, 2899, 1699, 1575, 1329, 1175, 1104, 978, 916, 881 cm−1.
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.8b01940
J. Org. Chem. XXXX, XXX, XXX−XXX
E
161
MS (ESI, +) (m/z): 307 [(M+Na+MeOH)+, 100%], 275 [(M+Na)+,
55]. HRMS (ESI, +): [M + H]+ Calcd for C6H6IO3, 252.9356; found,
252.9361.
Compound 17. A magnetically stirred suspension of compound 15
(297 mg, 1.2 mmol), o-iodonitrobenzene (2) (200 mg, 0.79 mmol),
and copper powder (250 mg, 4.0 g.atom) in dry DMSO (6 mL)
maintained at 80 °C was treated with Pd2(dba)3 (72 mg, 0.08 mmol).
After 16 h, the reaction mixture was cooled to 22 °C, diluted with
ethyl acetate (5 mL), and then ﬁltered through a plug of TLC-grade
silica topped with diatomaceous earth. The solids so retained were
washed with ethyl acetate (1 × 10 mL), and the combined ﬁltrates
were washed with ammonia (2 × 15 mL of a 5% v/v aqueous
solution), water (2 × 15 mL), and then brine (1 × 15 mL) before
being dried (Na2SO4), ﬁltered, and concentrated under reduced
pressure. The ensuing residue was subjected to ﬂash column
chromatography (silica, 2:8 to 1:1 v/v diethyl ether/40−60 petroleum
ether elution) and thus aﬀorded, after concentration of the
appropriate fractions (Rf = 0.3 in 4:6 v/v ethyl acetate/40−60
petroleum ether), compound 17 (135 mg, 69%) as a white, crystalline
solid, mp 137 °C. 1H NMR (400 MHz, acetone-d6, δ): 7.92 (m, 1H),
7.53 (m, 1H), 7.27−7.18 (complex m, 2H), 5.88 (d, J = 4.5 Hz, 1H),
5.38 (s, 1H), 4.03 (dd, J = 7.1 and 4.5 Hz, 1H), 3.84 (d, J = 7.1 Hz,
1H) (resonance due to one proton not observed). 13C NMR (100
MHz, acetone-d6, δ): 186.8, 151.6, 137.1, 125.1, 124.4, 123.3, 121.5,
113.4, 108.3, 103.2, 72.2, 68.0. IR (ATR) νmax: 2967, 2899, 1703,
1523, 1354, 1108, 984, 895, 794 cm−1. MS (ESI, +) (m/z): 270 [(M
+Na)+, 100%]. HRMS (ESI, +): [M + H]+ Calcd for C12H10NO5,
248.0553; found, 248.0553.
Compound 18. A magnetically stirred suspension of compound 15
(2.77 g, 11.0 mmol), 3-bromo-2-nitropyridine (16)8 (1.0 g, 5.0
mmol), copper(I) iodide (1.43 g, 7.5 mmol), and copper powder
(1.58 g, 25.0 g.atom) in dry DMSO (50 mL) maintained at 50 °C was
treated with Pd(dppf)Cl2·CH2Cl2 (204 mg, 0.25 mmol). After 5 h,
the reaction mixture was cooled to 22 °C, diluted with ethyl acetate
(20 mL), and then ﬁltered through a plug of TLC-grade silica topped
with diatomaceous earth. The solids so retained were washed with
ethyl acetate (1 × 40 mL), and the combined ﬁltrates were washed
with ammonia (2 × 25 mL of a 5% v/v aqueous solution), water (2 ×
25 mL), and then brine (1 × 25 mL) before being dried (Na2SO4),
ﬁltered, and concentrated under reduced pressure. The residue so
obtained was subjected to ﬂash column chromatography (silica, 1:4 v/
v ethyl acetate/40−60 petroleum ether elution) and thus aﬀorded,
after concentration of the appropriate fractions (Rf = 0.2), compound
18 (1.133 g, 91%) as a yellow, crystalline solid, mp 170 °C. 1H NMR
(400 MHz, CDCl3, δ): 8.59 (dd, J = 4.7 and 1.7 Hz, 1H), 7.79 (dd, J
= 7.6 and 1.7 Hz, 1H), 7.65 (dd, J = 7.6 and 4.7 Hz, 1H), 7.32 (d, J =
4.8 Hz, 1H), 5.51 (s, 1H), 5.20 (t, J = 4.6 Hz, 1H), 4.05−3.96
(complex m, 2H). 13C NMR (100 MHz, CDCl3, δ): 185.4, 156.8,
148.8, 144.4, 141.6, 134.7, 128.1, 123.5, 101.3, 72.3, 66.9. IR (ATR)
νmax: 2971, 2888, 1702, 1541, 1407, 1364, 1101, 984, 930, 890, 819,
647 cm−1. MS (ESI, +) (m/z): 271 [(M+Na)+, 100%]. HRMS (ESI,
+): [M + H]+ Calcd for C11H9N2O5, 249.0506; found, 249.0509.
Compound 19. A magnetically stirred solution of compound 18
(40 mg, 0.16 mmol) in THF (1.7 mL) maintained at 22 °C was
treated with titanium(III) chloride (0.85 mL of a 12% w/v solution in
hydrochloric acid, 0.81 mmol). After 18 h, the reaction mixture was
quenched with sodium carbonate (5 mL of a saturated aqueous
solution), and the resulting heterogeneous mixture was ﬁltered
through a pad of diatomaceous earth. The solids so retained were
washed with ethyl acetate (1 × 10 mL), the combined ﬁltrates were
separated, and the aqueous phase was extracted with ethyl acetate (2
× 5 mL). The combined organic phases were washed with brine (1 ×
30 mL), dried (Na2SO4), ﬁltered, and concentrated under reduced
pressure. The residue so obtained was subjected to ﬂash column
chromatography (silica, 4:6 v/v ethyl acetate/40−60 petroleum ether
elution) and thus aﬀorded, after concentration of the appropriate
fractions (Rf = 0.4), compound 19 (34 mg, 97%) as a white,
crystalline solid, mp > 250 °C. 1H NMR (400 MHz, CDCl3, δ): 8.09
(d, J = 8.1 Hz, 1H), 7.65 (m, 1H), 7.56 (m, 1H), 7.28−7.24 (complex
m, 2H), 5.51 (s, 1H), 5.19 (t, J = 4.6 Hz, 1H), 4.06−3.95 (complex
m, 2H). 13C NMR (100 MHz, CDCl3, δ): 185.7, 148.5, 142.7, 137.3,
133.5, 131.5, 129.8, 128.8, 124.6, 101.3, 72.1, 66.8. IR (ATR) νmax:
3278, 2924, 1651, 1479, 1452, 1076, 869 cm−1. MS (ESI, +) (m/z):
238 [(M+Na)+, 100%]. HRMS (ESI, +): [M + H]+ Calcd for
C12H10NO3, 216.0655; found, 216.0658.
Compound 20. A magnetically stirred solution of compound 18
(52 mg, 0.21 mmol) and hydrochloric acid (9 mL of a 1 M aqueous
solution) in 1,2-dimethoxyethane (5 mL) maintained at 50 °C was
treated with iron powder (59 mg, 1.10 g.atom). After 18 h, the
reaction mixture was cooled to 22 °C, diluted with ethyl acetate (10
mL), and then ﬁltered through a plug of TLC-grade silica topped with
diatomaceous earth, and the solids so retained were washed with ethyl
acetate (1 × 10 mL). The combined ﬁltrates were washed with water
(2 × 20 mL) and brine (1 × 20 mL) before being dried (Na2SO4),
ﬁltered, and then concentrated under reduced pressure. The ensuing
residue was subjected to ﬂash column chromatography (silica, 2:1 v/v
ethyl acetate/40−60 petroleum ether elution) and thus aﬀorded, after
concentration of the appropriate fractions (Rf = 0.2), compound 20
(26 mg, 58%) as a white, crystalline solid, mp 275 °C. 1H NMR (400
MHz, acetone-d6, δ): 8.37 (m, 1H), 8.25 (dd, J = 7.8 and 1.6 Hz, 1H),
7.29 (dd, J = 7.8 and 4.8 Hz, 1H), 5.95 (d, J = 4.6 Hz, 1H), 5.44 (s,
1H), 4.11 (dd, J = 7.2 and 4.6 Hz, 1H), 3.96 (d, J = 7.2 Hz, 1H)
(signal due to N−H group proton not observed). 13C NMR (100
MHz, acetone-d6, δ): 186.5, 152.2, 149.8, 145.6, 129.6, 119.4, 117.4,
107.1, 103.1, 72.1, 68.0. IR (ATR) νmax: 2981, 2888, 1679, 1592,
1480, 1426, 1109, 1075, 889, 805 cm−1. MS (ESI, +) (m/z): 239 [(M
+Na)+, 100%], 217 [(M+H)+, 10]. HRMS (ESI, +): [M + H]+ Calcd
for C11H9N2O3, 217.0608; found, 217.0609.
Compounds 22 and 23. A magnetically stirred solution of trans-
chalcone (21) (475 mg, 2.28 mmol) in dry dichloromethane (7 mL)
maintained at 22 °C was treated, in portions, with powdered
molecular iodine (2.00 g, 7.98 mmol) and then pyridine (7 mL). After
48 h, the reaction mixture was quenched with sodium sulﬁte (30 mL
of a saturated aqueous solution), and vigorous stirring continued until
two clear layers had formed. The separated aqueous phase was
extracted with dichloromethane (2 × 10 mL), and the combined
organic phases were washed with sodium sulﬁte (1 × 60 mL of a
saturated aqueous solution), hydrochloric acid (1 × 500 mL of a 0.5
M aqueous solution), and brine (1 × 50 mL) before being dried
(Na2SO4) and then ﬁltered through a plug of TLC-grade silica. The
ﬁltrate was concentrated under reduced pressure, and the residue so
obtained was subjected to ﬂash column chromatography (silica, 5:95
to 1:9 v/v diethyl ether/40−60 petroleum ether gradient elution).
Two fractions, A and B, were thus obtained.
Concentration of fraction A (Rf = 0.5 in 1:9 diethyl ether/40−60
petroleum ether) gave compound 2212 (439 mg, 58%) as a light-
yellow oil. 1H NMR (400 MHz, CDCl3, δ): 8.01−7.92 (complex m,
2H), 7.58−7.40 (complex m, 6H), 7.17 (m, 3H). 13C NMR (100
MHz, CDCl3, δ): 193.0, 148.5, 135.5, 135.3, 132.7, 130.2, 130.0,
129.4, 128.5, 128.4, 103.5. IR (ATR) νmax: 3057, 3024, 2923, 1657,
1595, 1446, 1238, 1176, 1059, 748, 689 cm−1. MS (ESI, +) (m/z):
357 [(M+Na)+, 100%]. HRMS (ESI, +): [M + H]+ Calcd for
C15H12IO, 334.9927; found, 334.9916.
Concentration of fraction B (Rf = 0.6 in 1:9 diethyl ether/40−60
petroleum ether) gave compound 2312 (79 mg, 10%) as a light-yellow
oil. 1H NMR (400 MHz, CDCl3, δ): 7.98 (m, 2H), 7.53 (m, 2H),
7.40 (m, 2H), 7.16 (m, 5H). 13C NMR (100 MHz, CDCl3, δ): 193.6,
143.4, 136.0, 134.0, 132.5, 129.9, 128.8, 128.7, 128.5, 128.1, 92.7. IR
(ATR) νmax: 3058, 3024, 2924, 1659, 1596, 1447, 1221, 1173, 1012,
750, 685 cm−1. MS (ESI, +) (m/z): 357 [(M+Na)+, 100%]. HRMS
(ESI, +): [M + H]+ Calcd for C15H12IO, 334.9927; found, 334.9916.
Compounds 24 and 25. Method i: A magnetically stirred mixture
of compound 22 (160 mg, 0.48 mmol), 3-bromo-2-nitropyridine (16)
(155 mg, 0.76 mmol), and copper powder (182 mg, 2.87 g.atom) in
dry DMSO (5 mL) maintained at 80 °C was treated with Pd2(dba)3
(43 mg, 0.05 mmol). After 16 h, the reaction mixture was cooled to
22 °C, diluted with ethyl acetate (10 mL), and then ﬁltered through a
plug of TLC-grade silica topped with diatomaceous earth. The solids
so retained were washed with ethyl acetate (1 × 5 mL), and the
combined ﬁltrates were washed with ammonia (2 × 10 mL of a 5% v/
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v aqueous solution), water (2 × 10 mL), and brine (1 × 10 mL)
before being dried (Na2SO4), ﬁltered, and then concentrated under
reduced pressure. The residue so obtained was subjected to ﬂash
column chromatography (silica, 3:7 to 1:1 v/v diethyl ether/40−60
petroleum ether gradient elution) and so aﬀorded two fractions, A
and B.
Concentration of fraction A (Rf = 0.3 in 3:7 ethyl acetate/40−60
petroleum ether) gave compound 24 (122 mg, 77%) as a light-yellow
oil. 1H NMR (400 MHz, CDCl3, δ): 8.53 (dd, J = 4.6 and 1.8 Hz,
1H), 8.16 (dd, J = 7.8 and 1.8 Hz, 1H), 7.90 (m, 2H), 7.62 (dd, J =
7.8 and 4.6 Hz, 1H), 7.40 (m, 1H), 7.29−7.22 (complex m, 3H),
7.17−7.08 (complex m, 5H). 13C NMR (100 MHz, CDCl3, δ): 195.6,
156.4, 147.8, 141.9, 138.3, 135.9, 134.3, 133.7, 133.4, 130.0, 129.4,
129.1, 128.3, 128.2(1), 128.9(9), 127.3. IR (ATR) νmax: 3060, 2982,
1734, 1646, 1540, 1447, 1359, 1245, 694 cm−1. MS (ESI, +) (m/z):
353 [(M+Na)+, 100%]. HRMS (ESI, +): [M + H]+ Calcd for
C20H15N2O3, 331.1077; found, 331.1080. On standing this oil
solidiﬁed and thus yielding crystals (mp 96 °C), one of which was
suitable for X-ray analysis.
Concentration of fraction B (Rf = 0.4 in 3:7 ethyl acetate/40−60
petroleum ether) gave compound 25 (12 mg, 8%) as a light-yellow
oil. 1H NMR (400 MHz, CDCl3, δ): 8.63 (dd, J = 4.6 and 1.9 Hz,
1H), 7.92 (m, 2H), 7.73 (m, 1H), 7.60 (m, 2H), 7.53 (m, 2H), 7.48
(s, 1H), 7.29 (m, 1H), 7.23 (m, 2H), 7.00 (m, 2H). 13C NMR (100
MHz, CDCl3, δ): 195.6, 156.4, 148.3, 143.8, 143.5, 137.4, 135.9,
133.3, 132.4, 130.1, 129.9, 129.8, 128.7, 128.4, 128.3, 127.9. IR
(ATR) νmax: 3060, 2981, 1647, 1541, 1447, 1365, 1231, 695 cm
−1.
MS (ESI, +) (m/z): 353 [(M+Na)+, 100%]. HRMS (ESI, +): [M +
H]+ Calcd for C20H15N2O3, 331.1077; found, 331.1079.
Method ii: Compound 23 was subjected to cross-coupling with
bromopyridine 16 in the same manner as described immediately
above in Method i. Subjection of the product mixture obtained on
workup to ﬂash column chromatography (silica, 3:7 to 1:1 v/v diethyl
ether/40−60 petroleum ether gradient elution) aﬀorded two
fractions, A and B.
Concentration of fraction A (Rf = 0.3 in v/v 3:7 ethyl acetate/40−
60 petroleum ether) gave compound 24 (18%) as a light-yellow oil.
This material was identical, in all aspects, with that obtained by
Method i.
Concentration of fraction B (Rf = 0.4 in 3:7 v/v ethyl acetate/40−
60 petroleum ether) gave compound 25 (41%) as a light-yellow oil.
This material was identical, in all aspects, with that obtained by
Method i.
Compound 26. Method i: A magnetically stirred mixture of
compound 24 (23 mg, 0.07 mmol) and 10% palladium on carbon (10
mg) in ethyl acetate (5 mL) maintained at 22 °C was placed under a
hydrogen atmosphere. After 16 h, the reaction mixture was ﬂushed
with nitrogen and then ﬁltered through a pad of diatomaceous earth,
and the ﬁltrate was concentrated under reduced pressure. The residue
thus obtained was subjected to ﬂash column chromatography (silica,
3:7 to 1:1 v/v ethyl acetate/40−60 petroleum ether gradient elution)
and thus aﬀorded, after concentration of the appropriate fractions (Rf
= 0.4 in 3:7 v/v ethyl acetate/40−60 petroleum ether), compound
2613 (13 mg, 63%) as a white, crystalline solid, no mp, decomposition
above 120 °C. 1H NMR (400 MHz, CDCl3, δ): 11.77 (broad s, 1H),
8.18 (m, 1H), 7.69 (m, 3H), 7.50 (m, 2H), 7.42 (m, 1H), 7.32−7.15
(complex m, 5H), 6.99 (m, 1H), 4.32 (s, 2H). 13C NMR (100 MHz,
CDCl3, δ): 148.1, 140.9, 136.9, 132.3, 130.1, 129.6, 128.9, 128.6,
128.5, 128.3(1), 128.2(9), 128.2, 126.0, 115.5, 109.1, 30.5. IR (ATR)
νmax: 3026, 2920, 2849, 1739, 1600, 1579, 1490, 1461, 1411, 765, 699
cm−1. MS (ESI, +) (m/z): 285 [(M+H)+, 100%]. HRMS (ESI, +):
[M + H]+ Calcd for C20H17N2, 285.1386; found, 285.1388.
Method ii: Compound 25 was subjected to reductive cyclization in
the same manner as described immediately above in Method i.
Subjection of the product mixture obtained on workup to ﬂash
column chromatography (silica, 3:7 to 1:1 v/v diethyl ether/40−60
petroleum ether gradient elution) aﬀorded, after concentration of the
appropriate fractions (Rf = 0.4 in 3:7 to 1:1 v/v ethyl acetate/40−60
petroleum ether), compound 26 (80%) as a white, crystalline solid.
This material was identical, in all aspects, with that obtained by
Method i.
Compound 27. A magnetically stirred mixture of compound 24
(45 mg, 0.14 mmol) in THF (5 mL) maintained at 22 °C was treated
with titanium(III) chloride (0.9 mL of a 12% w/v solution in
hydrochloric acid, 0.86 mmol). After 16 h, the reaction mixture was
quenched with sodium carbonate (10 mL of a saturated aqueous
solution), and the resulting heterogeneous mixture was ﬁltered
through a pad of diatomaceous earth. The solids so retained were
washed with ethyl acetate (1 × 20 mL), the combined ﬁltrates were
separated, and the aqueous phase was extracted with ethyl acetate (4
× 10 mL). The combined organic phases were washed with brine (1
× 50 mL), dried (Na2SO4), and ﬁltered before being concentrated
under reduced pressure. The residue so obtained was subjected to
ﬂash column chromatography (silica, 2:8 to 1:1 v/v ethyl acetate/40−
60 petroleum ether gradient elution) and thus aﬀorded, after
concentration of the appropriate fractions (Rf = 0.2 in 3:7 v/v ethyl
acetate/40−60 petroleum ether), compound 27 (20 mg, 49%) as a
yellow, crystalline solid, mp 159 °C. 1H NMR (400 MHz, CDCl3, δ):
8.37 (d, J = 7.9 Hz, 1H), 8.15 (broad s, 1H), 7.64 (m, 2H), 7.52 (m,
2H), 7.34 (m, 4H), 7.21 (m, 4H). 13C NMR (100 MHz, CDCl3, δ):
192.7, 148.1, 145.4, 142.5, 139.3, 131.7, 131.5, 131.1, 129.8, 129.6,
129.3, 128.4, 127.8, 117.9, 111.6 (one signal obscured or over-
lapping). IR (ATR) νmax: 2917, 2849, 1615, 1459, 1435, 1292, 936,
896, 766, 730, 698 cm−1. MS (ESI, +) (m/z): 321 [(M+Na)+, 100%],
299 [(M+H)+, 70%]. HRMS (ESI, +): [M + H]+ Calcd for
C20H15N2O, 299.1179; found, 299.1181.
Method ii: Compound 25 was subjected to reductive cyclization in
the same manner as described immediately above in Method i.
Subjection of the product mixture obtained on workup to ﬂash
column chromatography (silica, 2:8 to 1:1 v/v ethyl acetate/40−60
petroleum ether gradient elution) aﬀorded, after concentration of the
appropriate fractions (Rf = 0.2 in 3:7 v/v ethyl acetate/40−60
petroleum ether), compound 27 (15%) as a yellow, crystalline solid.
This material was identical, in all aspects, with that obtained by
Method i.
Compound 32. A magnetically stirred mixture of compound 311
(516 mg, 2.00 mmol), o-iodonitrobenzene (2) (996 mg, 4.00 mmol),
and copper powder (636 mg, 10.0 g.atom) in dry DMSO (10 mL)
maintained at 50 °C was treated with Pd(dppf)Cl2·CH2Cl2 (82 mg,
0.10 mmol). After 4 h, the reaction mixture was cooled to 22 °C and
then diluted with ethyl acetate (10 mL) before being ﬁltered through
a plug of TLC-grade silica topped with diatomaceous earth. The
solids so retained were washed with ethyl acetate (1 × 30 mL), and
the combined ﬁltrates were washed with ammonia (2 × 40 mL of a
5% v/v aqueous solution), water (2 × 40 mL), and brine (1 × 40 mL)
before being dried (Na2SO4), ﬁltered, and then concentrated under
reduced pressure. The residue so obtained was subjected to ﬂash
column chromatography (silica, toluene elution) and thus aﬀorded,
after concentration of the appropriate fractions (Rf = 0.3), compound
321 (390 mg, 77%) as a clear, yellow oil. 1H NMR (400 MHz, CDCl3,
δ): 9.73 (s, 1H), 8.23 (m, 1H), 7.63−7.56 (complex m, 2H), 7.54 (s,
1H), 7.37−7.22 (complex m, 3H), 7.17 (complex m, 3H). 13C NMR
(100 MHz, CDCl3, δ): 191.8, 148.9, 139.7, 133.9, 133.3, 132.0, 130.5,
130.4, 129.6(1), 129.5(9), 128.7, 125.0 (one signal obscured or
overlapping). IR (ATR) νmax: 3348, 3062, 2830, 1682, 1627, 1521,
1346, 1110, 1062, 856, 713 cm−1. MS (ESI, +) (m/z): 276 [(M
+Na)+, 100%], 254 [(M+H)+, 8]. HRMS (ESI, +): [M + H] + Calcd
for C15H12NO3, 254.0182; found, 254.0182.
Compounds 33 and 34. A magnetically stirred solution of
compound 32 (134 mg, 0.53 mmol) in acetone (5 mL) maintained at
22 °C was treated with titanium(III) chloride (3.3 mL of a 12% w/v
solution in hydrochloric acid, 3.18 mmol). After 23 h, the reaction
mixture was quenched with sodium carbonate (10 mL of a saturated
aqueous solution,) and the resulting heterogeneous mixture was
ﬁltered through a pad of diatomaceous earth. The solids so retained
were washed with ethyl acetate (1 × 20 mL), the combined ﬁltrates
were separated, and the aqueous phase was extracted with ethyl
acetate (2 × 20 mL). The combined organic phases were washed with
brine (1 × 50 mL), dried (Na2SO4), and ﬁltered before being
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concentrated under reduced pressure. The residue so obtained was
subjected to ﬂash column chromatography (silica, 1:9 v/v diethyl
ether/dichloromethane elution) and thus aﬀorded a partially
separable, ca. 5−3:1, and slowly interconverting mixture of
compounds 3314 and 3414 (64 mg, 55%) as an oily solid. Rf = 0.2
and 0.4, respectively. 1H NMR (400 MHz, CDCl3, δ) (for compound
33): 8.20 (broad s, 1H), 7.85 (s, 1H), 7.70−7.60 (complex m 3H),
7.52−7.41 (complex m, 3H), 7.22 (m, 1H), 6.88 (m, 2H). 13C NMR
(100 MHz, CDCl3, δ) (for compound 33): 170.1, 141.6, 137.7, 135.0,
130.0, 129.8, 129.5, 128.8, 127.6, 123.2, 122.0, 121.9, 110.2. 13C
NMR (100 MHz, CDCl3, δ) (for a ca. 3:1 mixture of compounds 33
and 34): 170.0, 167.7, 141.4, 139.6, 137.6(1), 137.5(9), 134.8, 133.7,
131.9, 130.6, 139.9, 129.7, 129.3, 128.9, 128.6, 128.3, 127.4, 126.2,
125.3, 123.0, 121.8(1). 121.7(9), 121.7, 119.3, 110.1, 109.5. IR
(ATR) νmax (for a mixture): 3222, 3062, 1704, 1613, 1463, 1329,
1202, 781, 747, 722, 696 cm−1. MS (ESI, +) (m/z) (for a mixture):
465 [(2M+Na)+, 60%], 244 [(M+Na)+, 100], 222 [(M+H)+, 13].
HRMS (ESI, +): [M + H]+ Calcd for C15H12NO, 222.0913; found,
222.0906.
Crystals of compound 33 suitable for X-ray analysis were grown
from diethyl ether (mp 169 °C).
Compound 36. A magnetically stirred mixture of 3-iodo-2-
methylcyclohex-2-enone16 (213 mg, 0.90 mmol), o-iodonitrobenzene
(2) (449 mg, 1.80 mmol), and copper powder (286 mg, 4.5 g.atom)
in dry DMSO (10 mL) maintained at 80 °C was treated with
Pd2(dba)3 (77 mg, 0.08 mmol). After 16 h, the reaction mixture was
cooled to 22 °C and diluted with ethyl acetate (10 mL) before being
ﬁltered through a plug of TLC-grade silica topped with diatomaceous
earth, and the solids so retained were washed with ethyl acetate (1 ×
10 mL). The combined ﬁltrates were washed with ammonia (2 × 40
mL of a 5% v/v aqueous solution), water (2 × 40 mL), and brine (1 ×
40 mL) before being dried (Na2SO4), ﬁltered, and then concentrated
under reduced pressure. The residue so obtained was subjected to
ﬂash column chromatography (silica, 1:4 to 1:1 v/v diethyl ether/40−
60 petroleum ether elution) and thus aﬀorded, after concentration of
the appropriate fractions (Rf = 0.3 in 2:3 v/v diethyl ether/40−60
petroleum ether elution), compound 36 (120 mg, 61%) as a clear,
light-yellow oil. 1H NMR (400 MHz, CDCl3, δ): 8.18 (dd, J = 8.3 and
1.3 Hz, 1H), 7.71 (m, 1H), 7.55 (m, 1H), 7.24 (dd, J = 7.6 and 1.6
Hz, 1H), 2.65 (m, 2H), 2.59−2.46 (complex m, 2H), 2.27 (m, 1H),
2.15 (m, 1H), 1.52 (s, 3H). 13C NMR (100 MHz, CDCl3, δ): 198.8,
153.9, 146.3, 136.7, 134.0, 131.8, 129.1, 128.8, 124.9, 37.8, 32.5, 23.0,
12.5. IR (ATR) νmax: 2947, 2870, 1665, 1523, 1344, 1111, 908, 727
cm−1. MS (ESI, +) (m/z): 254 [(M+Na)+, 100%], 232 [(M+H)+,
15]. HRMS (ESI, +): [M + H]+ Calcd for C13H14NO3, 232.0968;
found, 232.0966.
Compound 37. A magnetically stirred solution of compound 3516
(150 mg, 0.69 mmol) in acetone (7 mL) maintained at 22 °C was
treated with titanium(III) chloride (3.6 mL of a 12% w/v solution in
hydrochloric acid, 3.45 mmol). After 16 h, the reaction mixture was
quenched with sodium carbonate (15 mL of a saturated aqueous
solution), and the resulting heterogeneous mixture was ﬁltered
through a pad of diatomaceous earth. The solids so retained were
washed with ethyl acetate (1 × 20 mL), and the aqueous phase
associated with combined ﬁltrates was extracted with ethyl acetate (4
× 10 mL). The combined organic phases were washed with brine (1
× 50 mL), dried (Na2SO4), and ﬁltered before being concentrated
under reduced pressure. The residue so obtained was subjected to
ﬂash column chromatography (silica, 2:3 v/v ethyl acetate/40−60
petroleum ether elution) and thus aﬀorded, after concentration of the
appropriate fractions (Rf = 0.3), compound 37 (130 mg, quant.) as a
yellow, crystalline solid, mp 108 °C. 1H NMR (400 MHz, CDCl3, δ):
7.20 (m, 1H), 7.06 (dd, J = 7.6 and 1.7 Hz, 1H), 6.82 (m, 1H), 6.77
(m, 1H), 3.64 (broad s, 2H), 2.84 (m, 2H), 2.51 (m, 2H), 1.73 (t, J =
2.1 Hz, 3H). 13C NMR (100 MHz, CDCl3, δ): 209.6, 167.7, 142.5,
138.6, 129.7, 127.4, 122.2, 118.1, 115.7, 34.4, 30.8, 9.5. IR (ATR)
νmax: 3453, 3357, 2917, 1689, 1686, 1622, 1494, 1451, 1342, 1222,
1094, 1061, 747 cm−1. MS (ESI, +) (m/z): 210 [(M+Na)+, 100%],
188 [(M+H)+, 17]. HRMS (ESI, +): [M + H]+ Calcd for C12H14NO,
188.1070; found, 188.1069.
Compound 38. Method i: A magnetically stirred solution of
compound 3616 (45 mg, 0.19 mmol) in THF (2 mL) maintained at
22 °C was treated with titanium(III) chloride (1.0 mL of a 12% w/v
solution in hydrochloric acid, 0.96 mmol). After 16 h, the reaction
mixture was quenched with sodium carbonate (5 mL of a saturated
aqueous solution), and the resulting heterogeneous mixture was
ﬁltered through a pad of diatomaceous earth. The solids so retained
were washed with ethyl acetate (1 × 10 mL), the phases associated
with the combined ﬁltrates were separated, and the aqueous one was
extracted with ethyl acetate (4 × 10 mL). The combined organic
phases were washed with brine (1 × 50 mL), dried (Na2SO4), and
ﬁltered before being concentrated under reduced pressure. The
residue so obtained was subjected to ﬂash column chromatography
(silica, 1:1 v/v ethyl acetate/40−60 petroleum ether elution) and thus
aﬀorded, after concentration of the appropriate fractions (Rf = 0.6),
compound 38 (40 mg, 98%) as light-yellow crystals, mp 73 °C. 1H
NMR (400 MHz, CDCl3, δ): 7.13 (m, 1H), 6.92 (dd, J = 7.6 and 1.7
Hz, 1H), 6.79 (m, 1H), 6.74 (dd, J = 7.9 and 1.1 Hz, 1H), 3.57
(broad s, 2H), 2.55 (m, 4H), 2.10 (m, 2H), 1.65 (t, J = 2.0 Hz, 3H).
13C NMR (100 MHz, CDCl3, δ): 199.6, 154.9, 141.5, 133.6, 128.8,
127.1, 126.6, 118.4, 115.5, 37.9, 31.9, 22.9, 12.3. IR (ATR) νmax: 3459,
3362, 2945, 2923, 1660, 1618, 1494, 1452, 1354, 1106, 750 cm−1. MS
(ESI, +) (m/z): 224 [(M+Na)+, 100%], 202 [(M+H)+, 28]. HRMS
(ESI, +): [M + H]+ Calcd for C13H16NO, 202.1226; found, 202.1219.
Method ii: Reduction of compound 36 with TiCl3/HCl in the
same manner as detailed above but using acetone instead of THF as
the solvent gave, after workup and ﬂash chromatography, compound
38 (80%) as light-yellow crystals. This material was identical, in all
aspects, with that obtained by Method i.
Compounds 40 and 41. A magnetically stirred mixture of
compound 3916 (200 mg, 0.92 mmol) in acetone (10 mL) maintained
at 22 °C was treated with titanium(III) chloride (5.0 mL of a 12% w/
v solution in hydrochloric acid, 4.79 mmol). After 16 h, the reaction
mixture was quenched with sodium carbonate (20 mL of a saturated
aqueous solution), and the resulting heterogeneous mixture was
ﬁltered through diatomaceous earth. The solids so retained were
washed with ethyl acetate (40 mL), the combined ﬁltrates were
separated, and the aqueous phase was extracted with ethyl acetate (4
× 10 mL). The combined organic phases were washed with brine (1
× 100 mL), dried (Na2SO4), ﬁltered, and then concentrated under
reduced pressure. The residue so obtained was subjected to ﬂash
column chromatography (silica, 1:9 to 4:6 v/v ethyl acetate/40−60
petroleum ether elution) and so aﬀorded two fractions, A and B.
Concentration of fraction A (Rf = 0.4 in 1:1 v/v ethyl acetate/40−
60 petroleum ether elution) gave compound 4017 (80 mg, 40%) as
orange-colored crystals, mp 90 °C. 1H NMR (400 MHz, CDCl3, δ):
7.16 (m, 1H), 7.07 (dd, J = 7.8 and 1.7 Hz, 1H), 6.78 (m, 1H), 6.73
(dd, J = 8.1 and 1.2 Hz, 1H), 6.26 (t, J = 1.6 Hz, 1H), 3.84 (broad s,
2H), 2.67 (m, 2H), 2.51 (m, 2H), 2.15 (m, 2H). 13C NMR (100
MHz, CDCl3, δ): 199.6, 161.2, 142.8, 129.7, 127.9, 127.7, 125.5,
118.3, 116.2, 37.3, 30.2, 23.1. IR (ATR) νmax: 3443, 3354, 2925, 1655,
1608, 1490, 1449, 1244, 1188, 747 cm−1. MS (ESI, +) (m/z): 210
[(M+Na)+, 100%], 188 [(M+H)+, 9]. HRMS (ESI, +): [M + H]+
Calcd for C12H14NO, 188.1070; found, 188.1072.
Concentration of fraction B (Rf = 0.5 in 1:1 v/v diethyl ether/40−
60 petroleum ether elution) gave compound 41 (135 mg, 60%) as
red-colored crystals, mp 113 °C. 1H NMR (400 MHz, CDCl3, δ):
7.21 (dd, J = 7.9 and 1.5 Hz, 1H), 7.11 (m, 1H), 6.65 (m, 1H), 6.45
(dd, J = 8.0 and 1.2 Hz, 1H), 3.64 (broad s, 1H), 2.69 (t, J = 6.1 Hz,
2H), 2.43 (dd, J = 7.4 and 6.1 Hz, 2H), 2.03 (m, 2H), 1.52 (s, 6H).
13C NMR (100 MHz, CDCl3, δ): 196.8, 148.2, 145.2, 133.8, 131.7,
125.2, 120.2, 117.5, 113.8, 53.8, 38.7, 29.0, 25.9, 21.6. IR (ATR) νmax:
3336, 2952, 2925, 1637, 1607, 1380, 1269, 743 cm−1. MS (ESI, +)
(m/z): 250 [(M+Na)+, 100%], 228 [(M+H)+, 70%]. HRMS (ESI,
+): [M + H]+ Calcd for C15H18NO, 228.1383; found, 228.1384.
Compound 44. A magnetically stirred solution of compound 40
(35 mg, 0.19 mmol, 1.0 equiv) in butanone (5 mL) was treated with
HCl (100 μL of a 12 M aqueous solution), and the ensuing mixture
was maintained at 22 °C for 16 h. The resulting mixture was
quenched with sodium carbonate (5 mL of a saturated aqueous
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solution), and the separated aqueous layer was extracted with ethyl
acetate (3 × 5 mL). The combined organic phases were then dried
(Na2SO4), ﬁltered, and concentrated under reduced pressure. The
residue so obtained was subjected to ﬂash column chromatography
(silica, 5:35 v/v diethyl ether/40−60 petroleum ether elution) to
aﬀord, after concentration of the appropriate fractions (Rf = 0.6 in 3:7
v/v diethyl ether/40−60 petroleum ether elution), compound 44 (33
mg, 73%) as a red, crystalline solid, mp 118 °C. 1H NMR (400 MHz,
CDCl3, δ): 7.19 (dd, J = 7.9 and 1.3 Hz, 1H), 7.07 (m, 1H), 6.59 (m,
1H), 6.41 (dd, J = 8.0 and 1.1 Hz, 1H), 3.54 (broad s, 1H), 2.70 (m,
2H), 2.45 (m, 3H), 2.04 (m, 2H), 1.49 (s, 3H), 1.34 (m, 1H), 0.87 (t,
J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3, δ): 197.1, 149.2, 145.8,
131.9(1), 131.8(9), 125.3, 119.5, 116.9, 113.3, 57.3, 38.8, 33.8, 28.5,
26.1, 21.7, 9.3. IR (ATR) νmax: 3349, 2957, 2932, 2871, 1638, 1609,
1566, 1455, 1378, 1262, 1152 cm−1. MS (ESI, +) (m/z): 264 [(M
+Na)+, 100%], 242 [(M+H)+, 37]. HRMS (ESI, +): [M + H]+ Calcd
for C16H20NO 242.1545; found, 242.1547.
Compound 45. A magnetically stirred solution of compound 40
(65 mg, 0.35 mmol, 1.0 equiv) and cyclohexanone (136 mg, 1.39
mmol, 4.0 mol eq) in THF (5 mL) was treated with HCl (100 μL of a
12 M aqueous solution), and the ensuing mixture was stirred at 22 °C
for 16 h. The resulting mixture was quenched with sodium carbonate
(5 mL of a saturated aqueous solution), and the separated aqueous
layer was extracted with ethyl acetate (3 × 5 mL). The combined
organic layers were then dried (Na2SO4), ﬁltered, and concentrated
under reduced pressure. The residue thus obtained was dissolved in
methanol/CH2Cl2 (5 mL of a 1:1 v/v mixture), the resulting solution
was cooled to −78 °C, and NaBH4 (58 mg, 1.55 mmol, 5.0 mol eq)
was then added (so as to reduce the excess cyclohexenone). The
reaction mixture was stirred at −78 °C for 1 h and then treated with
acetone (5 mL) and warmed to 22 °C before being concentrated
under reduced pressure. The residue so obtained was subjected to
ﬂash column chromatography (silica, 3:7 v/v diethyl ether/40−60
petroleum ether elution) and so aﬀorded, after concentration of the
appropriate fractions (Rf = 0.6), compound 45 as orange crystals (59
mg, 64%), mp 136 °C. 1H NMR (400 MHz, CDCl3, δ): 7.20 (d, J =
7.8 Hz, 1H), 7.11 (m, 1H), 6.66 (m, 1H), 6.52 (dd, J = 8.0 and 1.1
Hz, 1H), 4.57 (broad s, 1H), 2.68 (t, J = 6.1 Hz, 2H), 2.51−2.34
(complex m, 4H), 2.01 (m, 2H), 1.79 (dm, J = 13.2 Hz, 2H), 1.70−
1.56 (complex m, 3H), 1.47−1.31 (complex m, 3H). 13C NMR (100
MHz, CDCl3, δ): 196.9, 149.1, 144.8, 134.1, 131.6, 125.3, 121.1,
117.7, 114.2, 55.4, 39.1, 32.7, 26.3, 24.7, 21.5, 21.0. IR (ATR) νmax:
3382, 2920, 2854, 1637, 1605, 1374, 1311, 1198 cm−1. MS (ESI, +)
(m/z): 290 [(M+Na)+, 100%], 268 [(M+H)+, 9]. HRMS (ESI, +):
[M + H]+ Calcd for C18H22NO, 268.1701; found, 268.1697.
Compound 46. A magnetically stirred solution of compound 40
(35 mg, 0.19 mmol, 1.0 equiv) and benzaldehyde (1.0 mL, 9.72
mmol, 52 mol eq ) in THF (3 mL) was maintained at 22 °C for 16 h
and then concentrated under reduced pressure. The ensuing residue
was subjected to ﬂash column chromatography (silica, 1:4 to 1:1 v/v
diethyl ether/40−60 petroleum ether gradient solution) and so
aﬀorded, after concentration of the appropriate fractions (Rf = 0.5 in
2:3 v/v diethyl ether/40−60 petroleum ether), compound 46 (51 mg,
quant.) as a light-yellow oil. 1H NMR (400 MHz, CDCl3, δ): 8.38 (s,
1H), 7.87 (dd, J = 7.5 and 2.1 Hz, 2H), 7.56−7.44 (complex m, 3H),
7.40 (m, 1H), 7.33−7.24 (complex m, 2H), 7.04 (dd, J = 7.8 and 1.1
Hz, 1H), 6.13 (broad s, 1H), 2.80 (m, 2H), 2.47 (m, 2H), 2.09 (m,
2H). 13C NMR (100 MHz, CDCl3, δ): 199.8, 163.2, 160.4, 149.5,
136.0, 134.8, 131.6, 129.9, 129.0, 128.8(1), 128.7(9), 128.1, 125.9,
118.7, 37.5, 30.7, 23.3. IR (ATR) νmax: 3060, 2943, 1661, 1625, 1578,
1451, 1188, 888, 764, 754, 691 cm−1. MS (ESI, +) (m/z): 298 [(M
+Na)+, 100%], 276 [(M+H)+, 15]. HRMS (ESI, +): [M + H]+ Calcd
for C19H18NO, 276.1383; found, 276.1382.
X-ray Crystallographic Studies. Crystallographic Data.
Crystallographic Data for Compound 5. C12H11NO2. M = 201.22.
T = 150 K. Monoclinic, space group P21/c, Z = 8, a = 8.6966(2), b =
12.4116(4), c = 21.1857(7) Å. β = 96.602(3)°. V = 2271.59(12) Å3.
Dx = 1.177 g cm
−3. 4391 unique data (2θmax = 144.0°). R = 0.057 [for
3120 reﬂections with I > 2.0σ(I)]. Rw = 0.164 (all data). S = 1.03.
Crystallographic Data for Compound 19. C12H9NO3. M =
215.20. T = 150 K. Orthorhombic, space group P212121, Z = 4, a =
6.7281(1), b = 9.5441(2), c = 15.1689(4) Å. V = 974.08 Å3. Dx =
1.467 g cm−3. 1951 unique data (2θmax = 147.4°). R = 0.038 [for 1890
reﬂections with I > 2.0σ(I)]. Rw = 0.101 (all data). S = 1.05.
Crystallographic Data for Compound 24. C20H14N2O3. M =
330.33. T = 150 K. Monoclinic, space group P21/c, Z = 4, a =
12.5226(3), b = 12.7446(3), c = 10.8100 Å. β = 107.865(2)°. V =
1642.04 Å3. Dx = 1.336 g cm
−3. 3297 unique data (2θmax = 147.6°). R
= 0.046 [for 3062 reﬂections with I > 2.0σ(I)]. Rw = 0.129 (all data).
S = 1.03.
Crystallographic Data for Compound 26. C20H16N2. M = 284.35.
T = 150 K. Triclinic, space group P1̅, Z = 4, a = 10.2371(7), b =
12.0551(8), c = 12.5051(9) Å. α = 93.572(6)°. β = 105.062(6)°. γ =
99.112(6) °. V = 1462.73 (18) Å3. Dx = 1.291 g cm−3. 5940 unique
data (2θmax = 52.8°). R = 0.046 [for 4420 reﬂections with I > 2.0σ(I)].
Rw = 0.120 (all data). S = 1.04.
Crystallographic Data for Compound 33. C15H11NO. M =
221.25. T = 150 K. Monoclinic, space group P21/c, Z = 4, a =
4.0072(1), b = 22.2268(5), c = 12.2592(3) Å. β = 95.112(2)°. V =
1087.55(5) Å3. Dx = 1.351 g cm
−3. 2147 unique data (2θmax =
148.4°). R = 0.052 [for 2026 reﬂections with I > 2.0σ(I)]. Rw = 0.144
(all data). S = 1.04.
Crystallographic Data for Compound 38. C13H15NO. M =
201.26. T = 150 K. Monoclinic, space group P21/c, Z = 12, a =
13.9326(3), b = 31.3218(6), c = 7.6013(1) Å. β = 98.270(2)°. V =
3282.67(11) Å3. Dx = 1.222 g cm
−3. 6363 unique data (2θmax =
144.2°). R = 0.058 [for 5008 reﬂections with I > 2.0σ(I)]. Rw = 0.163
(all data). S = 1.07.
Crystallographic Data for Compound 40. C12H13NO. M =
187.23. T = 150 K. Monoclinic, space group P21, Z = 2, a =
7.0538(7), b = 8.4543(7), c = 8.3005(10) Å. β = 99.725(10)°. V =
487.89(9) Å3. Dx = 1.275 g cm
−3. 1859 unique data (2θmax = 52.8°). R
= 0.038 [for 1663 reﬂections with I > 2.0σ(I)]. Rw = 0.081 (all data).
S = 1.09.
Crystallographic Data for Compound 41. C15H17NO. M =
227.29. T = 150 K. Monoclinic, space group P21/n, Z = 4, a =
8.8038(8), b = 12.8773(9), c = 11.2318(10) Å. β = 109.578(10)°. V =
1199.72(19) Å3. Dx = 1.258 g cm
−3. 2446 unique data (2θmax =
52.8°). R = 0.039 [for 2055 reﬂections with I > 2.0σ(I)]. Rw = 0.107
(all data). S = 1.04.
Crystallographic Data for Compound 44. C16H17NO. M =
239.30. T = 150 K. Monoclinic, space group P21/n, Z = 4, a =
9.3856(3), b = 12.2110(3), c = 12.1822(4) Å. β = 108.645(4)°. V =
1322.90(7) Å3. Dx = 1.202 g cm
−3. 2640 unique data (2θmax =
147.2°). R = 0.082 [for 2373 reﬂections with I > 2.0σ(I)]. Rw = 0.244
(all data). S = 1.06.
Crystallographic Data for Compound 45. C18H21NO. M =
267.36. T = 150 K. Monoclinic, space group P21/n, Z = 4, a =
11.0667(3), b = 10.0284(2), c = 14.0170(3) Å. β = 112.696(3)°. V =
1435.16(6) Å3. Dx = 1.237 g cm
−3. 2883 unique data (2θmax =
148.0°). R = 0.047 [for 2635 reﬂections with I > 2.0σ(I)]. Rw = 0.132
(all data). S = 1.06.
Structure Determinations. The images for compounds 5, 19, 24,
26, 33, 38, 40, 41, 44, and 45 were measured on either a SuperNova
(Cu Kα, mirror monochromator, λ = 1.54184 Å) or Xcalibur (Mo Kα,
mirror monochromator, λ = 0.71073 Å) diﬀractometer ﬁtted with an
area detector, and the data were extracted using the CrysAlis package.
The structures of these compounds were solved with ShelXT20 and
reﬁned using ShelXL21 in OLEX2.22 Atomic coordinates, bond
lengths and angles, and displacement parameters have been deposited
at the Cambridge Crystallographic Data Centre (CCDC no.
1852687−1852695 and 1855327). These data can be obtained free-
of-charge via www.ccdc.cam.ac.uk/data_request/cif, by emailing
data_request@ccdc.cam.ac.uk, or by contacting The Cambridge
Crystallographic Data Centre, 12 Union Road, Cambridge CB2
1EZ, U.K.; fax: + 44 1223 336033.
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Novel Palladium-Catalyzed Synthesis of 1,2-Dihydro-4(3H)-carbazo-
lones. Tetrahedron Lett. 2002, 43, 1621−1624. (b) Scott, T. L.;
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Figure S1: Structure of compound 5 (CCDC 1852687). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S2: Structure of compound 19 (CCDC 1852688). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S3: Structure of compound 24 (CCDC 1852689). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S4: Structure of compound 26 (CCDC 1852690). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S5: Structure of compound 33 (CCDC 1852691). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S6: Structure of compound 38 (CCDC 1852692). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S7: Structure of compound 40 (CCDC 1852693). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S8: Structure of compound 41 (CCDC 1852694). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S9: Structure of compound 44 (CCDC 1855327). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S10: Structure of compound 45 (CCDC 1852695). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Synthesis of a Highly Functionalised and Homochiral
2-Iodocyclohexenone Related to the C-Ring of the
Polycyclic, Indole Alkaloids Aspidophytine and
Haplophytine
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The enzymatically-derived and enantiomerically pure (1S,2S)-3-bromocyclohexa-3,5-diene-1,2-diol (7) has been elabo-
rated over 10 steps into cyclohexenone 8. The latter compound embodies the enantiomeric form of the C-ring associated
with the hexacyclic framework of the alkaloid aspidophytine (2). As such, this work sets the stage for effecting the
conversion of the enantiomeric metabolite ent-7 into compound ent-8, and thence, through previously established
protocols, including a palladium-catalysed Ullmann cross-coupling reaction, into the title alkaloids.
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Introduction
The hetero-dimeric indole alkaloid haplophytine (1)[1–3] (Fig. 1)
is, as confirmed by X-ray analysis,[2] a structurally distinctive
metabolite derived from the Central American plant Haplo-
phyton cimicidum, the dried leaves of whichwere first employed
by the Aztecs for insecticidal purposes.[1] The right-hand seg-
ment of compound 1 embodies the aspidophytine framework 2
that is itself obtained from Haplophyton crooksii (otherwise
known as the cockroach plant) found in the Southern United
States as well as the north of Mexico. It too is used as an
insecticide, especially against cockroaches.[3]
The elaborate molecular architectures of haplophytine (1)
and aspidophytine (2) have prompted a range of synthetic
studies. In 1999 Corey and his co-workers reported the first
assembly of (–)-aspidophytine.[4] Subsequently, Fukuyama
(2003), Padwa (2006), Marino (2006), Nicolaou (2008),
Tokuyama (2013), and Qiu (2013)[5] achieved the same target.
Even more dramatically, after years of sustained effort by many
groups, total syntheses of haplophytine (1) were reported,
contemporaneously in 2009, by the Fukuyama/Tokuyama[6]
and the Nicolaou/Chen[7] groups.[8] In 2016, and inspired by
earlier biosynthetic proposals, Tokuyama and co-workers were
able to couple an advanced precursor to aspidophytine (2) with
one associated with the left-hand segment of compound 1.[9] By
such means, and after conducting a key, one-pot aerobic oxida-
tion/skeletal rearrangement cascade, the completion of a more
convergent total synthesis of haplophytine was realised.
Our own interest in constructing various Aspidosperma
alkaloids has resulted in the establishment of methods for
assembling a close structural analogue of vindoline (3)[10] as
well as total syntheses of the racemic modifications of aspidos-
permidine (4),[11] limaspermidine (5),[12] and its oxidative
cyclisation product 1-acetylaspidoalbidine (6)[12] (Fig. 2). The
analogue of vindoline was obtained in enantiomerically pure
form as a result of employing a homochiral and enzymatically
derived cis-1,2-dihydrocatechol as the starting material.[10,13]
Compounds 3–6 each embody an ABCDE-ring system that is
enantiomerically related to the one seen in aspidophytine (2)
while the last of these, namely 6, also incorporates the tetrahy-
drofuran substructure. A key step associated with all of these
syntheses was the palladium-catalyzed Ullmann cross-coupling
of a 2-iodocyclohexenone with an o-iodinated nitroarene.[14]
This was followed by reductive cyclisation of the resulting 2-
arylated cyclohexenone, often using dihydrogen in the presence
of Raney-cobalt.[15] The piperidine-annulated tetrahydrocarba-
zoles so-formed were each subjected to an annulation protocol
developed by Heathcock and co-workers[16] and thus complet-
ing the assembly of the ABCDE-ring system associated with
compounds 3–6.
We are now seeking to apply our earlier work in developing
total syntheses of the title alkaloids. As part of this program,
we report herein the conversion of the readily obtained and
homochiral cis-1,2-dihydrocatechol 7[13] (Fig. 3) into the
HN
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Fig. 1. The structures of haplophytine (1) and aspidophytine (2).
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2-iodocyclohexenone 8 that embodies key elements associated
with the C-ring of ent-aspidophytine (ent-2). Given that com-
pound ent-7 is also available,[17] albeit less readily, this work
should eventually allow for the synthesis of compounds 1 and 2
as well as their optical antipodes.
Results and Discussion
The route employed in the synthesis of target 8 is shown in
Scheme 1. This starts with the conversion of diol 7, using 2,2-
dimethoxypropane (2,2-DMP) in the presence of catalytic
quantities of p-toluenesulfonic acid monohydrate (p-
TsOHH2O), into the corresponding and known acetonide 9.[10]
Given that the latter compound shows a ready propensity to
engage in a Diels–Alder dimerisation reaction,[18] it was
immediately subjected to a regio- and diastereo-selective dihy-
droxylation reaction using K2OsO4 . 2H2O as the catalytic oxi-
dant and N-methylamine N-oxide (NMO) as the stoichiometric
one.[19] This resulted in the formation of the bromoconduritol
mono-acetonide 10[10] (70% from 7). The more accessible
allylic hydroxy group associated with compound 10 could be
selectively protected using tert-butyldimethylsilyl chloride
(TBS-Cl) in the presence of imidazole and thus providing the
mono-ether 11[10] in 90% yield. Treatment of compound 11
with chloromethyl methyl ether (MOM-Cl) in the presence of
Hu¨nig’s base (N,N-diisopropylethylamine) and 4-(N,N-dime-
thylamino)pyridine (DMAP) then gave product 12[10] in 95%
yield. Suzuki–Miyaura cross-coupling of the bromocyclohexene
12with the previously unreported, 9-BBN-derived carbamate 13
(readily prepared in situ from 9-BBN and benzyl allylcarba-
mate) gave the anticipated product 14 (91%). On treating
compound 14 with tetra-n-butylammonium fluoride (TBAF)
desilylation took place to give the allylic alcohol 15 (95%). In a
critical step of the reaction sequence, compound 15 was readily
engaged in an Eschenmoser–Claisen rearrangement[10,12,20] on
treatment with dimethylacetamide dimethyl acetal (DMADMA)
in refluxing toluene and so cleanly produced the allylic ether 16
(85% based on recovered starting material or brsm).
Significantly, compound 16 incorporates one of the two
quaternary carbon centres associated with the enantiomeric form
of theC-rings of the alkaloids haplophytine (1) and aspidophytine
(2). As implied above, the correct configuration at this stereo-
genic centre, and fromwhich the ones at the others automatically
follow,[11,12] could be established by using metabolite ent-7
(rather than 7) as the starting material in this sequence.
The conversion of compound 16 into target 8 involved three
additional steps, the first of which was the cleavage of the
methoxy methyl (MOM)-ether. This was achieved using con-
centrated aqueous HBr at ambient temperatures. To prevent
accompanying hydrolysis of the associated acetonide unit, this
reaction was run in 2,2-DMP. As a result the allylic alcohol 17
was obtained, albeit in just 56% yield. Oxidation of compound
17 was best effected with the Dess–Martin periodinane
(DMP)[21] and resulted in the formation of enone 18 (64%).
Subjection of the latter compound to a Johnson a-iodination
reaction[22] then provided target 8 in 87% yield. All of the
spectroscopic data acquired on compound 8 were in complete
accord with the assigned structure. In particular, a molecular-
associated ion ([M þ H]þ) was observed in the electrospray
ionisation mass spectrum and an accurate mass measurement on
this species established it was of the required composition, that
is C24H31IN2O6. In the
13C NMR spectrum the expected 22
signals were observed while in the infrared spectrum carbonyl
absorption bands were observed at 1697 and 1633 cm1.
Conclusions
The reaction sequence detailed here will allow for the conversion
of the homochiral metabolite ent-7 into the cyclohexenone ent-8.
Furthermore, our earlier studies on the synthesis of aspi-
dopsermidine (4),[11] limaspermidine (5),[12] and 1-acet-
ylaspidoalbidine (6),[12] will informus as to effectivemethods for
the elaboration of compound ent-8 into the structurally related
aspidophytine (2) and even, perhaps, the more elaborate haplo-
phytine (1). The conversion ent-8- 2 is likely to involve, in the
first stages, a palladium-catalysed Ullmann cross-coupling
reaction so as to install the required dimethoxyaryl group and the
associated nitrogen. Subsequent hydrogenolysis and reductive
cyclisation steps leading to theB- andD-rings are likely to follow.
A Heathcock annulation (to install the E-ring) and an oxidative
cyclisation reaction (involving an angular acetic acid group) to
form the lactone ring would then be deployed. At some point the
acetonide residue associatedwith compound ent-8will need to be
converted into the corresponding cyclohexene and this is most
likely to involve a Corey–Winter olefin synthesis.[20b] Efforts
directed towards such ends will be reported in due course.
Experimental
General Experimental Procedures
Unless otherwise specified, proton (1H) and carbon (13C) NMR
spectra were recorded at room temperature in base-filtered
CDCl3 on a spectrometer operating at 400 MHz for proton and
OH
7 ent-7 8
O
I O
O
CONMe2Br
OH
Br
OH
CbzHN
OH
C
Fig. 3. The structure of the homochiral starting material 7, its enantiomer
(ent-7) and the target 2-iodocyclohexenone 8.
N
N
H
MeO
OAcMe OH
MeO2C
N
N
HAc
O
N
N
H XH
3 4 (X  H) 
5 (X  OH) 
6
A
B C
DE
Fig. 2. The structures of vindoline (3), aspidospermidine (4), limaspermidine (5) and 1-acetylaspidoal-
bidine (6).
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101 MHz for carbon nuclei. The signal due to residual CHCl3
appearing at dH 7.26 and the central resonance of the CDCl3
‘triplet’ appearing at dC 77.0 were used to reference
1H and 13C
NMR spectra, respectively. 1H NMR data are recorded as fol-
lows: chemical shift (d) (multiplicity, coupling constant(s) J
(Hz), relative integral) where multiplicity is defined as: s¼
singlet, d¼ doublet, t¼ triplet, q¼ quartet, and m¼multiplet or
combinations of the above. Infrared spectra (nmax) were recorded
on an ATR-FTIR spectrometer. Samples were analysed in neat
form. Optical rotations were recorded in the indicated solvent at
228C. Low-resolution eletrospray ionisation (ESI) mass spectra
were recorded on a single quadrupole liquid chromatograph–
mass spectrometer while high-resolution measurements were
conducted on a time-of-flight instrument. Analytical thin-layer
chromatography (TLC) was performed on aluminium-backed
0.2 mm thick silica gel 60 F254 plates. Eluted plates were
visualised using a 254 nm UV lamp and/or by treatment with
a suitable dip followed by heating. These dips included phos-
phomolybdic acid/ceric sulfate/sulfuric acid (conc.)/water
(37.5 g : 7.5 g : 37.5 g : 720 mL) or potassium permanganate/
potassium carbonate/5% sodium hydroxide aqueous solution/
water (3 g : 20 g : 5 mL : 300 mL). Flash chromatographic
separations were carried out following protocols defined by Still
et al.[23] with silica gel 60 (40–63 mm) as the stationary phase and
using the AR- or HPLC-grade solvents indicated. Starting
materials, reagents, drying agents, and other inorganic salts were
generally commercially available and used as supplied. Tetra-
hydrofuran (THF), methanol and, dichloromethane were dried
using a solvent purification system that is based upon a tech-
nologyoriginally described byGrubbs et al.[24]Where necessary,
reactions were performed under an atmosphere of nitrogen.
Specific Chemical Transformations
(3aS,7aS)-4-Bromo-2,2-dimethyl-3a,7a-dihydrobenzo
[d][1,3]dioxole (9)
A magnetically stirred solution of compound 7[13b] (4.78 g,
25.0 mmol) in 2,2-DMP (50 mL) was treated with
O
O
2,2-DMP,
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O
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O
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Scheme 1. Conversion of metabolite 7 into the target 2-iodocyclohexenone 8.
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p-TsOHH2O (43 mg, 0.23 mmol, 1 mol-%) and the ensuing
mixture stirred at 228C for 2 h and then concentrated, without
heating, under reduced pressure. The residue thus obtained
was dissolved in ethyl acetate/CH2Cl2 (100 mL of a 1 : 1 v/v
mixture) and the resulting solution washed with water
(2 30 mL) before being dried (Na2SO4), filtered, and
then concentrated under reduced pressure (no heating) to
give compound 9[10,18] (,5.75 g) as a light-brown oil. This
material was used immediately in the next step of the reaction
sequence.
(3aS,4R,5R,7aS)-7-Bromo-2,2-dimethyl-3a,4,5,7a-
tetrahydrobenzo[d][1,3]dioxole-4,5-diol (10)
A magnetically stirred solution of the crude acetonide 9
(,5.75 g, 24. 9 mmol, 1.0 mol equiv.) in acetone/water
(100 mL of a 4 : 1 v/v mixture) was cooled to 08C and then
treated with K2OsO4 . 2H2O (158 mg, 0.25 mmol, 0.01 mol
equiv.) and NMO (6.41 g, 54.8 mmol, 2.2 mol equiv.). The
ensuing mixture was allowed to warm to 228C and then stirred
at this temperature for 16 h before being diluted with ethyl
acetate (50 mL). The separated aqueous layer was extracted
with ethyl acetate (3 30 mL) and the combined organic
layers were dried (Na2SO4), filtered, and concentrated under
reduced pressure. The residue was subjected to flash column
chromatography (silica, 3 : 7 v/v ethyl acetate/40–60 petro-
leum spirits elution) and thus afforded, after concentration of
the appropriate fractions (Rf¼ 0.3 in 2 : 3 v/v ethyl acetate/40–
60 petroleum spirits), the title diol 10[10] (4.67 g, 70% over 2
steps) as a light-brown solid, mp 1128C, [a]D 4.0 (c 1.0,
CHCl3). dH 6.16 (br s, 1H), 4.66 (m, 1H), 4.45 (t, J 5.4, 1H),
4.36 (br s, 1H), 4.19 (t, J 4.6, 1H), 2.53 (s, 2H), 1.44 (s, 3H),
1.41 (s, 3H). dC 131.1, 123.9, 110.5, 76.5, 76.4, 69.6, 67.4,
27.8, 26.3. nmax/cm
1 3401, 2987, 2934, 1645, 1382, 1373,
1229, 1079, 1050, 856, 628. m/z (ESI, þve) 289 and 287
([M þ Na]þ, 95 and 100%). HRMS 286.9880; calcd for
C9H13
79BrO4Na [M þ Na]þ 286.9889.
(3aS,4S,5R,7aS)-7-Bromo-5-((tert-butyldimethylsilyl)
oxy)-2,2-dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]
dioxol-4-ol (11)
A suspension of compound 10 (8.00 g, 30.2 mmol) in
CH2Cl2 (100 ml) was maintained at 08C and then imidazole
(5.28 g, 77.6 mmol, 2.56 mol equiv.) and TBS-Cl (8.19 g,
54.3 mmol, 1.8 mol equiv.) added to it. The ensuing mixture
was stirred at 228C for 1 h and then quenched with water
(50 mL). The separated aqueous layer was extracted with
CH2Cl2 (3 30 mL) and the combined organic phases then
dried (Na2SO4), filtered, and concentrated under reduced pres-
sure. The residue so obtained was subjected to flash column
chromatography (silica, 1 : 15 v/v ethyl acetate/40–60 petro-
leum spirits elution) and thus afforded, after concentration of
the appropriate fractions (Rf 0.6 in 1 : 9 v/v ethyl acetate/40–60
petroleum spirits), ether 11[10] (10.34 g, 90%) as a light-yellow
solid, mp 858C, [a]D 32.0 (c 1.0, CHCl3). dH 5.91 (m, 1H),
4.62 (m, 1H), 4.49 (t, J4.8, 1H), 4.37 (m, 1H), 4.16 (m, 1H),
2.62 (d, J1.7, 1H), 1.43 (s, 3H), 1.40 (s, 3H), 0.92 (s, 9H), 0.15
(s 3H), 0.13 (s 3H). dC 130.8, 123.6, 110.1, 76.1, 75.8, 69.3,
68.2, 27.7, 26.3, 25.9, 18.2,4.5,4.7. nmax/cm1 3558, 2988,
2952, 2929, 2857, 1646, 1471, 1370, 1076, 1052, 865, 837, 777,
681. m/z (ESI, þve) 403 and 401 ([M þ Na]þ, 98 and 100%).
HRMS 401.0761; calcd for C15H27
79BrO4SiNa [M þ Na]þ)
401.0760.
(((3aS,4S,5R,7aS)-7-Bromo-4-(methoxymethoxy)-2,2-
dimethyl-3a,4,5,7a-tetrahydrobenzo[d][1,3]dioxol-5-yl)
oxy)(tert-butyl)dimethylsilane (12)
A magnetically stirred solution of compound 11 (1.00 g,
2.64 mmol) in CH2Cl2 (5 mL) maintained at 08C was treated
with DMAP (322 mg, 2.63 mmol, 1.0 mol equiv.) and then
Hu¨nig’s base (2.7 mL, 15.8 mmol, 6.0 mol equiv.) and MOM-
Cl[25] (2.1mL, 19.8 mmol, 7.5 mol equiv.). The ensuingmixture
was stirred at 228C for 16 h before being quenched with NH4Cl
(30 mL of a saturated aqueous solution) and the separated
aqueous phase extracted with CH2Cl2 (3 20 mL). The com-
bined organic phases were dried (Na2SO4), filtered, and con-
centrated under reduced pressure. The residue thus obtained was
subjected to flash column chromatography (silica, 1 : 19 v/v
ethyl acetate/40–60 petroleum spirits elution) and thus afford-
ing, after concentration of the appropriate fractions (Rf 0.5), the
title compound 12[10] (1.06 g, 95%) as a colourless, semi-solid,
[a]D71.4 (c 1.0, CHCl3). dH 6.06 (br s, 1H), 4.82 (d, J 6.7, 1H),
4.72 (d, J 6.7, 1H), 4.65 (d, J 5.5, 1H), 4.47 (m, 2H), 4.08 (m,
1H), 3.40 (s, 3H), 1.43 (s, 3H), 1.40 (s, 3H), 0.91 (s, 9H), 0.12 (s,
3H), 0.10 (s, 3H). dC 132.8, 122.6, 110.3, 97.3, 77.0, 76.0, 75.6,
68.1, 55.9, 27.7, 26.4, 25.9, 18.3, 4.6 (one signal obscured or
overlapping). nmax/cm
1 2988, 2953, 2930, 1644, 1464, 1381,
1371, 1253, 1133, 1115, 1078, 1037, 865, 776, 680. m/z (ESI,
þve) 447 and 445 ([M þ Na]þ, 99 and 100%). HRMS
445.1019; calcd for C17H31
79BrO5SiNa [M þ Na]þ 445.1022.
Benzyl (3-((1S,5S)-9-Borabicyclo[3.3.1]nonan-9-yl)
propyl)carbamate (13)
Following a protocol reported by Rychnovsky,[26] benzyl
allylcarbamate[27] (500 mg, 2.61 mmol) was added to magneti-
cally stirred 9-BBN (5mLof a 0.5M solution in THF, 2.5mmol)
maintained at 228C. Stirring was continued at this temperature
for 16 h and the solution thus obtained, and presumed to contain
compound 13, used directly in the Suzuki–Miyaura cross-
coupling with compound 12 as detailed immediately below.
Benzyl (3-((3aR,6R,7S,7aR)-6-((tert-Butyldimethylsilyl)
oxy)-7-(methoxymethoxy)-2,2-dimethyl-
3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)propyl)
carbamate (14)
A solution of compound 13 (1.04 mL of a 0.5 M solution in
THF, 0.52 mmol), prepared as described immediately above,
was dissolved in THF (1.5 ml) containing NaOH (2.3 mL of a
3 M aqueous solution). The ensuing mixture was stirred mag-
netically at 228C for 0.3 h and then added to a magnetically
stirred solution of compound 12 (200 mg, 0.47 mmol, 1.0 mol
equiv.) in THF (1 mL) maintained at 228C. The resulting
mixture was deoxygenated with nitrogen and then PdCl2dppf .
CH2Cl2 (40mg, 0.05mmol, 10mol-%) was added. Themixture
thus obtained was stirred at 228C under nitrogen for 16 h before
being quenched with NaHCO3 (5 mL of a saturated aqueous
solution). The separated aqueous layer was extracted with ethyl
acetate (3 15mL) and the combined organic phases then dried
(Na2SO4), filtered, and concentrated under reduced pressure.
The residue so obtained was subjected to flash column chroma-
tography (silica, 1 : 4 v/v ethyl acetate/40–60 petroleum spirits
elution) and thus afforded, after concentration of the appropriate
fractions (Rf 0.4), carbamate 14 (243 mg, 81%) as a clear,
colourless oil, [a]D 72.7 (c 0.83, CHCl3). dH 7.41–7.26
(complex m, 5H), 5.51 (br s, 1H), 5.09 (s, 2H), 4.94 (br s, 1H),
4.78 (d, J 6.6, 1H), 4.71 (d, J 6.6, 1H), 4.52 (d, J 6.0, 1H), 4.41
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(t, J 6.0, 1H), 4.35 (t, J 3.7, 1H), 3.87 (m, 1H), 3.37 (s, 3H), 3.22
(m, 2H), 2.18 (m, 2H), 1.73 (m, 2H), 1.38 (s, 3H), 1.36 (s, 3H),
0.89 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H). dC 156.5, 137.2, 136.8,
128.6, 128.2(3), 128.1(7), 126.2, 109.2, 96.3, 76.3, 75.1, 74.6,
66.7, 66.5, 55.6, 40.9, 31.2, 27.7, 27.6, 26.0(2), 25.9(6), 18.3,
4.4, 4.6. nmax/cm1 3349, 2929, 2857, 1709, 1525, 1472,
1246, 1031, 885, 775. m/z (ESI,þve) 558 ([Mþ Na]þ, 100%).
HRMS 558.2864; calcd for C28H45NO7SiNa [M þ Na]þ
558.2863.
Benzyl (3-((3aR,6R,7R,7aR)-6-Hydroxy-7-
(methoxymethoxy)-2,2-dimethyl-3a,6,7,7a-
tetrahydrobenzo[d][1,3]dioxol-4-yl)propyl)
carbamate (15)
A magnetically stirred solution of compound 14 (3.19 g,
5.95 mmol) in THF (14 mL) was cooled to 08C and then treated
with TBAF (12.4 mL of a 0.5 M solution in THF, 1.05 mol
equiv.). The ensuing mixture was allowed to warm to 228C over
2 h and stirring continued at this temperature for 16 h. The
reaction mixture was then diluted with NaHCO3 (20 mL of a
saturated aqueous solution) and the separated aqueous layer
extracted with ethyl acetate (3 15mL). The combined organic
phases were dried (Na2SO4), filtered, and concentrated under
reduced pressure and the residue thus obtained subjected to flash
column chromatography (silica, 4 : 6- 7 : 3- 8 : 2 v/v ethyl
acetate/40–60 petroleum spirits gradient elution). Concentration
of the appropriate fractions (Rf 0.2 in 1 : 1 v/v ethyl acetate/40–
60 petroleum elution) then gave allylic alcohol 15 (2.40 g, 95%)
as a clear, colourless oil, [a]D 35.7 (c 0.48, CHCl3). dH 7.41–
7.27 (complex m, 5H), 5.63 (br s, 1H), 5.09 (s, 2H), 4.90 (br s,
1H), 4.77 (m, 2H), 4.51 (d, J 6.2, 1H), 4.43 (m, 1H), 4.35–4.24
(br s, 1H), 3.87 (m, 1H), 3.40 (s, 3H), 3.23 (m, 2H), 2.68 (d, J 6.1,
1H), 2.22 (m, 2H), 1.74 (m, 2H), 1.40 (s, 3H), 1.37 (s, 3H). dC
156.5, 138.3, 136.7, 128.6, 128.2(1), 128.1(8), 125.0, 109.5,
96.9, 78.0, 74.8, 74.5, 66.7, 65.5, 55.8, 40.8, 31.1, 27.8, 27.4,
26.1. nmax/cm
1 3348, 2985, 2934, 1699, 1531, 1455, 1380,
1240, 1027, 916, 698. m/z (ESI,þve) 444 ([Mþ Na]þ, 100%).
HRMS 444.1192; calcd for C22H31NO7Na [M þ Na]þ
444.1998.
Benzyl (3-((3aR,4S,7R,7aS)-4-(2-(Dimethylamino)-
2-oxoethyl)-7-(methoxymethoxy)-2,2-dimethyl-
3a,4,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)propyl)
carbamate (16)
A magnetically stirred solution of compound 15 (1.86 g,
4.41 mmol,) in toluene (23 mL) was treated with DMADMA
(6.0 mL, 39.7 mmol, 9 mol equiv.) and the ensuing mixture
heated under reflux for 1 h before being cooled to 908C and the
reaction vessel vented for 0.5 h so as to allow the by-product
methanol to evaporate. The reaction mixture was then heated
again under reflux for 1 h, cooled to 908C and vented once more
for 0.5 h. Further DMADMA (3.0 mL, 19.9 mmol, 4.5 mol
equiv.) was added to the reaction mixture that was then heated
under reflux for 16 h. The cooled reaction mixture was concen-
trated under reduced pressure and the residue thus obtained
subjected to flash column chromatography (silica, 7 : 3 v/v ethyl
acetate/40–60 petroleum spirits elution) and so affording two
fractions, A and B.
Concentration of fraction A (Rf 0.2 in 1 : 1 v/v ethyl acetate/
40–60 petroleum spirits) afforded allylic alcohol 15 (290 mg,
16% recovery) as a clear, colourless oil that was identical, in all
respects, with an authentic sample.
Concentration of fraction B (Rf 0.2 in 1 : 4 v/v ethyl acetate/
diethyl ether) afforded compound 16 (1.55 g, 72 or 85%brsm), as
a white, crystalline solid:mp 848C, [a]D18.3 (c 1.0, CHCl3). dH
7.36–7.20 (complexm, 5H), 5.75 (m, 2H), 5.09 (s, 2H), 5.03 (br s,
1H), 4.81 (d, J 6.7, 1H), 4.72 (d, J 6.7, 1H), 4.31 (s, 2H), 4.19 (s,
1H), 3.39 (s, 3H), 3.16 (m, 2H), 3.01 (s, 3H), 2.91 (s, 3H), 2.50 (m,
2H), 1.76–1.48 (complex m, 3H), 1.41 (s, 3H), 1.33 (s, 3H). dC
170.5, 156.5, 136.8, 135.9, 128.5, 128.1, 128.0, 125.8, 108.2,
95.5, 79.3, 78.2, 74.4, 66.5, 55.5, 41.6, 40.8, 39.1, 37.9, 35.5, 31.8,
26.8, 24.9, 24.2. nmax/cm
1 3332, 2936, 1717, 1635, 1525, 1455,
1240, 1041, 731.m/z (ESI,þve) 513 ([MþNa]þ, 100%).HRMS
513.2578; calcd for C26H38N2O7Na [M þ Na]þ 513.2577.
Benzyl (3-((3aR,4S,7R,7aS)-4-(2-(dimethylamino)-
2-oxoethyl)-7-hydroxy-2,2-dimethyl-
3a,4,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)propyl)
carbamate (17)
A magnetically stirred solution of compound 16 (47 mg,
0.09 mmol) in 2,2-DMP (1.6 mL) was cooled to 08C and then
treated with HBr (5 drops of a 48% aqueous solution). The
reaction mixture was kept at 08C for 0.1 h and then warmed to
228C, maintained at this temperature for 1.5 h and then quenched
with NaHCO3 (5 mL of a saturated aqueous solution) and the
separated aqueous layer extracted with ethyl acetate (3 5 mL).
The combined organic phases were dried (Na2SO4), filtered, and
concentrated under reduced pressure. The residue thus obtained
was subjected to flash column chromatography (silica, ethyl
acetate eltuion) and thus afforded, after concentration of the
appropriate fractions (Rf 0.2), compound 17 (24 mg, 56%) as a
clear, colourless oil, [a]D 33.8 (c 1.07, CHCl3). dH 7.45–7.28
(complex m, 5H), 5.75 (m, 1H), 5.68 (m, 1H), 5.09 (s, 2H), 4.96
(br s, 1H), 4.35 (d, J 7.3, 1H), 4.29 (dd, J 7.3 and 3.9, 1H), 4.22
(br s, 1H), 3.17 (m, 2H), 3.01 (s, 3H), 2.91 (s, 3H), 2.55 (s, 2H),
2.46 (d, J 6.2, 1H), 1.55 (br s, 4H), 1.41 (s, 3), 1.34 (s, 3H). dC
170.9, 156.5, 136.8, 134.6, 128.6, 128.2, 128.1, 128.0, 108.1,
81.0, 78.3, 69.8, 66.6, 41.6, 41.0, 40.0, 38.0, 35.6, 32.9, 26.9, 25.0,
24.4. nmax/cm
1 3338, 2978, 2934, 1705, 1627, 1527, 1241, 1045,
752, 698. m/z (ESI, þve) 469 ([M þ Na]þ, 100%). HRMS
469.2307; calcd for C24H34N2O6Na [M þ Na]þ 469.2315.
Benzyl (3-((3aR,4S,7aR)-4-(2-(Dimethylamino)-
2-oxoethyl)-2,2-dimethyl-7-oxo-3a,4,7,7a-
tetrahydrobenzo[d][1,3]dioxol-4-yl)propyl)
carbamate (18)
A magnetically stirred solution of compound 17 (41 mg,
0.09 mmol) in CH2Cl2 (3 mL) maintained at 08C under a
nitrogen atmosphere was treated with DMP (98 mg, 0.23 mmol,
2.5 mol equiv.). The ensuing mixture was allowed to stir at 08C
for 0.1 h and then at 228C for 16 h before being quenched with
NaHCO3 (2 mL of a saturated aqueous solution) and the
separated aqueous layer extracted with ethyl acetate
(3 3 mL). The combined organic layers were dried (Na2SO4),
filtered, and concentrated under reduced pressure. The residue
thus obtained was subjected to flash column chromatography
(silica, ethyl acetate elution) and thus afforded, after concentra-
tion of the appropriate fractions (Rf 0.3), enone 18 (26 mg,
64%), as a clear, colourless oil, [a]D 13.7 (c 0.9, CHCl3). dH
7.47–7.25 (complex m, 5H), 6.80 (d, J 10.4, 1H), 6.05 (d, J 10.4,
1H), 5.09 (s, 2H), 4.99 (br s, 1H), 4.48 (s, 2H), 3.20 (q, J 6.5, 2H),
2.97 (s, 3H), 2.90 (s, 3H), 2.58 (m, 2H), 1.81 (m, 1H), 1.63
(m, 3H), 1.36 (s, 3H), 1.32 (s, 3H). dC 196.0, 169.2, 156.5, 154.8,
136.7, 128.6, 128.2(3), 128.2(1), 126.4, 109.5, 78.7, 75.1, 66.7,
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41.4, 41.2, 40.4, 38.1, 35.7, 33.4, 27.3, 25.8, 23.8. nmax/cm
1
3347, 2984, 2935, 1717, 1684, 1637, 1372, 1237, 1044, 698.m/z
(ESI, þve) 467 ([M þ Na)]þ, 100%). HRMS 467.2159; calcd
for C24H32N2O6Na [M þ Na]þ 467.2158.
Benzyl (3-((3aR,4S,7aR)-4-(2-(Dimethylamino)-2-
oxoethyl)-6-iodo-2,2-dimethyl-7-oxo-3a,4,7,7a-
tetrahydrobenzo[d][1,3]dioxol-4-yl)propyl)carbamate (8)
A magnetically stirred solution of compound 18 (72 mg,
0.16 mmol) in chloroform/pyridine (10 mL of a 1 : 1 v/v
mixture) was treatedwithmolecular iodine (226mg, 0.89mmol,
5.5 mol equiv.) and the resulting mixture stirred at 228C for 16 h
and then quenched with Na2SO3 (10 mL of a saturated aqueous
solution) and the separated aqueous layer extracted with ethyl
acetate (3 10 mL). The combined organic phases were dried
(Na2SO4), filtered, and concentrated under reduced pressure and
the residue thus obtained subjected to flash column chromatog-
raphy (silica, ethyl acetate elution). Concentration of the appro-
priate fractions (Rf 0.5) afforded compound 8 (80 mg, 87%) as a
clear, colourless oil, [a]D75.6 (c 0.8, CHCl3). dH 7.49 (s, 1H),
7.42–7.27 (complexm, 5H), 5.10 (s, 2H), 4.96 (br s, 1H), 4.66 (d,
J 5.3, 1H), 4.51 (d, J 5.3, 1H), 3.21 (m, 2H), 2.98 (s, 3H), 2.89 (s,
3H), 2.56 (m, 2H), 1.88 (m, 1H), 1.77 (m, 1H), 1.63 (m, 2H),
1.36 (s, 3H), 1.29 (s, 3H). dC 189.8, 168.8, 162.4, 156.5, 136.7,
128.6, 128.2(0), 128.1(5), 109.7, 100.0, 78.9, 74.2, 66.7, 45.4,
41.2, 40.3, 38.0, 35.7, 33.4, 27.3, 25.7, 23.8. nmax/cm
1 3348,
2985, 2934, 1697, 1633, 1522, 1454, 1238, 1078, 1044, 749.m/z
(ESI,þve) 593 ([MþNa]þ, 100%). HRMS 571.1301; calcd for
C24H32IN2O6 [M þ H]þ 571.1300.
Supplementary Material
1H and 13C NMR spectra for compounds 10–18 and 8 are
available on the Journal’s website.
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Syntheses of Structurally and Stereochemically Varied Forms of 
C7N Aminocyclitol Derivatives from Enzymatically-derived and 
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ABSTRACT: The structurally and stereoisomerically varied C7N aminocyclitol derivatives 2-4 have been prepared, using a versatile and 
flexible range of protocols, from the cis-1,2-dihydrocatechols 5 and 6, homochiral metabolites derived from the whole-cell biotransformation 
of the corresponding halobenzene. Reaction sequences that enable syntheses of the enantiomeric forms of these derivatives have also been 
established. 
The C7N aminocyclitols are microbially-derived and biologically 
active compounds that have been deployed in a number of thera-
peutic and agrochemical roles, either in their own right or as com-
ponents of structurally more complex systems.1 So, for example, 
they are used as agents for the treatment of bacterial infections, 
type-II diabetes and as antifungal agents to treat rice blight.1 Given 
such pivotal activities and the emergence of resistance to their more 
heavily exploited forms,2 efforts continue apace to identify new 
variants,3 to establish how they are produced in vivo4 and to devel-
op syntheses of them and structural analogues.5 The 2015 report6 
by Gademann and co-workers on the isolation of the C7N aminocy-
clitol kirkamide (1) from an obligate leaf nodule symbiont of the 
Rubiaceous shrub Psychotria kirkii emphasizes the ongoing levels of 
interest in such systems. So, for example, various biological studies 
established that kirkamide is toxic to both aquatic anthropods and 
insects with the latter effect suggesting that the compound plays a 
protective (anti-feedant) role in the plant hosting the symbiont. 
The structure of kirkamide, which embodies a homoallylic rather 
than the normally located allylic nitrogen, was established by NMR 
spectroscopic methods and confirmed by single-crystal X-ray analy-
sis. An eleven-step total synthesis of this natural product was estab-
lished using methyl N-acetyl-D-glucosamine as starting material 
and employed a Ferrier carbocyclization7 for the pivotal ring-
forming step. 
 
Figure 1: The recently reported C7N aminocyclitol kirkamide (1) 
 
By virtue of their diverse biological activities and structural varia-
tions, there remains an intense interest in developing new methods 
for the synthesis of aminocyclitols, including C7 variants.5 As part 
of our ongoing efforts in this area,5b we now report syntheses of 
compounds such as 6-epi-kirkamide (2), the ent-kirkamide deriva-
tive 3 and the β,γ-unsaturated amide 4 from the homochiral cis-
dihydrocatechols 5 and 6 that are, themselves, readily obtained 
through the whole-cell biotransformation of bromo- and iodo-
benzene, respectively.8 Means for accessing the enantiomeric forms 
of these C7N aminocyclitol derivatives are also described. 
 
 
 
Figure 2: The structures of the  target C7N aminocyclitol deriva-
tives 2-4 and the homochiral cis-1,2-dihydrocatechols 5 and 6 used 
as starting materials 
 
The opening stages of the synthetic route to 6-epi-kirkamide (2) 
are shown in Scheme 1 and involve the ready and well-established 
conversion of diol 5 into the acetonide 7.9 Subjection of the latter 
compound to reaction with N-bromoacetamide (NBA) in the pres-
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 ence of tin tetrachloride at –40 °C afforded, in both a regio- and 
diastereo-selective manner, the anticipated and previously reported 
adduct 810 (77%), the structure of which was confirmed by single-
crystal X-ray analysis (see Supporting Information – SI – for de-
tails). On treating bromo-acetamide 8 with potassium hexamethyl-
disilazide (KHMDS) and tetra-n-butylammonium bromide 
(TBAB) under conditions similar to those defined by Hudlicky and 
co-workers for the formation of acylaziridine 9,10 then the oxazoline 
10 was obtained in 39% yield. The structure of compound 10 fol-
lows from the derived spectroscopic data and the single-crystal X-
ray analysis of a derivative (see below). Subjection of an authentic 
sample of compound 9 to the reaction conditions just described 
also afforded the isomeric heterocycle 10, an observation con-
sistent with the behavior of other N-acyl aziridines.11 The regiose-
lectivity associated with the conversion 9 → 10 process (a Heine-
type reaction11) is intriguing and presumably the consequence of 
the mesomerically electron-donating properties of the flanking 
bromo-olefin subunit within the substrate. On treating compound 
10 with aqueous acetic acid the associated oxazoline ring was 
cleaved and thereby affording the aminocyclitol 11 (48%) wherein 
the amine residue is in a homoallylic relationship with the cyclo-
hexene double bond, as seen in kirkamide.  
Scheme 1: Opening stages of the route to C7N aminocyclitol 2 
 
The elaboration of compound 11 to target 2 requires the introduc-
tion of a hydroxymethyl group at the bromine-bearing carbon and 
we sought to do this using one of various possible palladium-
catalyzed carbonylation processes.12 Unfortunately, all such efforts 
proved unsuccessful and so bromide 11 was converted (Scheme 2) 
into the corresponding iodide 12 (81%) in the expectation that the 
latter would serve as a more effective cross-coupling partner. How-
ever, even the later electrophile proved ineffective in this regard 
until we adapted a previously reported procedure13 allowing for the 
formation of the Weinreb amide 13 (95%). O-Silylation of this by 
now long-sought product was achieved under standard conditions 
using tert-butyldimethylsilyl chloride (TBS-Cl) and the resulting 
ether 14 (95%) subjected to reduction with lithium aluminium 
hydride and so forming, after work-up, the unsaturated aldehyde 15 
(84%). Luche reduction14 of the last compound then afforded the 
hydroxymethylated product 16 (95%), the structure of which was 
confirmed by single-crystal X-ray analysis (See SI for details). 
Treatment of compound 16 with aqueous acetic acid at 60 °C for 7 
h then afforded target 2 (the C6-epimer of kirkamide) (83%), the 
spectral data for which were in complete accord with the assigned 
structure. 
Scheme 2: Closing stages of the route to target 2 (6-epi-kirkamide) 
 
An alternate route to the kirkamide “scaffold” that allows for the 
creation of a trans-relationship between the amine residue and its 
neigbouring, homoallylic hydroxyl group, as seen in the natural 
product 1, is shown in Scheme 3. This starts with the conversion of 
diol 6 into the known bromohydrin 1715 (74%) and on treating the 
later with sodium methoxide the previously reported epoxide 1815 
(91%) was obtained. Compound 18 itself could be engaged in a 
two-fold Mitsunobu reaction using p-nitrobenzoic acid as the nu-
cleophile and thus producing the bis-ester 19 (98%), treatment of 
which with potassium carbonate in methanol afforded the diol 20 
(84%). On treating this last compound with freshly prepared p-
toluenesulfonyl isocyanate (TsNCO) then reaction occurred selec-
tively at the hydroxyl group remote from the iodinated carbon cen-
ter and thereby forming, regioselectively and through cyclization of 
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 the initially formed tosylcarbamate,16 the anticipated oxazolidinone 
21 (61%) that could either be acetylated under standard conditions 
to give diacetate 22 (98%) or treated with methanolic sodium hy-
droxide to give triol 23 (90%). The structure of compound 22 was 
confirmed by single-crystal X-ray analysis (see SI for details). 
Scheme 3: A protocol for establishing the aminoconduritol core of 
ent-kirkamide (ent-1) 
 
The reactions used in the elaboration of compound 23 to the ent-
kirkamide derivative 3 and its analogue 24 are shown in Scheme 4.  
Scheme 4: Conversion of triol 23 into target 3 and analogue 24 
 
Thus, cyclohexenyl iodide 23 could be converted into the corre-
sponding dimethyl or Weinreb amides 3 (91%) and 24 (87%), 
respectively, using conditions similar to those employed in the 
conversion 12 → 13. All of the NMR spectral data obtained on 
these amide-containing products were entirely consistent with the 
illustrated structures and that of compound 3 confirmed by single-
crystal X-ray analysis. 
On treating compound 3 with freshly prepared sodium naphtha-
lenide17 in THF at –78 °C a smooth reductive deoxygenation reac-
tion took place (Scheme 5) and thus providing the novel C7N ami-
nocyclitol 4 in 81%, the structure of which was also confirmed by 
single-crystal X-ray analysis. Like congeners 2 and 3, product 4 
should be a useful precursor to a range of aminocarbasugars,18 
compounds that display a range of important biological properties 
including by acting as inhibitors of enzymes that process carbohy-
drates and as anti-bacterial agents. 
Scheme 5: The regiocontrolled, reductive deoxygenation of amide 
3 leading to compound 4 
 
Since the cis-1,2-dihydrocatechol ent-5 is available,19 the reaction 
sequences shown in Schemes 1 and 2 also provide access to com-
pound ent-2. However, congener ent-6 is not accessible by analo-
gous means and so the protocols defined in Schemes 3-5 cannot be 
used to gain access to the enantiomers of compounds 3 and 4. Ac-
cordingly, the reaction sequence shown in Scheme 6 was estab-
lished to address this matter.  
Scheme 6: Conversion of cis-1,2-dihydrocatechol 5 into iodo-triol 
23 
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 Thus, compound 5 was converted, using established protocols15 
and via intermediate bromohydrin 25 (77%), into the known15 
epoxide 26 (85%). Subjection of this last compound to a two-fold 
Mitsunobu reaction using p-nitrobenzoic acid as nucleophile then 
afforded ester 27 (64%) that upon saponification afforded diol 28 
(82%), the bromo-analogue of compound 20. Reaction of com-
pound 28 with TsNCO then afforded the anticipated cyclic carba-
mate 29 and on treatment of this with methanolic sodium hydrox-
ide then the brominated aminocondurtiol derivative 30 (77% from 
28) was obtained. Application of a trans-halogenation reaction to 
this last compound using the same conditions as employed for the 
conversion 11 → 12 then gave the iodo-triol 23 (57%), an ad-
vanced precursor to targets 3 and 4. As such a connection has been 
established between cis-1,2-dihydrocatechol 5 and these C7N ami-
nocyclitol derivatives, meaning, therefore, that their enantiomeric 
forms can now be obtained from ent-5. 
The protocols detailed above provide a capacity to generate a range 
of the novel C7N aminocyclitols in either enantiomeric form and so 
allowing for the development of further structure-activity-
relationship (SAR) profiles for these endlessly fascinating com-
pounds. 
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General Experimental Protocols 
Unless otherwise specified, proton (1H) and carbon (13C) NMR spectra were recorded at room 
temperature in base-filtered CDCl3 on a Varian spectrometer operating at 400 MHz for 
proton and 100 MHz for carbon nuclei. For 1H NMR spectra, signals arising from the residual 
protio-forms of the solvent were used as the internal standards. 1H NMR data are recorded as 
follows: chemical shift (δ) [multiplicity, coupling constant(s) J (Hz), relative integral] where 
multiplicity is defined as: s = singlet; d = doublet; t = triplet; q = quartet; m = multiplet or 
combinations of the above. The signal due to residual CHCl3 appearing at δH 7.26 and the 
central resonance of the CDCl3 “triplet” appearing at δC 77.0 were used to reference 1H and 
13C NMR spectra, respectively. Infrared spectra (νmax) were recorded on a Perkin–Elmer 1800 
Series FTIR Spectrometer. Samples were analyzed as thin films on KBr plates. Low-
resolution ESI mass spectra were recorded on a single quadrupole liquid chromatograph-mass 
spectrometer, while high-resolution measurements were conducted on a time-of-flight 
instrument. Low- and high-resolution EI mass spectra were recorded on a magnetic-sector 
machine. Melting points were measured on an Optimelt automated melting point system and 
are uncorrected. Analytical thin layer chromatography (TLC) was performed on aluminum-
backed 0.2 mm thick silica gel 60 F254 plates as supplied by Merck. Eluted plates were 
visualized using a 254 nm UV lamp and/or by treatment with a suitable dip followed by 
heating. These dips included phosphomolybdic acid : ceric sulfate : sulfuric acid (conc.) : 
water (37.5 g : 7.5 g : 37.5 g : 720 mL) or potassium permanganate : potassium carbonate : 
5% sodium hydroxide aqueous solution : water (3 g : 20 g: 5 mL : 300 mL). Flash 
chromatographic separations were carried out following protocols defined by Still et al.1 with 
silica gel 60 (40–63 µm) as the stationary phase and using the AR- or HPLC-grade solvents 
indicated. Starting materials and reagents were generally available from the Sigma–Aldrich, 
Merck, TCI, Strem or Lancaster Chemical Companies and were used as supplied. Drying 
agents and other inorganic salts were purchased from the AJAX, BDH or Unilab Chemical 
Companies. Tetrahydrofuran (THF), methanol and dichloromethane were dried using a Glass 
Contour solvent purification system that is based upon a technology originally described by 
Grubbs et al.2 Petroleum ether refers to the fraction boiling between 40 and 60 °C. Where 
necessary, reactions were performed under an nitrogen atmosphere. 
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Specific Chemical Transformations 
 
Compound 7 
 
 
A magnetically stirred solution of cis-1,2-dihydrocatechol 5 (1.0 g, 5.23 mmol) in 2,2-
dimethoxypropane (50 mL) containing p-TsOH•H2O (70 mg, 0.36 mmol) was stirred at 22 °C 
for 0.15 h then treated with NaHCO3 (15 mL of a saturated aqueous solution) before being 
extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried (Na2SO4), 
filtered then concentrated under reduced pressure to give a light-yellow oil presumed to 
contained acetonide 7.3 This material was used directly in the synthesis of compound 8 as 
detailed below. 
 
Compound 8   
 
 
 
A magnetically stirred solution of N-bromoacetamide (867 mg, 6.28 mmol) in dry acetonitrile 
(40 mL) maintained under a nitrogen atmosphere was cooled to –40 °C and, while being 
protected from light, was treated with SnBr4 (137 mg, 0.31 mmol). The ensuing mixture was 
then treated, over 2 h, with a solution of compound 7 (1.21 g, 5.23 mmol) in acetonitrile (15 
mL). After being maintained for a further 1 h at –40 °C, the reaction mixture was quenched 
with NaHCO3 (10 mL of a saturated aqueous solution) then extracted with ethyl acetate (3 × 
10 mL). The combined organic layers were dried (Na2SO4), filtered then and concentrated 
under reduced pressure. The resulting light-yellow oil was subjected to flash column 
chromatography (CH2Cl2 → ethyl acetate gradient elution) to yield, after concentration of the 
appropriate fractions (Rf = 0.4 in 1:1 v/v ethyl acetate/petroleum ether), compound 84 (1.50 g, 
77%) as a white, crystalline solid, m.p. = 170 °C (lit.4 m.p. = 181 °C), [α]D = +180.9 (c 0.45, 
CHCl3) {lit.4 [α]D = +188.2 (c 0.50, CHCl3)}. 1H NMR (400 MHz, CDCl3) δ 6.22 (d, J = 9.7 
Hz, 1H), 6.18–6.13 (complex m, 1H), 4.94 (m, 1H), 4.68 (m, 1H), 4.60 (m, 1H), 4.21 (m, 
1H), 1.97 (s, 3H), 1.51 (s, 3H), 1.42 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 169.1, 128.1, 
124.8, 112.1, 77.9, 75.9, 50.4, 44.5, 27.9, 26.6, 23.4; IR (ATR) νmax 3308, 2985, 1657, 1537, 
1372, 1216, 1074, 868 cm–1; MS (ESI, +ve) m/z 394, 392 and 390 [(M+Na)+, 50, 100 and 
49%]. 
These spectroscopic data matched literature values.4 
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Compound 10 
 
 
 
A magnetically stirred solution of compound 8 (7.00 g, 19.0 mmol) in THF (300 mL) 
maintained under nitrogen was cooled to –10 °C then treated with KHMDS (42 mL of a 0.5 
M solution in THF, 20.8 mmol, 1.1 mole eq.). Stirring was continued at –10 °C for 0.5 h, at 0 
°C for 0.5 h then at 22 °C for 16 h before the reaction mixture was treated with 1,2-
dimethoxyethane (DME) (50 mL) and TBAB (12.2 g, 37.9 mmol). Stirring was continued at 
22 °C for a further 16 h then additional DME (50 mL) was added followed by another portion 
of TBAB (12.2 g, 37.9 mmol). Stirring was continued for another 24 h then the reaction 
mixture was quenched with water (30 mL) and extracted with ethyl acetate (5 × 30 mL). The 
combined organic phases were dried (Na2SO4), filtered then concentrated under reduced 
pressure. The resulting light-yellow oil was subjected to flash column chromatography (1:1 
v/v petroleum ether/ethyl acetate → ethyl acetate gradient elution) and concentration of the 
appropriate fractions (Rf = 0.3 in ethyl acetate) gave compound 10 (4.60 g, 39%) as an clear, 
orange oil, [α]D = +28.6 (c 1.25, CHCl3). 1H NMR (400 MHz, CDCl3) δ 6.40 (d, J = 4.6 Hz, 
1H), 4.71 (m, 1H), 4.53–4.44 (complex m, 2H), 4.33 (m, 1H), 2.03 (s, 3H), 1.43 (s, 3H), 1.38 
(s, 3H); 13C NMR (101 MHz, CDCl3) δ 166.8, 130.7, 124.5, 110.6, 75.4, 74.8, 73.4, 62.4, 
27.7, 26.7, 14.3; IR (ATR) νmax 2986, 2888, 1735, 1664, 1370, 1217, 1057, 984, 866, 673, 
625 cm–1; MS (ESI, +ve) m/z 290 and 288  [(M+H)+, both 100%]; HRMS (ESI, +ve) (M+H)+ 
Calcd for C11H1579BrNO3 288.0230; Found 288.0232. 
 
Compound 11 
 
 
 
A magnetically stirred solution of compound 10 (3.39 g, 11.76 mmol) in glacial acetic acid 
(150 mL) was stirred at 35 °C for 48 then cooled and concentrated under reduced pressure 
and the clear, orange oil thus obtained subjected to flash column chromatography (ethyl 
acetate → 95:5 ethyl acetate/methanol). Concentration of the relevant fractions (Rf = 0.5 in 
95:5 v/v ethyl acetate/methanol) then gave compound 11 (1.74 g, 48%) as an clear, orange 
foam, [α]D = –32.6 (c 1.08, CHCl3). 1H NMR (400 MHz, CDCl3) δ 6.43 (d, J = 6.1 Hz, 1H), 
6.40 (broad d, J = 7.9 Hz, 1H), 4.63 (d, J = 5.0 Hz, 1H), 4.58 (m, 1H), 4.37 (m, 1H), 4.02 (m, 
1H), 2.88 (m, 1H), 2.09 (s, 3H), 1.51 (s, 3H), 1.38 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
170.0, 131.1, 127.7, 111.4, 77.3, 77.2, 67.2, 47.1, 28.0, 26.4, 23.4; IR (ATR) νmax 3518, 3314, 
2987, 2934, 1657, 1519, 1372, 1226, 1060, 867 cm–1; MS (ESI, +ve) m/z 330 and 328 
[(M+Na)+, 98 and 100%]; HRMS (ESI, +ve) (M+H)+ Calcd for C11H1779BrNO4 306.0335; 
Found 306.0342. 
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Compound 12 
 
 
 
A magnetically stirred solution of compound 11 (1.74 g, 5.69 mmol) in n-BuOH (40 mL) was 
treated with KI (1.42 g, 8.43 mmol, 1.5 mole eq.), CuI (108 mg, 0.57 mmol, 0.1 mole eq.) 
and 1,2-dimethylethylenediamine (1,2-DMEDA) (61 µL, 0.56 mmol) then a nitrogen 
atmosphere was established. The resulting mixture was stirred at 130 °C for 16 h before 
being cooled to 22 °C then concentrated under reduced pressure. The resulting light-yellow 
oil was subjected to flash column chromatography (1:9 v/v petroleum ether/ethyl acetate 
elution) to yield, after concentration of the appropriate fractions (Rf = 0.2 in ethyl acetate), 
compound 12 (1.63 g, 81%) as a white foam, m.p. = 44 °C, [α]D = –27.4 (c 0.50, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ 6.72 (d, J = 5.9 Hz, 1H), 6.40 (m, 1H), 4.61 (d, J = 5.0 Hz, 1H), 
4.53 (m, 1H), 4.37 (m, 1H), 3.98–3.81 (complex m, 1H), 2.91 (d, J = 11.7 Hz, 1H), 2.08 (s, 
3H), 1.50 (s, 3H), 1.37 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 170.0, 139.0, 111.2, 105.4, 
79.5, 77.0, 67.6, 46.9, 28.0, 26.5, 23.4; IR (ATR) νmax 3517, 3317, 2986, 2933, 1657, 1514, 
1372, 1225, 1057, 865, 730 cm–1; MS (ESI, +ve) m/z 376 [(M+Na)+, 100%]; HRMS (ESI, 
+ve) (M+Na)+ Calcd for C11H16INO4Na 376.0022; Found 376.0027. 
 
Compound 13 
 
 
 
A magnetically stirred solution of compound 12 (876 mg, 2.48 mmol, 1.0 mole eq.) in THF 
(40 mL) was treated with freshly distilled N,O-dimethylhydroxylamine (5 mL), triethylamine 
(1.5 mL) then Pd(PPh3)4 (280 mg, 0.25 mmol, 10 mole %). The reaction flask was evacuated 
then filled with CO three times and the resulting mixture stirred at 60 °C for 3 h before being 
cooled to 22 °C then concentrated under reduced pressure. The ensuing light-yellow oil was 
subjected to flash column chromatography (95:5 v/v ethyl acetate/methanol → 90:10 v/v 
ethyl acetate/methanol gradient elution) to yield, after concentration of the appropriate 
fractions (Rf = 0.3 in 90:10 v/v ethyl acetate/methanol), product 13 (740 mg, 95%) as a white, 
foam, m.p. = 60-61 °C, [α]D = –31.7 (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) δ 6.47 (d, J 
= 8.1 Hz, 1H), 6.40 (d, J = 5.5 Hz, 1H), 5.15 (d, J = 5.5 Hz, 1H), 4.60 (m, 1H), 4.33 (m, 1H), 
4.12 (q, J = 7.2 Hz, 1H), 3.67 (s, 3H), 3.27 (s, 3H), 2.92 (d, J = 11.6 Hz, 1H), 2.10 (s, 3H), 
1.49 (s, 3H), 1.35 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 170.2, 167.9, 135.2, 129.9, 111.3, 
75.9, 73.3, 65.1, 61.5, 47.3, 33.0, 28.0, 26.3, 23.5; IR (ATR) νmax 3321, 2985, 2936, 1660, 
1527, 1374, 1214, 1058, 873 cm–1; MS (ESI, +ve) m/z 337 [(M+Na)+, 100%]; HRMS (ESI, 
+ve) (M+H)+ Calcd for C14H23N2O6 315.1551; Found 315.1553. 
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Compound 14 
 
 
 
A magnetically stirred solution of compound 13 (530 mg, 1.69 mmol) in DMF (8 mL) 
maintained at 22 °C was treated with imidazole (287 mg, 4.22 mmol) then TBS-Cl (635 mg, 
4.22 mmol). The ensuing mixture was stirred at 22 °C for 5 h and then quenched with 
NaHCO3 (5 mL of a saturated aqueous solution) then treated with LiCl (15 mL of a saturated 
aqueous solution) before being extracted with ethyl acetate (3 × 5 mL). The combined 
organic layers were dried (Na2SO4), filtered and concentrated under reduced pressure and the 
ensuing light-yellow oil subjected to flash column chromatography (1:1 v/v petroleum 
ether/ethyl acetate elution). Concentration of the appropriate fractions (Rf = 0.5 in ethyl 
acetate) then gave compound 14 (690 mg, 95%) as a clear, colorless oil, [α]D = +59.6 (c 0.4, 
CHCl3). 1H NMR (400 MHz, CDCl3) δ 6.20–6.16 (complex m, 2H), 5.09 (d, J = 6.4 Hz, 1H), 
4.46 (m, 1H), 4.38–4.25 (complex m, 2H), 3.68 (s, 3H), 3.28 (s, 3H), 2.05 (s, 3H), 1.43 (s, 
3H), 1.33 (s, 3H), 0.92 (s, 9H), 0.10 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 169.6, 168.1, 
133.8, 130.7, 110.9, 73.9, 72.2, 64.2, 61.6, 47.5, 27.6, 26.1, 25.8, 23.6, 18.2, –4.3, –4.9 (one 
signal obscured or overlapping); IR (ATR) νmax 3449, 2931, 2857, 1674, 1633, 1508, 1473, 
1369, 1252, 1099, 1058, 840, 777 cm–1; MS (ESI, +ve) m/z 451 [(M+Na)+, 100%]; HRMS 
(ESI, +ve) (M+H)+ Calcd for C20H37N2O6Si 429.2415; Found 429.2419. 
 
Compound 15 
 
 
 
A magnetically stirred solution of compound 14 (160 mg, 0.37 mmol) in THF (4 mL) 
maintained at –78 °C under a nitrogen atmosphere was treated with LiAlH4 (0.5 mL of a 1 M 
solution in THF, 0.5 mmol). The ensuing mixture was stirred for 1.5 h at –78 °C then treated 
with acetone (2 mL) and methanol (2 mL) and after being warmed to 22 °C the ensuing 
mixture was filtered through a pad of TLC-grade silica gel. Concentration of the filtrate then 
gave aldehyde 15 (116 mg, 84%) as a clear, colorless oil, Rf = 0.6 (in ethyl acetate), [α]D = 
+67.0 (c 0.4, CHCl3). 1H NMR (400 MHz, CDCl3) δ 9.60 (s, 1H), 6.68 (d, J = 4.9 Hz, 1H), 
6.12 (d, J = 9.3 Hz, 1H), 4.94 (dd, J = 6.5 and 0.7 Hz, 1H), 4.53–4.38 (complex m, 2H), 4.32 
(m, 1H), 2.06 (s, 3H), 1.37 (s, 6H), 0.92 (s, 9H), 0.13 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 
192.7, 169.6, 146.1, 138.9, 111.1, 73.6, 69.1, 64.4, 47.9, 27.5, 25.9, 25.8, 23.6, 18.2, –4.3, –
4.9; IR (ATR) νmax 3449, 2953, 2930, 2857, 1693, 1509, 1370, 1253, 1096, 1060,  839 cm–1; 
MS (ESI, +ve) m/z 408 [(M+K)+, 100%]; HRMS (ESI, +ve) (M+H)+ Calcd for C18H32NO5Si 
370.2044; Found 370.2048. 
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Compound 16 
 
 
 
A magnetically stirred solution of compound 15 (93 mg, 0.25 mmol, 1.0 mole eq.) in 
methanol (4 mL) maintained at 0 °C was treated with CeCl3•7H2O (100 mg, 0.28 mmol) then 
NaBH4 (12 mg, 0.33 mmol). The ensuing mixture was stirred at 0 °C for 0.25 h before being 
quenched with acetone (2 mL) then filtered through a pad of TLC-grade silica gel. The 
filtrate was concentrated under reduced pressure and the resulting light-yellow oil subjected 
to flash column chromatography (1:1 v/v petroleum ether/ethyl acetate → ethyl acetate 
gradient elution) to give, after concentration of the appropriate fractions (Rf = 0.6), compound 
16 (89 mg, 95%) as a white, crystalline solid, m.p. = 135–136 °C, [α]D = +33.3 (c 1.1, 
CHCl3). 1H NMR (400 MHz, CDCl3) δ 6.13 (d, J = 8.9 Hz, 1H), 5.75 (m, 1H), 4.62 (d, J = 
6.1 Hz, 1H), 4.43 (m, 1H), 4.31 (m, 1H), 4.27–4.20 (complex m, 3H), 2.04 (s, 3H), 1.97 (m, 
1H), 1.40 (s, 3H), 1.34 (s, 3H), 0.90 (s, 9H), 0.08 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 
169.7, 137.7, 124.9, 110.8, 74.2, 73.0, 64.8, 64.3, 47.9, 27.8, 26.4, 25.9, 23.6, 18.2, –4.2, –
4.8; IR (ATR) νmax 3445, 2930, 2857, 1660, 1515, 1369, 1252, 1095, 1068, 837, 775, 673 cm–
1
; MS (ESI, +ve) m/z 394 [(M+Na)+, 100%]; HRMS (ESI, +ve) (M+Na)+ Calcd for 
C18H33NO5SiNa 394.2020; Found 394.2025. 
 
Compound 2 
 
 
 
A magnetically stirred solution of compound 16 (90 mg, 242 mmol, 1.0 mole eq.) in acetic 
acid/water (9 mL of a 2:1 v/v mixture) was stirred at 60 °C for 7 h then cooled to 22 °C and 
concentrated under reduced pressure. The resulting light-yellow oil was subjected to flash 
column chromatography (4:1 v/v CH2Cl2/methanol elution) to yield, after concentration of 
the appropriate fractions (Rf = 0.2), compound 2 (44 mg, 83%) as a white, crystalline solid, 
m.p. = 52–54 °C, [α]D = –0.4 (c 0.8, CHCl3). 1H NMR [400 MHz, (CD3)2SO] δ 7.57 (d, J = 
7.8 Hz, 1H), 5.68 (s, 1H), 4.98 (s, 2H), 4.69 (s, 1H), 4.38 (d, J = 7.8 Hz, 1H), 4.10–3.94 
(complex m, 4H), 3.91 (m, 1H), 3.67 (s, 1H), 1.87 (s, 3H); 1H NMR (400 MHz, D2O) δ 5.87 
(s, 1H), 4.36 (s, 2H), 4.31–4.13 (complex m, 3H), 3.98 (s, 1H), 2.08 (s, 3H) (signals due to 
OH and NH group protons not observed); 13C NMR [101 MHz, (CD3)2SO] δ 169.5, 139.9, 
122.9, 69.9, 67.7, 66.0, 61.2, 51.0, 23.0; IR (ATR) νmax  3289, 2925, 1633, 1538, 1378, 1264, 
1047 cm–1; MS (ESI, +ve) m/z 240 [(M+Na)+, 100%]; HRMS (ESI, +ve) (M+H)+ Calcd for 
C9H16NO5 218.1023; Found 218.1021. 
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Compound 17 
 
 
 
A magnetically stirred solution of compound 6 (1.6 g, 6.722 mmol) in THF/H2O (60 mL of a 
5:1 v/v mixture) maintained at 22 °C was treated with N-bromosuccinimide (3.00 g, 16.86 
mmol). After 1 h the reaction mixture was concentrated under reduced pressure and the light-
yellow oil so-obtained was subjected to flash chromatography (2:1 v/v ethyl acetate/hexane 
elution) to afford, after concentration of the appropriate fractions (Rf = 0.4 in 8:2.5:5.5 v/v/v 
ethyl acetate/dichloromethane/hexane), compound 175 (1.67 g, 74%) as a white, crystalline 
solid, m.p. = 113–116 °C (lit.5 m.p. = 125-127 °C), [α]D = –61° (c = 0.5, CHCl3) {lit.5 [α]D = 
–63.5 (c 5.0, THF)}. 1H NMR (400 MHz, CD3OD) δ 6.38 (s, 1H), 4.28 (d, J = 4.0 Hz, 1H), 
4.20 (m, 1H), 4.00 (m, 1H), 3.70 (dd, J = 11.3 and 4.1 Hz, 1H) (signals due to OH group 
protons not observed); 13C NMR (100 MHz, CD3OD) δ 143.6, 100.1, 77.4, 76.2, 72.0, 58.6; 
IR νmax 3295, 2884, 1444, 1348, 1255, 1197, 1185, 1064, 865 cm–1; MS (ESI, +ve) m/z 359 
and 357 [(M+Na)+, both 100%]; HRMS (ESI, +ve) (M+Na)+ Calcd for C6H879BrIO3Na 
356.8593; Found 356.8594. 
 
Compound 18 
 
 
 
A magnetically stirred solution of compound 17 (758 mg, 2.263 mmol) in methanol (15 mL) 
maintained at 22 °C was treated with sodium methoxide (610 mg, 11.3 mmol). After stirring 
for 1 h the reaction mixture was filtered through a short pad of TLC-grade silica gel and the 
filtrate concentrated under reduced pressure. Subjection of the the resulting clear, colorless 
oil to flash chromatography (2:1 v/v ethyl acetate/hexane elution) and concentration of the 
appropriate fractions (Rf = 0.4 in 2:15 v/v methanol/dichloromethane) afforded compound 185 
(523 mg, 91%) as a white, crystalline solid, m.p. = 136–139 °C (lit.5 m.p. = 124-126 °C), [α]D 
= +29.5 (c = 0.2, methanol) {lit.5 [α]D = +26.4 (c 5.0, THF)}. 1H NMR (400 MHz, CD3OD) δ 
6.22 (s, 1H), 4.32 (s, 1H), 4.22 (s, 1H), 3.42 (m, 2H) (signals due to OH group protons not 
observed); 13C NMR (100 MHz, CD3OD) δ 139.3, 103.3, 69.4, 67.9, 55.6, 54.9; IR νmax 3342, 
2877, 1635, 1428, 1250, 1047, 871 cm–1; MS (ESI, +ve) m/z 277 [(M+Na)+, 100%]; HRMS 
(ESI, +ve) (M+Na)+ Calcd for C6H7IO3Na 276.9331; Found 276.9332. 
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Compound 19 
 
 
 
A magnetically stirred solution of compound 18 (1.41 g, 5.551 mmol) in THF (75 mL) was 
treated with 4-nitrobenzoic acid (2.30 g, 13.8 mmol), triphenylphosphine (3.80 g, 14.49 
mmol) then diethyl azodicarboxylate (DEAD) (2.30 mL, 14.61 mmol). After stirring for 18 h 
at 22 °C the reaction mixture was concentrated under reduced pressure. Subjection of the 
resulting light-yellow solid to flash chromatography (1:5 v/v ethyl acetate/hexane elution) 
and concentration of the appropriate fractions (Rf = 0.4 in 1:2.5:5.5 v/v/v ethyl 
acetate/dichloromethane/hexane) yielded compound 19 (3.02 g, 98%) as a white, crystalline 
solid, m.p. = 146–149 °C, [α]D = +49 (c = 0.2, CHCl3). 1H NMR (400 MHz, (CDCl3) 8.48–
8.22 (complex m, 8H), 6.76 (m, 1H), 6.03 (m, 1H), 5.77 (m, 1H), 3.54 (m, 2H); 13C NMR 
(100 MHz, CDCl3) δ 163.9, 163.8, 151.2, 151.1, 134.4(9), 134.5(3), 134.4, 131.4, 131.2, 
123.9(4), 123.8(9), 98.0, 72.4, 67.1, 51.3, 49.5; IR νmax 3112, 2930, 1731, 1527, 1257, 1096, 
718 cm–1; MS (ESI, +ve) m/z 575 [(M+Na)+, 100%]; HRMS (ESI, +ve) (M+H)+ Calcd for 
C20H13IN2O9Na 574.9564; Found 574.9579. 
 
Compound 20 
 
 
 
Potaasium carbonate (3.50 g, 25.89 mmol) was added to a magnetically stirred solution of 
compound 19 (3.48 g, 6.302 mmol) in anhydrous methanol (40 mL) maintained at 22 °C. 
After 1 h the reaction mixture was filtered through a short pad of TLC-grade silica gel and 
the filtrate concentrated under reduced pressure. Subjection of the ensuing clear, light-yellow 
oil to flash chromatography (2:1 v/v ethyl acetate/hexane elution) and concentration of the 
appropriate fractions (Rf = 0.5 in 5:4:1 v/v/v ethyl acetate/hexane/methanol) provided 
compound 20 (1.35 g, 84%) as a white, crystalline solid, m.p. = 138–141 °C, [α]D = +45 (c = 
0.2, methanol). 1H NMR (400 MHz, CD3OD) δ 6.40 (m, 1H), 4.38 (m, 1H), 4.27 (m, 1H), 
3.26 (m, 2H) (signals due to OH group protons not observed); 13C NMR (100 MHz, CD3OD) 
δ 137.5, 103.4, 71.9, 65.6, 54.9, 52.7; IR νmax 3341, 2896, 1637, 1450, 1282, 1028, 802 cm–1; 
MS (ESI, +ve) m/z 277 [(M+Na)+, 100%]; HRMS (ESI, +ve) (M+Na)+ Calcd for C6H7IO3Na 
276.9338; Found 276.9338. 
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Compound 21 
 
 
 
A magnetically stirred solution of compound 20 (466 mg, 1.83 mmol) in anhydrous THF 
maintained at −78 °C was treated with p-toluenesulfonyl isocyanate (28 µL, 1.83 mmol) then 
stirring continued at −78 to 22 °C for 18 h. The resulting mixture was concentrated under 
reduced pressure and the yellow oil thus obtained subjected to flash chromatography (2:1 v/v 
ethyl acetate/hexane elution) to furnish, after concentration of the appropriate fractions (Rf = 
0.5 in 5:4:1 v/v/v ethyl acetate/hexane/methanol), compound 21 (504 mg, 61%) as a white, 
crystalline solid, m.p. = 188–201 °C, [α]D = +60 (c = 0.2, methanol). 1H NMR (400 MHz, 
CD3OD) δ 8.03 (d, J = 8.3 Hz, 2H), 7.40 (d, J = 8.3 Hz, 2H), 6.58 (m, 1H), 4.94 (m, 1H), 
4.64 (m, 1H), 3.92 (m, 1H), 3.68 (m, 1H), 2.45 (s, 3H) (signals due to OH group protons not 
observed); 13C NMR (100 MHz, CD3OD) δ 153.2, 146.7, 137.0, 131.7, 130.4, 130.0, 115.4, 
75.8, 75.1, 73.4, 60.8, 21.6; IR νmax 3516, 2971, 2873, 1780, 1597, 1360, 1167, 1090, 665, 
572 cm–1; MS (ESI, +ve) m/z 474 [(M+Na)+, 100%]; HRMS (ESI, +ve) (M+Na)+ Calcd for 
C14H14INO6SNa 473.9484; Found 473.9487. 
 
Compound 22 
 
 
 
A magnetically stirred solution of compound 21 (96 mg, 0.21 mmol) in pyridine (5 mL) 
maintained at 22 °C was treated with acetic anhydride (100 µL, 1.06 mmol) and 4-(N,N-
dimethylamino)pyridine (DMAP) (15 mg, 0.12 mmol). After 3 h, the reaction mixture was 
concentrated under reduced pressure and the residue thus obtained subjected to flash 
chromatography (2:1 v/v ethyl acetate/hexane elution) to give, after concentration of the 
appropriate fractions (Rf = 0.5 in 4:2.5:5.5 v/v/v ethyl acetate/dichloromethane/hexane), 
compound 22 (112 mg, 98%) as a white, crystalline solid, m.p. = 198–202 °C, [α]D = +181 (c 
= 0.2, CHCl3). 1H NMR (400 MHz, CD3OD) δ 7.94 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.3 Hz, 
2H), 6.63 (m, 1H), 5.79 (m, 1H), 5.54 (m, 1H), 4.81 (m, 1H), 4.47 (m, 1H), 2.44 (s, 3H), 2.17 
(s, 3H), 2.10 (s, 3H); 13C NMR (100 MHz, CD3OD) δ 169.9, 169.2, 151.4, 146.3, 134.4, 
133.3, 130.1, 128.8, 100.4, 71.7, 71.2, 68.2, 54.2, 21.8, 20.9, 20.8; IR νmax 2916, 1789, 1755, 
1371, 1226, 1173, 1043, 665 cm–1; MS (ESI, +ve) m/z 558 [(M+Na)+, 100%]; HRMS (ESI, 
+ve) (M+Na)+ Calcd for C18H18INO8SNa 557.9696; Found 557.9698. 
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Compound 23 
 
 
 
A magnetically stirred suspension of compound 21 (436 mg, 0.97 mmol) in methanol/water 
(20 mL of a 1:1 v/v mixture) maintained at 22 °C was treated with sodium hydroxide (195 
mg, 4.88 mmol). After 2 h the reaction mixture was treated with sufficient HCl (2.0 M 
aqueous solution) so as to adjust the pH to 7∼9 then it was filtered through a short pad of 
TLC-grade silica gel. The filtrate was concentrated under reduced pressure and the residued 
thus obtained subjected to flash column chromatography (1:10 v/v methanol/dichloromethane 
elution) to afford, after concentration of the appropriate fractions (Rf = 0.5 in 6:3:1 v/v/v ethyl 
acetate/hexane/methanol), compound 23 (368 mg, 90%) as a white, crystalline solid, m.p. = 
168–171 °C, [α]D = −8 (c = 0.2, methanol). 1H NMR (400 MHz, CD3OD) δ 7.79 (d, J = 8.0 
Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 6.45 (m, 1H), 3.75 (m, 2H), 3.67 (m, 1H), 3.25 (m, 1H), 
2.42 (s, 3H) (signals due to NH and OH group protons not observed); 13C NMR (100 MHz, 
CD3OD) δ 144.6, 139.9, 139.7, 130.6 , 128.2, 109.8, 78.5, 71.2, 68.5, 58.3, 21.5; IR νmax 3420, 
3321, 2956, 2877, 1598, 1434, 1326, 1158, 1092, 815 cm–1; MS (ESI, +ve) m/z 448 [(M+Na)+, 
100%]; HRMS (ESI, +ve) (M+Na)+ Calcd for C13H16INO5SNa 447.9692; Found 447.9688. 
 
Compound 3 
 
 
 
A magnetically stirred mixture of compound 23 (365 mg, 0.858 mmol) and palladium acetate 
(75 mg, 0.334 mmol) in dimethylamine/ethanol (6 mL of 1:2 v/v mixture) was exposed to a 
balloon of CO. After stirring at 22 °C for 48 h, the reaction mixture was concentrated under 
reduced pressure, and the residue thus obtained subjected to flash column chromatography 
(1.5:10 v/v methanol/dichloromethane elution) to provide, after concentration of the 
appropriate fractions (Rf = 0.4 in 3:20 v/v methanol/dichloromethane), compound 3 (289 mg, 
91%) as a ca. 10:1 mixture of rotamers and as a white, crystalline solid, m.p. = 174-178 °C, 
[α]D = −5 (c = 0.2, methanol). 1H NMR (400 MHz, CD3OD) δ (major rotamer) 7.81 (d, J = 
8.3 Hz, 2H), 7.26 (d, J = 8.3 Hz, 2H), 5.69 (m, 1H), 4.20 (m, 1H), 3.99 (m, 1H), 3.66 (dd, J = 
10.7 and 7.4 Hz, 1H), 3.19 (dd, J = 10.7 and 4.0 Hz, 1H), 3.07 (s, 3H), 2.96 (s, 3H), 2.42 (s, 
3H) (signals due to NH and OH group protons not observed); 13C NMR (100 MHz, CD3OD) 
δ (major rotamer) 171.8, 144.6, 139.9, 139.8, 130.6, 128.3, 127.7, 73.7, 71.3, 66.3, 58.3, 39.4, 
35.0, 21.5; IR νmax 3330, 2933, 2876, 1607, 1448, 1326, 1158, 1092, 668 cm–1; MS (ESI, +ve) 
m/z 393 [(M+Na)+, 100%], 371 [(M+H)+, 10]; HRMS (ESI, +ve) (M+H)+ calcd for 
C16H23N2O6S 371.1266; Found 371.1271. 
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Compound 24 
 
 
 
A magnetically stirred solution of compound 23 (275 mg, 0.52 mmol) in THF (12 mL) 
maintained at 22 °C was treated with freshly distilled N,O-dimethylhydroxylamine (300 µL, 
5.82 mmol) then triethylamine (400 µL, 2.12 mmol) and Pd(PPh3)4 (55 mg, 0.05 mmol, 10 
mole %). The reaction flask was evacuated then refilled with CO three times and the resulting 
mixture stirred at 70 °C for 2 h. The cooled reaction mixture was concentrated under reduced 
pressure and the residue thus obtained subjected to flash column chromatography (1:9 v/v 
methanol/ethyl acetate elution) and afforded, after concentration of the appropriate fractions 
(Rf = 0.3), the title compound 24 (176 mg, 86%) as a clear, yellow oil, [α]D = –19.4 (c 1.0, 
methanol). 1H NMR [400 MHz, (CD3)2SO] δ 7.91 (d, J = 8.3 Hz, 2H), 7.44 (d, J = 8.3 Hz, 
2H), 6.01 (m, 1H), 4.90 (s, 5H), 4.36 (m, 1H), 4.10 (t, J = 4.6 Hz, 1H), 3.77 (s, 3H), 3.73 (m, 
1H), 3.44 (s, 2H), 3.34 (s, 3H), 3.31 (m, 1H); 13C NMR [101 MHz, (CD3)2SO] δ 160.2, 135.0, 
130.2, 129.7, 121.1(0), 121. 0(7), 120.2, 118.7, 63.8, 61.7, 56.6, 52.2, 48.6, 12.0; IR (ATR) 
νmax 3326, 2935, 2490, 1615, 1436, 1323, 1155, 1092, 815, 667 cm–1; MS (ESI, +ve) m/z 409 
[(M+Na)+, 100%]; HRMS (ESI, +ve) (M+H)+ Calcd for C16H23N2O7S 387.1220; Found 
387.1228. 
 
Compound 4 
 
 
 
A magnetically stirred solution of compound 3 (60 mg, 0.162 mmol) in anhydrous THF (15 
mL) maintained at −78 °C under a nitrogen atmosphere was treated with sodium 
naphthalenide (1.0 mL of a ca. 0.8 M solution in THF, ca. 0.8 mmol). After stirring at  −78 
°C for 3 h, the reaction was quenched with ethanol (2 mL). Evaporation of the ensuing 
mixture under reduced pressure followed by subjection of the residue so-obtained to flash 
column chromatography (1.5:10 v/v methanol/dichloromethane elution) afforded, after 
concentration of the appropriate fractions (Rf = 0.5 in 3:20 v/v methanol/dichloromethane), 
compound 4 (46 mg, 81%) as a ca. 10:1 mixture of rotamers and as a white, crystalline solid, 
m.p. = 189–193 °C, [α]D = −122 (c = 0.2, methanol). 1H NMR (400 MHz, CD3OD) δ 7.78 (d, 
J = 8.0 Hz, 2H), 7.36 (d, J = 8.0 Hz, 2H), 5.25 (m, 2H), 3.85 (t, J = 9.4 Hz, 1H), 3.76 (m, 1H), 
3.58 (m, 1H), 3.44 (t, J = 9.4 Hz, 1H), 3.14 (s, 3H), 2.95 (s, 3H), 2.42 (s, 3H) (signals due to 
NH and OH group protons not observed); 13C NMR (100 MHz, CD3OD) δ (major 
rotamer)174.6, 144.6, 140.2, 130.7, 130.6, 130.1, 128.2, 126.2, 76.0, 73.8, 58.5, 48.0, 38.2, 
36.4, 21.4; IR νmax 3170, 2926, 1625, 1498, 1328, 1161, 1092, 665 cm–1; MS (ESI, +ve) m/z 
377 [(M+Na)+, 100%], 355 [(M+H)+, 9]; HRMS (ESI, +ve) (M+H)+ Calcd for C16H23N2O5S 
355.1324; Found 355.1322. 
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Compound 25 
 
 
 
A magnetically stirred solution of compound 5 (660 mg, 3.46 mmol, 1.0 mole eq.) in THF (5 
mL) maintained at 0 °C was treated with water (2 mL) and N-bromosuccinimide (645 mg, 
3.63 mmol). The reaction mixture was then warmed to 22 °C and stirred at this temperature 
for 1 h before being quenched with sodium sulfite (5 mL of a saturated aqueous solution). 
The separated aqueous phase was extracted with ethyl acetate (3 × 10 mL) and the combined 
organic layers were dried (Na2SO4), filtered then concentrated under reduced pressure. The 
residue thus obtained was subjected to flash column chromatography (2:3 v/v ethyl 
acetate/petroleum ether elution) and so affording, after concentration of the appropriate 
fractions (Rf = 0.2), compound 255 (767 mg, 77%) as a white, crystalline solid, m.p. = 115–
116 °C (lit.5 m.p. = 116–118 °C), [α]D = –77.3 (c 1.2, ethanol) {lit.5 [α]D = –61.7 (c 5.0, 
ethanol)}. 1H NMR [400 MHz, (CD3)2SO] δ 6.00 (d, J = 2.6 Hz, 1H), 5.77 (d, J = 7.2 Hz, 
1H), 5.70 (d, J = 6.2 Hz, 1H), 5.43 (d, J = 7.7 Hz, 1H), 4.14 (m, 1H), 4.06 (m, 1H), 3.92 (m, 
1H), 3.58 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 134.9, 123.5, 73.3, 73.0, 70.4, 59.6; IR 
(ATR) νmax 3351, 2905, 1692, 1647, 1405, 1339, 1199, 1098, 1064, 870 cm–1. 
 
Compound 26 
 
 
 
A magnetically stirred solution of compound 25 (3.60 g, 12.5 mmol) in THF (60 mL) was 
maintained at 0 °C under nitrogen atmosphere then treated with NaH (600 mg of a 60 % 
dispersion in mineral oil, 15.0 mmol). The reaction mixture was them warmed to 22 °C and 
stirred at this temperature for 16 h before being quenched with sodium bicarbonate (3 mL of 
a saturated aqueous solution) and the ensuing mixture concentrated under reduced pressure. 
The residue thus obtained was subjected to flash column chromatography (2:3 v/v ethyl 
acetate/petroleum ether elution) and thus affording, after concentration of the appropriate 
fractions (Rf = 0.3), compound 265 (2.20 g, 85%) as a white, crystalline solid, m.p. = 149 °C 
(lit.5 m.p. = 134–136 °C), [α]D = +18.8 (c 1.15, THF) {lit.5 [α]D = +16.6 (c 5.0, THF)}. 1H 
NMR [400 MHz, (CD3)2SO] δ 5.77 (q, J = 2.2 Hz, 2H), 5.47 (m, 1H), 4.33 (m, 1H), 4.25 (m, 
1H), 3.42–3.34 (complex m, 2H); 13C NMR [101 MHz, (CD3)2SO] δ 130.3, 123.9, 65.8, 65.4, 
54.3, 54.1; IR (ATR) νmax 3339, 2924, 2872, 1703, 1047, 911 cm–1; MS (ESI, +ve) m/z 231 
and 229 [(M+Na)+, 98 and 100%]; HRMS (ESI, +ve) (M+Na)+ Calcd for for C6H779BrO3Na 
228.9476; Found 228.9481. 
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Compound 27 
 
 
 
A magnetically stirred solution of compound 26 (1.85 g, 8.94 mmol, 1.0 mole eq.) in THF 
(80 mL) maintained under nitrogen at 22 °C was treated with triphenylphosphine (5.86 g, 
22.34 mmol) and p-nitrobenzoic acid (3.73 g, 22.34 mmol). The ensuing mixture was cooled 
to 0 °C, DEAD (3.51 mL, 22.34 mmol) added, dropwise, after which it was warmed to 22 °C 
and stirred at this temperature for another 16 h. The reaction mixture was then concentrated 
under reduced pressure and the residue thus obtained was subjected to flash column 
chromatography (1:9 to 1:4 v/v ethyl acetate/petroleum ether gradient elution) and thus 
affording, after concentration of the appropriate fractions (Rf = 0.6 in 3:7 v/v ethyl 
acetate/petroleum ether elution), compound 27 (2.87 g, 64%) as a white, crystalline solid, 
m.p. = 182 °C, [α]D = +39.5 (c 1.22, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 8.52–8.00 
(complex m, 8H), 6.48 (m, 1H), 6.05 (s, 1H), 5.88 (m, 1H), 3.60 (s, 1H), 3.55 (s, 1H); 13C 
NMR (101 MHz, CDCl3) δ 163.9, 163.8, 151.2, 151.1, 134.5, 134.3, 131.3, 131.2, 126.8, 
123.9(1), 123.8(9), 123.3, 70.2, 66.9, 51.8, 49.7; IR (ATR) νmax 3114, 3081, 2951, 2859, 
1733, 1722, 1523, 1258, 1091, 841, 715 cm–1; MS (ESI, +ve) m/z 529 and 527 [(M+Na)+, 98 
and 100%]; HRMS (ESI, +ve) (M+Na)+ Calcd for for C20H1379BrN2O9Na 526.9702; Found 
526.9698. 
 
Compound 28 
 
 
 
A magnetically stirred suspension of compound 27 (2.38 g, 4.71 mmol, 1.0 mole eq.) in dry 
methanol (80 mL) maintained at 0 °C was treated with a suspension of sodium methoxide 
(254 mg, 4.71 mmol) in methanol (30 mL). The ensuing mixture was warmed to 22 °C and 
stirred at this temperature for 2 h then quenched with ammonium chloride (10 mL of a 
saturated aqueous solution) and the mixture then concentrated under reduced pressure. The 
residue thus obtained was subjected to flash column chromatography (1:1 → 1:4 v/v ethyl 
acetate/petroleum ether gradient elution) and afforded, after concentration of the appropriate 
fractions (Rf = 0.2) compound 28 (797 mg, 82%) as a pink solid, m.p. = 96 °C, [α]D = +27.4 
(c 1.15, methanol). 1H NMR (400 MHz, CDCl3) δ 6.20 (dd, J = 5.4 and 1.7 Hz, 1H), 4.59 (s, 
1H), 4.53 (s, 1H), 3.45 (s, 1H), 3.35 (s, 1H), 3.04 (s, 1H), 2.62 (broad s, 1H); 13C NMR (101 
MHz, CDCl3) δ 128.4, 126.2, 69.3, 64.7, 53.7, 51.4; IR (ATR) νmax 3310, 3007, 2900, 1651, 
1023, 954, 804 cm–1; MS (ESI, +ve) m/z 231 and 229 [(M+Na)+, 30 and 100%]; HRMS (ESI, 
+ve) (M+Na)+ Calcd for for C6H779BrO3Na 228.9476; Found  228.9473. 
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Compound 30 
 
 
 
A magnetically stirred solution of compound 28 (3.60 g, 17.39 mmol) in dry THF (80 mL) 
maintained at –78 °C under nitrogen atmosphere was treated, dropwise, with p-
toluenesulfonyl isocyanate (3.0 mL, 19.13 mmol) then the reaction mixture was allowed to 
warm to 22 °C over 5 h. Stirring was continued at this temperature for another 10 h then the 
reaction mixture concentrated under reduced pressure. The residue thus obtained (and 
presumed to contain compound 29) was dissolved in methanol/water (140 mL of a 1:1 v/v 
mixture) then treated, dropwise, with sodium hydroxide (10 mL of a 17.5 M aqueous 
solution). The ensuing mixture was stirred at 22 °C for 5 h then neutralised with HCl (10 mL 
of a 1 M aqueous solution) before being concentrated under reduced pressure to half the 
original volume. The separated aqueous layer was extracted with ethyl acetate (5 × 30 mL) 
and the combined organic phases dried (Na2SO4), filtered then concentrated under reduced 
pressure. The residue thus obtained was subjected to flash column chromatography (ethyl 
acetate elution) and afforded, after concentration of the appropriate amounts (Rf = 0.6), 
compound 30 (5.04 g, 77%) as a clear, yellow oil, [α]D = –15.5 (c 1.0, acetone). 1H NMR 
[400 MHz, (CD3)2CO] δ 7.81 (d, J = 8.2 Hz, 2H), 7.37 (d, J = 8.2 Hz, 2H), 6.15 (dd, J = 5.4 
and 1.5 Hz, 1H), 4.90 (broad s, 1H), 4.31 (broad m, 1H), 4.13–3.99 (complex m, 2H), 3.94 
(m, 1H), 3.79 (m, 1H), 3.39–3.24 (complex m, 2H), 2.41 (s, 3H); 13C NMR [101 MHz, 
(CD3)2CO]  δ 143.8, 139.6, 131.5, 130.3, 128.0, 76.2, 71.6, 67.0, 57.6, 21.4 (one signal 
obscured or overlapping); IR (ATR) νmax 3419, 3200, 2922, 1704, 1451, 1313, 1154, 1045, 
810, 664 cm–1; MS (ESI, +ve) m/z 402 and 400 [(M+Na)+, 100 and 99%]; HRMS (ESI, +ve) 
(M+Na)+ Calcd for for C13H1679BrNO5SNa 399.9825; Found 399.9823. 
 
Compound 23 
 
 
 
A magnetically stirred suspension of compound 30 (85 mg, 0.22 mmol, 1.0 mole eq.) in n-
BuOH (5 mL) maintained at 22 °C was treated with KI (261 mg, 1.57 mmol, 7.0 mole eq.), 
CuI (5 mg, 0.02 mmol, 0.1 mole eq.) and tetramethylethylenediamine (TMEDA) (3 µL, 0.02 
mmol, 0.1 mole eq.). The reaction vessel was flushed with nitrogen then sealed and the 
contents stirred at 130 °C for 36 h. The cooled reaction mixture was concentrated under 
reduced pressure and the residue thus obtained subjected to flash column chromatography 
(ethyl acetate) to afford, after concentration of the appropriate amounts (Rf = 0.6), compound 
23 (54 mg, 57%) as a brown solid. This material was identical, in all respects, with that 
obtained by the protocol defined above.  
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Crystallographic Studies.  
Crystallographic Data.  
 
Compound 3. C16H22N2O6S M = 370.43, T = 150 K, triclinic, space group P1, Z = 1, a = 
5.7776(2) Å, b = 6.4485(2) Å, c = 12.4143(4) Å; α = 96.716(3)°, β = 91.948(3), γ = 
112.530(3)°, V = 422.72(1) Å3, Dx = 1.455 Mg m–3, 2620 unique data (2θmax = 147.8°), R = 
0.046 [for 2593 reflections with I > 2.0σ(I)]; Rw = 0.124 (all data), S = 1.00. 
Compound 4. C16H22N2O5S, M = 354.43, T = 150 K, monoclinic, space group, P21, Z = 2, a = 
7.3573(2) Å, b = 7.5270(2) Å, c = 15.5741(5) Å; β = 93.163(3)°, V = 861.15(3) Å3, Dx = 
1.367 Mg m–3, 2361 unique data (2θmax = 148.2°), R = 0.064 [for 2230 reflections with I > 
2.0σ(I)]; Rw = 0.173 (all data), S = 1.00. 
Compound 8. C11H15Br2NO3, M = 369.06, T = 150 K, monoclinic, space group P21, Z = 2, a 
= 5.0336(3) Å, b = 17.7799(12) Å, c = 7.6856(5) Å; β = 94.134(5)°, V = 686.05(8) Å3, Dx = 
1.787 Mg m–3, 2788 unique data (2θmax = 52.8°), R = 0.034 [for 2611 reflections with I > 
2.0σ(I)]; Rw = 0.070 (all data), S = 1.01. 
Compound 16. C18H33NO5Si, M = 371.54, T = 150 K, triclinic, space group P1, Z = 1, a = 
7.2377(6) Å, b = 8.2340(6) Å, c = 9.9721(10) Å; α = 99.215(7)°, β = 108.174(8), γ = 
105.551(7)°, V = 524.33(8) Å3, Dx = 1.177 Mg m–3, 3258 unique data (2θmax = 60°), R = 
0.044 [for 2997 reflections with I > 2.0σ(I)]; Rw = 0.119 (all data), S = 1.13. 
Compound 22. C18H18INO8S•CH2Cl2 M = 620.22, T = 150 K, monoclinic, space group C2, Z 
= 4, a = 25.1349(5) Å, b = 8.03077(13) Å, c = 12.0325(2) Å; β = 97.6645 (16)°, V = 
2407.10(7) Å3, Dx = 1.711 Mg m–3, 4760 unique data (2θmax = 147.8°), R = 0.034 [for 4695 
reflections with I > 2.0σ(I)]; Rw = 0.091 (all data), S = 1.04. 
 
Structure Determinations. 
Images for compounds 3, 4, 8, 16 and 22 were measured on a diffractometer (Cu Kα, mirror 
monochromator, λ = 1.54184 Å) fitted with an area detector and the data extracted using the 
CrysAlis package.6 The structures of compounds 2 and 3 were refined using the CRYSTALS7 
program package while the remainder were solved with ShelXT8 and refined using ShelXL9 
in OLEX2.10 Atomic coordinates, bond lengths and angles, and displacement parameters have 
been deposited at the Cambridge Crystallographic Data Centre (CCDC nos. 1870597, 
1870598, 1870599, 1870600, and 1870601). These data can be obtained free-of-charge via 
www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@ccdc.cam.ac.uk, or by 
contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 
1EZ, UK; fax: +44 1223 336033. 
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Figure S1: Structure of compound 3 (CCDC 1870597). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S2: Structure of compound 4 (CCDC 1870598). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S3: Structure of compound 8 (CCDC 1870599) showing the two molecules in the unit 
cell. Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen atoms are 
drawn as circles with small radii. 
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Figure S4: Structure of compound 16 (CCDC 1870600). Anisotropic displacement ellipsoids 
show 30% probability levels. Hydrogen atoms are drawn as circles with small radii. 
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Figure S5: Structure of compound 22 (CCDC 1870601) and associated dichloromethane. 
Anisotropic displacement ellipsoids show 30% probability levels. Hydrogen atoms are drawn 
as circles with small radii. 
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The cochliomycins (7–12) are a group of six resorcylic acid lactones that have recently been isolated from
culture broths of marine fungi found in the South China Sea. These natural products have attracted atten-
tion as synthetic targets because of (in certain instances) their novel structural features and their capac-
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The value of small molecule natural products (SMNPs) as ther-
apeutic agents, as precursors to such agents or as the inspirations
for them is well known.1 Indeed, there are now indications that
SMNPs, perhaps especially ones derived from marine environ-
ments,2 are enjoying something of a renaissance not least because
of their enormous structural diversity and their occupation ofunique parts of chemical space.3 Among the plethora of different
natural product classes, the resorcylic acid lactones (RALs) are
notable for the frequency with which they are isolated from fungal
sources, their distinctive structural features and their breadth of
biological activities.4 In the following section an overview of the
structural variations within the RAL class is provided along with
a brief commentary on the source organisms and certain of their
biological properties. As a recently discovered and interesting sub-
set of RALs that has not been the subject of any previous reviews,
the cochliomycins are then described and a summary of the syn-
thetic work carried out on them follows.
4026 M.G. Banwell et al. / Tetrahedron Letters 58 (2017) 4025–4038Resorcylic acids lactones (RALs) as a natural product class
The RALs are mycotoxins and the products of a distinctive
polyketide biosynthesis that exploits an acetyl CoA starter unit
together with malonyl-CoA extenders and involves two fungal
polyketide synthases (PKS) that work co-operatively.4e
Specifically, a non-reducing PKS is coupled with a highly
reducing one that enables the assembly of the relevant resorcylic
acid core annulated to a 14-membered macrolactone (and
wherein most of the structural variation resides). Unsurprisingly
perhaps, the final step in the biosynthesis is the
macrolactonisation event that releases the substrate from the
enzyme complex. Post-PKS-mediated processes such as
epoxidation, halogenation and alkylation may then follow so as
to provide the fully ‘‘decorated” (isolated) metabolite.4e
Radiciol (1) was the first RAL to be isolated (from Monosporium
nordinii) and characterised in the 1950s4 and it has since been
obtained from various other fungal strains. In the intervening per-
iod numerous other RALs have been identified and these vary in
the nature of the substitution pattern on the aromatic ring as well
as the location and degree of unsaturation and/or oxygenation
within the macrolactone ring. The structures of the RALs hypothe-
mycin (2), zearalenone (3), pochonin C (4), L-783,277 (5) and aigia-
lomycin D (6) shown in Fig. 1 serve to highlight such degrees of
variation.O
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Fig. 1. Examples of the structural variations possible within the RAL class.Initial biological evaluation of radiciol (1) showed it to possess
anti-bacterial properties and to act as a mild sedative. However,
the later revelation that it acts as a powerful inhibitor of heat shock
protein 90 (HSP90) – and thus representing an important lead in
the development of oncolytic agents – caused much greater atten-
tion to be given to the RALs. In contrast to radiciol (1), the cis-
enone-containing hypothemycin (2) has been shown to strongly
inhibit the kinase MEK1, while zearalenone (3) acts as an estrogen
agonist and its hormone-like properties have been shown to pro-
mote growth in cattle and sheep. A closely related RAL is now com-
mercially available and employed to alleviate post-menopausal
stress in women and as an anabolic cattle-growth stimulant.
Pochonin C (4), on the other hand, inhibits herpes simplex virus
(HSV) replication in a potentially therapeutically useful way while
the cis-enone L-783,277 (5), like congener 2, inhibits MEK1. Aigia-
lomycin D (6), despite the absence of a cis-enone moiety, also acts
as a kinase inhibitor as well as an anti-malarial agent (the latter
property seemingly being unrelated to the former).34The discovery of cochliomycins A–F
In papers published in 20115 and 2014,6 Wang and co-workers
from the Ocean University of China in Qingdao reported the isola-
tion of cochliomycins A–F (7–12) (Fig. 2) from the culture broths of
Cochliobolus lunatus (M351) or C. lunatus (TA26-46), fungi associ-
ated with the gorgonian Dichotella gemmacea or the sea anemone
Palythoa haddoni, respectively. Both host organisms were collected
in the South China Sea. The structures of these RALs were estab-
lished through the application of the usual battery of spectroscopic
methods and the absolute stereochemistries of the last three deter-
mined using the CD exciton chirality method in conjunction with
TDDFT ECD calculations.6
The most striking features of this subset of RALs are the pres-
ence of acetonide units within the structures of congeners A and
B (7 and 8, respectively). Since acetone was not used in the isola-
tion, purification or spectroscopic characterisation of these com-
pounds they must be considered as natural products rather than
artefacts. Wang and co-workers also noted5 that on standing in
CDCl3 at ambient temperatures cochliomycin B (8) slowly iso-
merised to congener 7 and so suggesting the latter is the thermo-
dynamically more stable compound. Cochliomycin C (9) is the only
member of the series lacking a second double bond within the
macrocyclic ring. Cochliomycins D (10) and E (11) are isomeric
while congener F (12) is not simply a chlorinated derivative ofone or other of the first two because of the differing configuration
at one or other of the hydroxyl-bearing methine carbons. Nor, for
the same reasons, can cochliomycin F (12) simply be the product
of the twofold oxidation of congener 9.Related, co-occurring natural products
In the course of structurally characterising the cochliomycins, it
was noted5 that congener C (9) is the chlorinated derivative of co-
isolated paecilomycin F (13) (Fig. 3), a previously reported RAL that
displays anti-malarial properties. Other RALs also isolated along-
side compounds 7–9 were zeaenol (14), LL-Z1640-1 (15) and LL-
Z1640-2 (16). During the course of isolating cochliomycins D, E
and F (10, 11 and 12, respectively), cochliomycin A (7), zeaenol
(14), LL-Z1640-1 (15), LL-Z1640-2 (16), its E-isomer 17 [(70E)-60-
oxozeaenol], deoxyaigialomycin C (18) and aigialomycin B (19)
were also observed in the mixture of isolates. Clearly certain of
these co-isolates are isomeric with the cochliomycins or otherwise0
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Fig. 2. The structures of cochliomycins A–F (7–12, respectively).
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Fig. 3. The structures of RALs found to co-occur with cochliomycins A–C and/or cochliomycins D–E.
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tected” analogue of cochliomycins A (7) and B (8).Biological properties of the cochliomycins
The most notable biological properties of at least certain of the
cochliomycins are their anti-fouling properties. So, for example,341on evaluating the effects of cochliomycins A–C (7–9) on the larval
settlement of the barnacle Balanus amphitrite, the first of these
completely inhibited this process at concentrations of 20.0 lg/
mL and still displayed significant effects at 5.0 lg/mL. Zeaenol
(14) and compound 7 as well as two acetate derivatives of the
latter displayed potent anti-fouling activities at non-toxic concen-
trations with EC50 values of 5.0, 1.2, 15.4 and 12.5 lg/mL, respec-
tively. These values are well below the threshold requirement
4028 M.G. Banwell et al. / Tetrahedron Letters 58 (2017) 4025–4038(EC50 25 lg/mL) set by the US Navy program as an efficacy level
for the development of natural anti-fouling agents. Given the
structural relationship between compounds 7 and 14, the pres-
ence of the acetonide moiety in the former compound clearly
has a beneficial effect on anti-fouling properties. Furthermore,
since these same compounds display high therapeutic ratios they
might well be useful as environmentally benign anti-fouling
agents. Cochliomycin A’s anti-fouling effects are now thought to
arise through stimulation of the NO/cGMP pathway in the cyprid
lavael phase of the barnacle’s lifecycle.7 The subsequent evalua-
tion of cochliomycins D, E and F revealed that the first and third
of these also displayed potent anti-fouling effects at non-toxic
concentrations (EC50 values of 17.3 and 6.67 lg/mL, respec-O
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34tively).6 Significantly, the most active compound among the iso-
lates from the culture broth of C. lunatus (TA26-46) was the cis-
enone-containing LL-Z1640-2 (16). The EC50 value of this com-
pound (1.82 lg/mL) is close to that of the commercially employed
anti-fouling agent SeaNine 211TM (1.23 lg/mL)8 but has a signifi-
cantly more favourable therapeutic ratio [LC50/EC50 >50 (for 16)
vs 20.3]. The differing anti-fouling behaviours of cochliomycins
D, E and F suggest that variations in stereochemistry can have a
notable impact on activity.
Interestingly, cochliomycin A (7) displayed moderate anti-bac-
terial activity against Staphylococcus aureus5 while, unlike cochlio-
mycins D, E and F, LL-Z1640-2 (16) displayed potent inhibitory
effects against various pathogenic fungi.6O
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As with other RALs, the cochliomycins have been the subject of
various synthetic studies, both for the purposes of confirming their
structures and as a means of providing more material (as well as
analogues). Almost invariably, a major consideration in such work
is the manner in which the 14-membered lactone ring is closed. A
range of methods has been successfully employed for this purpose
and these are presented within the individual descriptions given
below of the various syntheses reported to date.
(a). The Du Group syntheses
The Du group’s synthesis of cochliomycin A (7) was reported9 in
2014 and employed L-arabinose as the chiron for assembling the
three contiguous stereogenic centres within the macrolide along
with a base-promoted lactonisation reaction to close the ring itself.
The detailed reaction sequence is shown in Scheme 1 and started
with the conversion of L-arabinose (20) into the corresponding
bis-acetonide (21) under standard conditions and the latter com-
pound subjected to a Wittig olefination (to give 22) and then selec-
tive acetonide hydrolysis using aqueous acetic acid. Diol 23 so-HO
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343formed (77% from 21) was selectively tosylated and ester 24 then
treated with base so as to form epoxide 25 (78% from 23). Olefin
cross-metathesis of compound 25 with the commercially available
and S-configured alcohol 26 gave the E-alkene 27 (85%) and the
associated epoxide ring then opened using the anion derived from
trimethylsilylacetylene and thus producing the homopropargylic
alcohol 28 (78%).
Over three steps, including a Pd-catalysed hydrostannylation
reaction, the acetylenic unit associated with compound 28 was
converted into the alkenylstannane 29 (71%) that was itself
engaged in a Stille cross-coupling with the well known aryl triflate
30 and thus producing compound 31 (81%), the immediate precur-
sor to target 7. Indeed, on treatment with sodium hydride in DMF
the conversion 31? 7 was effected in 46% yield.
The Du Group’s synthesis of cochliomycin B (8) (Scheme 2)10
also started with L-arabinose but a ring-closing metathesis reaction
was now used to construct the associated macrolide ring. Thus,
compound 20 was converted, under conventional conditions, into
the corresponding 3,4-mono-acetonide and this itself subjected
to a Wittig olefination reaction and so affording compound 32
(72%). Over three steps this diol was manipulated so as to generate
aldehyde 33 (46%) and a Wittig-based homologation of this lastOH
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4030 M.G. Banwell et al. / Tetrahedron Letters 58 (2017) 4025–4038compound afforded, via enol ether 34 (77%), congener 35 (75%).
Takai-type olefination of this last compound then gave the E-con-
figured iodoalkene 36 (53%) that was engaged in a Suzuki-Miyaura
cross-coupling with the readily obtained arylboronate 37 and so
affording the trans-styrene 38 (68%). Reaction of this last com-
pound with the anion derived from homochiral alcohol 26 then
gave ester 39 (75%) that upon reaction with Grubbs’ second gener-
ation catalyst afforded, via ring-closing metathesis (RCM), the
required macrocycle (67%) and treatment of this with tetra-n-buty-
lammonium fluoride (TBAF) then gave cochliomycin B (8) in 85%
yield. Interestingly, in the penultimate step there was no compet-
ing RCM involving the styrenyl double bond and the proximate ter-
minal olefin (a process that would lead to side-chain fragmentation
and formation of a cyclohexene).HO
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34(b). The Nanda Group syntheses
Jana and Nanda reported a synthesis of cochliomycin A in
201211 and this started (Scheme 3) with the conversion, by well
established methods, of L-(+)-tartaric acid (40) into 2,3-di-O-iso-
propylidene-L-threitol (41) and mono-protection of the latter to
give ether 42 (85%). Oxidation of compound 42 under Swern con-
ditions gave the corresponding aldehyde 43 (90%) that was sub-
jected to a highly diastereoselective Keck asymmetric allylation
reaction and so affording, after protection of the resulting homoal-
lylic alcohol, cleavage of the TBS ether and oxidation of the result-
ing alcohol, aldehyde 44 (59%). A Julia-Kocienski olefination
reaction was then carried out on compound 44 using the readily
prepared sulfone 45, KHMDS and 18-crown-6 and so affording, inmono-
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M.G. Banwell et al. / Tetrahedron Letters 58 (2017) 4025–4038 4031a highly selective manner and after silyl ether cleavage, the target
E-alkene 46 in 75% yield. Mitsunobu coupling of this last com-
pound with acid 47 then gave, after cleavage of the PMB ether resi-
due, ester 48 (73%). Upon exposure to Grubbs’ second-generation
catalyst compound 48 was converted into cochliomycin A (7)
(72%).HO
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345The Nanda Group synthesis of cochliomycin C12 (Scheme 4) also
started with L-tartaric acid (40) and exploited a Mitsunobu-medi-
ated lactonisation reaction to form the macrolide ring. Specifically,
then, di-acid 40 was, once again, converted into the diol-acetonide
41 and the latter mono-protected as the corresponding p-
methoxybenzyl (PMB) ether 49 (85%). Upon Swern oxidation this+
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4032 M.G. Banwell et al. / Tetrahedron Letters 58 (2017) 4025–4038last compound gave the aldehyde 50 (90%), Wittig olefination of
which afforded the terminal olefin 51 (70–75%) that was subjected
to an olefin cross-metathesis (OCM) reaction with the unsaturated
and homochiral ether 52 using the Grubbs’ second-generation cat-
alyst. The primary product of this process was then hydrogenated
under conventional conditions so as to give compound 53 (79%).
Oxidative cleavage of the PMB-ether residue associated with bis-
ether 53 then gave the corresponding alcohol that was oxidised
to aldehyde 54 (80%) using the Dess-Martin periodinane. Reaction
of compound 54 with the propargyl anion proceeded stereoselec-
tively and Lindlar hydrogenation of the product alkyne gave the
corresponding homoallylic alcohol that was protected as the
MOM-ether 55 (78%). Heck coupling of the last compound with
the iodinated benzaldehyde 56 afforded styrene 57 (84–90%) and
oxidation of the associated aldehyde residue gave the correspond-
ing benzoic acid. Cleavage of the TBDPS-ether within product 57
then afforded the substrate 58 (61–79%) used in the macrolacton-60
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34isation reaction. So, compound 58 was subjected to an intramolec-
ular Mitsunobu reaction that provided macrolide 59 (P = MOM)
(78%), the MOM-group of which was cleaved and the product
RAL, viz. paecilomycin F (13), was then chlorinated using sulfuryl
chloride and thus affording cochliomycin C (9) in 71% yield.
Nanda and his colleagues have also reported13,14 related synthe-
ses of the C50- and C60-epimers of cochliomycin C.
(c). The Srihari Group approach
The Srihari Group synthesis of cochliomycin C (9)15 (Scheme 5)
is a formal one [in that it delivers paecilomycin F (13)], relies on D-
lyxose (60) as starting material and uses a RCM reaction to con-
struct the macrolide ring. The synthesis started with the conver-
sion of compound 60 into the previously reported mono-
acetonide 61 (95%) and this was subjected to an Ohira-Bestmann
alkyne forming reaction that delivered, with accompanyingO
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M.G. Banwell et al. / Tetrahedron Letters 58 (2017) 4025–4038 4033epimerisation, compound 62 (49%) as a mixture of diastereoiso-
mers. Conversion of this last pair of compounds into the corre-
sponding bis-acetonides and chromatographic separation of theScheme 6. The Banwell Group
Fig. 4. The starting material 70 and intermediate 71 used by the Banwell Group in
establishing total syntheses of RAL L-783,290 (72) and its cis-isomer 5.
347major product 63 (45%) was followed by the regioselective reaction
of the derived anion with the commercially available and homochi-
ral epoxide 64 and so affording the 2-alcohol 65 (82%). Exhaustive
reduction of the alkyne moiety associated with this last compound
and reaction of the oxyanion derived from product 66 (86%) with
the readily prepared arene 67 then gave, after acid treatment, the
vinylated salicylate 68 (65%). This was subjected to oxidative
cleavage and the ensuing aldehyde allylated in a diastereoselective
manner to give diene 69 (63%). Compound 69 was then engaged in
a RCM reaction using the Hoveyda-Grubbs second generation cat-
alyst and by such means, and after cleavage of the associated ace-
tonide residue, paecilomycin F (13) was obtained in 68% yield.
Since Nanda12 has previously converted compound 13 into cochlio-
mycin C (9) through electrophilic aromatic chlorination using sul-
furyl chloride a formal total synthesis of the latter natural product
was realised in this instance.
By related means C60-epi-cochliomycin C was obtained.15
(d). Background to the Banwell Group studies on the synthesis of RALs
Our group’s original efforts in the area arose through an interest
in exploiting enzymatically-derived and homochiral cis-1,2-dihy-
drocatechols16 such as 70 (Fig. 4) in the assembly of various RALs.
The pivotal building block employed for this purpose was Weinrebsynthesis of L-783,277 (5).
4034 M.G. Banwell et al. / Tetrahedron Letters 58 (2017) 4025–4038amide 7117 obtained through, inter alia, reduction of the non-halo-
genated double bond associated with the acetonide derivative of
diol 70 and ozonolytic cleavage of the remaining (halogenated)
one. Compound 71 served as a precursor to L-783,290 (72) and
its cis-isomer 5, the latter being, as noted above, a potent inhibitor
of MEK1. While the macrolide ring and the E-configured C@C bond
associated with target 72 was constructed using a RCM reaction, a
more novel means of assembling the analogous (Z-configured)
motif within congener 5 was developed.18 Details are provided
immediately below.
Our synthesis of the cis-enone-containing L-783,277 (5) is
shown in Scheme 6 and, like the pathway leading to congener
72, involved, in the early stages, the Heck coupling of aryl iodide
56 with the unsaturated Weinreb amide 71. The immediate pro-
duct of this process was oxidised to the corresponding acid (under
Pinnick conditions) and this then hydrogenated to give compound
73 (41%) that was, in turn, treated with the oxyanion derived from
the homochiral propargylic alcohol 74 (itself available through
enzymatic resolution of the corresponding racemate). The ester
75 (70%) so formed was treated with potassium hexamethyldisi-
lazide so as to generate the corresponding acetylide anion that
itself engaged in an intramolecular acylation reaction and so pro-
ducing the cyclic alkyne 76 (45%) and for which a single-crystal
X-ray analysis was undertaken. This analysis revealed an essen-
tially linear geometry about the internal triple bond and thus high-
lighting the capacity of the 14-membered macrolide ring of RALs toMeO
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34accommodate a range of structural motifs. The completion of the
synthesis of target 5 involved Lindlar-type hydrogenation of cycli-
sation product 76 and twofold deprotection of the ensuing cis-
enone gave L-783,277 (5) (40%) without compromising the integ-
rity of the Z-configured double bond.(e). The Banwell Group syntheses
Our syntheses of RALs 5 and 72 were completed just prior to
the report5 of the isolation and structural characterisation of
cochliomycins A–C (7–9, respectively). Given this, the presence
of the (unusual) acetonide residues within congeners A and B
and the novel biological properties they display we were
attracted to developing syntheses of them. Our route19 to the first
two of these (viz. the acetonide-containing ones) exploited a late-
stage and highly stereoselective Nozaki–Hiyama–Kishi (NHK)20
reaction to effect the necessary macrocyclisation process, a
relatively unusual one in terms of its application in the synthesis
of RALs.
The pivotal elements of the synthetic sequence used are shown
in Scheme 7 and involved an OCM of the readily available olefin 67
with the D-2-deoxyribose-derived and previously reported chiron
77 to give compound 78 (86%). The b-substituted styrene 78 was
then reacted with the readily prepared homoallylic alcohol 79 in
the presence of base and so affording, after protection of the phe-
nolic OH group, the ester 80 (80%). Treatment of ester 80with TBAFO
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tion of the resulting and rather sensitive 1-alcohol with the
Dess-Martin periodinane then gave the corresponding aldehyde.
This was immediately engaged in an intramolecular NHK reaction
to afford, with high levels of diastereocontrol, the SEM ether of
cochliomycin B (8) (77%). When this ether was treated with TBAF
in refluxing THF then cochliomycin B (8) itself was obtained in
73% yield. In contrast, on treating the SEM ether with HCl in349methanol at 22 C for 1 h then congener A (7) (91%) was obtained
while extended exposure of the same substrate to the same condi-
tions resulted in acetonide group cleavage and formation of the
previously reported RAL zeaenol (14) which was obtained in 84%
yield.
The end game associated with our approach21 to cochliomycin C
(9) was rather different and resulted in the identification of a new
means for forming the macrolide ring of RALs. The reaction
4036 M.G. Banwell et al. / Tetrahedron Letters 58 (2017) 4025–4038sequence started (Scheme 8) with an OCM reaction between the
readily available alkenes 81 and 82 (the former compound being
obtained from L-tartaric acid) and conventional hydrogenation of
the product olefin 83 (88%) to give alkane 84 (98%). The anion
derived from the last compound was reacted with arene 30 and
thus affording ester 85 (91%), the phenolic group of which was pro-
tected as the corresponding SEM-ether 86 (94%). A Stille cross-cou-
pling reaction between aryl triflate 86 and the alkenylstannane 87
then gave the cinnamyl alcohol 88 (76%) that was converted, over
three standard steps, into the rather unstable aldehyde 89 (66%).
Given our previous positive experiences with the NHK reaction
we sought to apply this in the macrocyclization of compound 89.
However, on exposing this to a mixture of chromous chloride
and nickel(II) chloride in DMF only the vinylated 12-membered
lactone 90 was obtained (as a single diastereoisomer in 33% yield).
In stark contrast, when the same substrate was treated with
indium in a mixture of water and dichloromethane then a Loh-type
a-allylation reaction took place and so affording, in a highly
diastereoselective manner, the 14-membered macrocycle 91
(61%). Removal of the acetonide and SEM protecting groups associ-
ated with this last compound using aqueous acid then gave pae-
cilomycin F (13) that was chlorinated with sulfuryl chloride and
so affording cochliomycin C (9) in 82% yield.
During the course of our work detailed above Cutler and col-
leagues reported22 the isolation of three new RALs from a fungus
Neocosmospora sp. (UM-031509). They were named neocosmosins
A–C and structures 92–94 (Fig. 5), respectively, assigned to them.
These RALs were found to co-occur with three previously reported
ones, namely radiciol (1), monocillin II (95) and monocillin IV (96).
Unlike any of the RALs we had previously targeted for synthesis, all
of the Neocosmospora-derived compounds embody a C10-keto resi-
due and three of them (1, 94 and 95) show good binding affinity for
the human opioid receptors. Accordingly, we sought to develop a
synthesis of the first of these, namely compound 92 embodying
the structure assigned to neocosmosin A.
Our synthesis of RAL 9223 is shown in Scheme 9 and began
with the OCM of styrene 67 and the unsaturated acetal 97. The
product E-alkene 98 (72%) was treated with dimethyl dioxirane
and the resulting epoxide 99 (quant.) engaged in a Meinwald-
type rearrangement on exposure to Pd(OAc)2 and n-Bu3P and
thus affording ketone 100 (88%) embodying the pivotal C10 car-O
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35bonyl unit (RAL numbering) associated with the target 92. Acid-
catalysed hydrolysis of the acetal moiety within compound 100
afforded the corresponding keto-aldehyde 101 (89%) that could
be selectively methylenated using the Wittig reagent and so giv-
ing the terminal alkene 102 (74%). Compound 102 was particu-
larly prone to cyclisation on treatment with either acid or
base. So, for example, when it was heated with p-TsOH in
toluene in the presence of ethylene glycol (in an effort to prepare
the corresponding ketal) then the unsaturated lactone 103 (82%)
was formed but this could be cleaved with potassium hydroxide
in aqueous THF and thus gave, after careful acidic work up, keto-
acid 104 (96%). Compound 104 then served as the nucleophile in
a Mitsunobu reaction with the homochiral 2-alcohol 26 and
thus affording the ester 105 (78%) that was itself engaged in a
RCM reaction using Grubb’s second generation catalyst and so
producing the target RAL 92 (83%). All of the NMR, IR and MS
spectral data acquired on this product matched those reported
for neocosmosin A. However, while the specific rotation of com-
pound 92 was of a similar magnitude to that reported for the
natural product it was of the opposite sign. As such we con-
cluded that the absolute configuration of neocosmosin A had
been incorrectly assigned and is, in fact, represented by structure
ent-92.
The synthesis of compound ent-92 (Scheme 10) involved a triv-
ial adaptation of the process just discussed. Thus, Mitsunobu cou-
pling of keto-acid 104 with the homochiral 2-alcohol ent-26 gave
ester ent-105 (92%) and this underwent an RCM reaction to give
neocosmosin A (ent-92) (67%), the structure of which was con-
firmed by single-crystal X-ray analysis.
During the course of these studies Das and co-workers
reported24 a distinctly different synthesis of compound ent-94.
Future Prospects/Conclusion
New RALs, including ones isolated from marine sources, that
display intriguing biological properties continue to be reported.25
Studies on the synthesis of such compounds have resulted, over
the decades, in the identification of a raft of new methods for their
construction and these have now provided chemists with the
capacity to prepare new RALs in a predictable manner. As such,
completions of total syntheses of RALs no longer elicit the excite-O
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M.G. Banwell et al. / Tetrahedron Letters 58 (2017) 4025–4038 4037ment they once did.26 Indeed, now synthetic studies usually just
provide the means by which the assigned structures can be
checked and additional material can be produced for the purposes
of biological profiling/evaluation. Of course, the production of ana-
logues is another important activity in this area, perhaps the most
promising aspect of which would be the production of potentially
more metabolically stable and bio-available macrolactam
equivalents.27351Acknowledgements
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